,generic_name,use_cases,mechanism_of_action,drug_interactions,food_interactions,contraindications,side_effects
0,adalimumab,not been established,blocks its interaction with the p55 and p75 cell surface tnf receptors,live vaccines,live vaccines,patients with known hypersensitivity toadalimumab,injection site reactions
1,acyclovir + hydrocortisone,amp,inactivation of the viral dna polymerase,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,inflammation
2,acyclovir (topical),immunocompetent adults and adolescents 12 years of age and older,antiviral,systemic drug interactions,systemic,patients with known hypersensitivity,"dry lips, desquamation, dryness of skin"
3,acyclovir (oral),immunocompromised patients,absorbed from gl tract,probenecid reduces aciclovir excretion,probenecid,patients known to be hypersensitive to aciclovir,"headache, neurological reaction, fatigue."
4,acyclovir (ophthalmic),herpes simplex keratitis,antiviral agent,clinically significant interactions,clinically significant interactions have been identified.,patients known to be hypersensitive,healed without apparent sequelae
5,acyclovir (injection),immunocompromised patients,intracellular conversion,urinary excretion and renal clearance correspondingly reduced,urinary excretion and renal clearance correspondingly reduced,patients known to be hypersensitive,local inflammatory reactions may occur if acyclovir iv
6,activated charcoal,"poisoning due to foods, heavy meals &amp",binds the poison and prevents its absorption by the gastrointestinal tract,ultracarbon,ultracarbon,intoxication,the stools turn black
7,aclidinium bromide + formoterol fumarate,maintenance treatment of patients with chronic obstructive pulmonary disease,formoterol fumarate,avoid administrations of this combination with other anticholinergic-containing drugs,drugs,patients with asthma,headache
8,acitretin,severe extensive psoriasis,unknown,"methotrexate, tetracyclines or vitamin a","methotrexate, tetracyclines or vitamin a",patients with rare glucose-galactosemalabsorption,dose-related and are usually well-tolerated at the recommended dosages
9,acidic component [hco3 hemodialysis solution],haemodialysis,sodium chloride,drug interactions,drug,known hypersensitivity,electrolyte imbalance
10,acetylcysteine,certain clinical condition,anti-oxidant action,inhibitory effect of thrombocyte aggregation,amoxicillin will increase the level of the antibiotic in tissues,patients suffering from phenylketonuria,not everybody gets them
11,acetazolamide,"open angle glaucoma, secondary glaucoma",carbonic anhydrase inhibitor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,marked kidney and liver diseases or dysfunction,"headache, drowsiness, dizziness, fatigue"
12,acetate formulation [hemodialysis solution],haemodialysis,treatment of hyperosmolar diabetes,drug interactions,drug,known hypersensitivity,fluid and electrolyte imbalance
13,acemetacin,joint disorders,blocking a substance in the body called cyclooxygenase,antihypertensive effect of b-blockers,quinolone,peptic ulcer,"anorexia, nausea, vomiting"
14,aceclofenac,"osteoarthritis, rheumatoid arthritis",potent inhibitor of the enzyme cyclooxygenase,monitoring of patients,methotrexate,patients with known hypersensitivity to it,"after oral administration, it is rapidly and completely absorbed an unchanged drug"
15,"bandish [oak galls, tannic acid]",epistaxis menorrhagia blood dysentery,synergistically acting valuable natural ingredients,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in the therapeutic dosage
16,balarista,sportsmen and geriatric patients,antiasthmatic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"hypertension, dm, bph, cardiovascular diseases",well tolerated
17,bacopa extract [natural memory enhancer],children,enzymes involved in generation and scavenging of reactive oxygen species in the brain,reduce the decline in cognitive function associated with phenytoin,thyroid stimulating drugs or decrease the effects of anti-thyroid medications,"hyperthyroidism, fever and acute infection",no side effects
18,aushokarist [saraca indica],indicated in- dysfunctional uterine bleeding,pgh2 synthetase inhibitor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,no health hazards or side effects are known
19,aswagandharista,nervous debility,sedative,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,no significant side effect
20,ashokarista,premenstrual syndrome,antibacterial activities,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindicated during pregnancy,not yet known
21,arjunarista,prevention &amp,cardiotonic and diuretic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,no significant side effect
22,aravindasav,malnutrition indigestion immune deficiency dysentery worm,antispasmodic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitive,no side effect
23,antacid [unani],peptic ulcer,prebiotic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been observed in proper dosage
24,aniseed + indian dill + black cardamom + peppermint,digestive disorders,curative herbs and natural oils in a modern formulation,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been reported in therapeutic dosage
25,andrographis paniculata,viral fever flu common cold sinusitis upper respiratory tract infection viral hepatitis,antihepatotoxic,isoniazid,isoniazid,cases of known allergy to plants of the acanthaceae family,"gastric discomfort, vomiting and loss of appetite"
26,ambergris + salep + galangal,antioxidant,synergistically acting precious natural ingredients,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been observed in proper dosage
27,ambar momiyaee,continuous,nervine tonic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,women and children,no significant side effect has been observed in proper dosage
28,amalaki rasayana,increase body immunity,phyllanthus emblica,<NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,NO SPECIFIC DATA AVAILABLE
29,aloe indica+ hyoscyamus niger + piper nigrum,acid reflux,anti-inflammatory agent,antiarrhythmic agents,corticosteroids,acutely inflamed intestinal diseases,allergic reaction
30,allopurinol,hyperuricosuria,it acts on purine catabolism,skin rash,azathioprine,patients withknown hypersensitive to allopurinol,"hypertension, alopecia,hepatotoxicity"
31,allium cepa + heparin + allantoin,scar treatment,amp; allantoin gel,drug interaction,drug,patients with known hypersensitivity,some local irritations are reported such as slight erythema and itching
32,alfuzosin hydrochloride,treatment of the signs and symptoms of benign prostatic hyperplasia,selective antagonist of post-synaptic a1 adrenoreceptors,profound hypotension,high fat meal,patients with severe renal impairment,flushing
33,alfacalcidol,certain illnesses.,binds to intracellular receptors,reduce the efficacy of vitamin d,corticosteroids,hypoparathyroidism,hypercalcaemia
34,alendronic acid + vitamin d3,amp,inhibitor of osteoclast mediated bone resorption,calcium supplement,mineral oils,stricture or achalasia,transient decreases in serum calcium and phosphate.
35,alendronic acid,men and women,inhibits the activity of osteoclasts,antacids and calcium supplements,supplements,patients at increased risk of aspiration,"nausea, vomiting, peptic ulceration, hypersensitivity reactions"
36,alectinib,patients,highly selective and potent alk and ret tyrosine kinase inhibitor,co-administered cyp3a substrates,drug-drug,patients with a known hypersensitivity,nausea
37,alcaftadine,topical ophthalmic use,histamine receptor antagonist,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with hypersensitivity to any component in the product,headache
38,albumin (human),hypoproteinemia,binds and carries a plethora of hydrophobic molecules,risk of atypical reactions to ace inhibitors,protein hydrolysates or alcoholic solutions,patients with severe anemia or cardiac failure,vascular overload with resultant pulmonary edema
39,albendazole,single and mixed infestations,"vermicidal, ovicidal and larvicidal activities",no interaction,pharmacodynamic or pharmacokinetic,during pregnancy or women thought to be pregnant,rarely reversible alopecia
40,agomelatine,major depressive disorder especially in non-responders,"mt1, mt2, and 5ht-2c receptors",potent cyp1a2 inhibitors,medicinal products,patients with hepatic impairment and hypersensitivity,"headache, nausea and diarrhea"
41,aflibercept,metastatic colorectal cancer,to suppress neovascularization and decrease vascular permeability,no dedicated drug-drug interaction studies,irinotecan,NO SPECIFIC DATA AVAILABLE,20% incidence and at least 2% greater incidence
42,afatinib dimaleate,limitation of use,inhibits tyrosine kinase autophosphorylation,not tolerated,not tolerated,NO SPECIFIC DATA AVAILABLE,"decreased appetite, nausea, vomiting, pruritus"
43,adsorbed tetanus vaccine,not to be used for the treatment of tetanus infection,shaking,neutralisation of tetanus immune globulin,different syringes,a minor febrile illness such as a mild upper respiratory infection,generally well tolerated
44,adrenaline,if a person begins exhibiting severe allergic reactions,stimulation of adrenergic nerves,drugs that sensitize the heart to arrhythmias,drugs,hypertension,local anaesthetics
45,dasamularista,spermatorrhoea,constructive action on uterus,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no reported,no side effect or adverse effect
46,curcuminoids [curcuma longa],rheumatoid arthritis,it inhibits the formation of prostaglandin,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,gallstones,occasionally gastrointestinal disturbance may occur with overdose
47,curcuma longa [turmeric extract],dyspeptic disorders,antiproliferative mechanism,risk of bleeding,antiplatelet,patients with hyperacidity or gastrointestinal ulcers,usually does not cause significant side effects
48,cranberry [vaccinium macrocarpon],urinary tract infection,cranberry inhibits adherence of bacteria,interactions with antibiotics or other drugs,omeprazole,uric acid or calcium oxalate stones,occasionally diarrhea or mild gastrointestinal upset
49,compound asparagus,"sexual weakness, oligospermia",antioxidant activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no reported,no side effect or adverse effect
50,collagen ii & gags,amp; gags helps to maintain stronger bones,can prevent and helps to repair the degeneration,drug interaction,drug,NO SPECIFIC DATA AVAILABLE>,no adverse effects
51,coenzyme q10 [ubidecarenone],mitochondrial disorders,antioxidant activity,antihypertensive drugs,warfarin,patients who have hypersensitivity to the active substance,"stomach upset, loss of appetite, nausea, vomiting, and diarrhea"
52,chirata [swertia chirata],long term uses of chiratacapsule destroy intestinal worms,NO SPECIFIC DATA AVAILABLE,there has no information for chirata interactions,no information for chirata interactions,pregnancy &amp; lactation,no significant side effects have been observed in proper dosage
53,chebulic myrobalan + barberry,constipation flatulence,natural ingredients,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,no known contraindication,no significant side effect has been observed in proper dosage
54,carica papaya leaf extract,-,gt,"- () , , , , , , , , , ,",-,bph,","
55,camphor + thymol + menthol + eucalyptus oil,"headache, toothache and burns",antiseptic,drug interactions,drug,contraindication,no significant side effect has been observed in proper dosage
56,calendula officinalis [marigold],topical application,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,not yet known
57,buzuri,hepatitis jaundice,"prebiotic, antioxidant",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
58,brahmi rasayan,memory deficiency impaired speech rough &amp,potent nerve tonic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,not reported,no side effect or adverse effect
59,black cohosh [cimicifuga racemosa],"premenstrual discomfort, dysmenorrhea",alternative to hormonal therapy,birth control pills,birth control pills,no significant contraindication is observed,"stomach upset, cramping, headache"
60,amino acid + calcium,protein,decreasing the formation of urea by re-using the amino group,disturbed absorption of the active substances,disturbed absorption of the active substances,hypercalcaemia,calcium
61,amino acid,when oral or enteral nutrition is impossible or insufficient or contraindicated,NO SPECIFIC DATA AVAILABLE,mixed with other drugs,drugs,pregnancy and lactation,amino acid imbalances and severe metabolic disorders
62,amikacin,bacterial septicemia,in vitro,the combination with other aminoglycoside antibiotics,aminoglycoside antibiotics,patients with a known history of hypersensitivity to amikacin,"skin rash, drug fever, headache, paraesthesia, nausea and vomiting"
63,ambroxol hydrochloride,productive cough,hydrating,antitussives,antitussives,hypersensitivity,allergic responses
64,ambrisentan,pulmonary arterial hypertension,predominantly by non-renal pathways,limit the dose of ambrisentan to 5 mg once daily,cyclosporine,patients with idiopathic pulmonary fibrosis,decreases in hemoglobin concentration and hematocrit
65,amantadine hydrochloride,parkinsonism,not clearly understood,close observation,alcohol,patients with known hypersensitivity to the active substances,mild
66,alverine citrate,irritable bowel syndrome,"directly on the muscle in the gut, causing it to relax",drug interactions,drug interactions reported with this medicine,paralytic ileus or known hypersensitivity,"nausea, headache, dizziness, itching, rash and allergic reactions"
67,aluminium oxide + magnesium trisilicate,aluminium oxide &amp; magnesium trisilicate,aluminum hydroxide neutralizes stomach hydrocloride,none well documented,none well documented,hypophosphataemia,"diarrhoea, constipation, nausea, vomiting"
68,aluminium hydroxide + magnesium hydroxide + simethicone,antiflatulent,neutralizing gastric acid secreted from parietal cells of the stomach,decrease the bioavailability,oral drugs,alkalosis and hypermagnesaemia,gastrointestinal side effects are uncommon
69,aluminium hydroxide + magnesium hydroxide,aluminium hydroxide,magnesium hydroxide possesses a slow but sustained acid neutralizing property,drugs,hydroxychloroquine and phenothiazines,alkalosis and hypermagnesaemia,calcium phosphate
70,aluminium chloride hexahydrate,"hands, feet and scalp",relieve hyperhidrosis,drug interactions,drug interactions for aluminium chloride hexahydrate topical solution,patients with known hypersensitivity to any of its components,mild and short-lasting
71,aluminium chloride + melaleuca alternifolia oil + geothermal water,hyperhidrosis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindicated,NO SPECIFIC DATA AVAILABLE
72,alteplase,pulmonary embolism,serine protease,bleeding,anticoagulants and antiplatelet drugs,acute myocardial infarction or pulmonary embolism,bleeding orolingual angioedema cholesterol embolization
73,alprazolam,with or without agoraphobia,benzodiazepines,alcohol and oral ontraceptives,oral,NO SPECIFIC DATA AVAILABLE,usually disappear upon continued medication
74,alphanate,withvon willebrand disease,temporarily increases the plasma level of fviii,none known,none known,patients who have manifested life-threatening immediate hypersensitivity reactions,"respiratory distress, pruritus, rash, urticaria"
75,ginkgo biloba,sexual dysfunction associated with ssri use,ginkgo inhibits binding of platelet-activating factor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,bleeding disorders,no side effects following proper administration of designated therapeutic dosages
76,garlitab,in- diabetes rheumatoid arthritis gout respiratory tract infection,prebiotic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
77,garlic oil,"hyperlipidemia, atherosclerosis, mild hypertension",enhances palmitate-induced inhibition of cholesterol biosynthesis,antiplatelet agents and anticoagulants,warfarin,patients with a known allergy to garlic and those taking warfarin,rare
78,flaxseed oil [linum usitatissimum],"hyperlipidemia, constipation",facilitates passage of feces through bowel through lubrication by oil.,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,blood thinning medication,adverse effects are rare at recommended dosages
79,"fishar [snake root, potassium, magnesium]",hypertension,tranquilizer and anti-psychotic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been reported in therapeutic dosage
80,fermented soy [lactobacillus delbrueckii],occasional heartburn gastric and duodenal ulcers,inhibit the action of the protease enzymes on stomach lining,depression,depression,known hypersensitivity to any of its active ingredients,well tolerated
81,"fennel [mouri, gohkshura, kasni]",jaundice,anti-microbial,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect
82,evening primrose oil,premenstrual syndrome symptoms,prostanoids pathway,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,schizophrenic patients,rare at recommended dosages
83,espand,spermatorrhoea,various natural active ingredients,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
84,emblica officinalis + piper longum,"tuberculosis of lungs, asthma and bronchitis",antiulcerogenic,vitamin c,large dose of vitamin c,hypersensitive,there is no known significant side effect
85,emblic myrobalan + sesame,dandruff insomnia,hair oil,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper usage
86,emblic myrobalan + chebulic + belleric,constipation anorexia indigestion diabetes,amp,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
87,emblic myrobalan + aswagandha + grape,it improves the immunity,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been observed in proper dosage
88,ejaz,all types of cough,non-sedative,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
89,echinacea,"common cold, cough, bronchitis and other upper respiratory tract infections",antiviral activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"fever, nausea, vomiting"
90,amorolfine hydrochloride (nail lacquer),onychomycosis,broad spectrum of action,drug interactions,drug,patients who have shown hypersensitivity to the treatment,a burning sensation
91,amorolfine hydrochloride (cream),dermatomycoses,fungicidal,nail varnish or artificial nails,nail varnish or artificial nails,patients who have shown hypersensitivity,"skin irritation, erythema, pruritus, skin burning sensation"
92,amlodipine besilate + valsartan,not indicated for the initial therapy of hypertension,independent of the pathways for angiotensin ii synthesis,drug interaction,drug,patients who are hypersensitive,peripheral edema
93,amlodipine besilate + telmisartan,"hypertension, alone or with other antihypertensive agents",amiodipine,"warfarin, or ibuprofen",grapefruit juice,pregnancy &amp; lactation,"dizziness, peripheral edema, migraine, headache, paraesthesia"
94,amlodipine besilate + olmesartan medoxomil,initial therapy in patients likely to need multiple antihypertensive agents,competitive inhibitor of the at1 receptor,nsaids including selective cox-2 inhibitors,nsaids including selective cox-2 inhibitors,patients with diabetes,"peripheral edema, headache, flushing, and dizziness"
95,amlodipine besilate + benazepril hydrochloride,not indicated for the initial therapy of hypertension,absorption,without evidence of clinically important adverse interactions,potassium supplements,hypersensitive,independent of race and (within the range of doses tested) of dose
96,amlodipine besilate + atorvastatin,combination with other antianginal drugs,calcium channel blocker and atorvastatin calcium,"digoxin, warfarin or cyclosporine",oral contraceptive,hypersensitivity,atorvastatin is generally well tolerated
97,amlodipine besilate + atenolol,nitrate therapy,fixed-dose combination,oral antidiabetics and insulin,ampicillin,hypersensitivity,amlodipine and atenolol is well tolerated
98,amlodipine besilate,essential hypertension,long duration,drug interactions,food,pregnant woman,vasodilatory action
99,amlexanox,aphthous ulcers,unknown,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,"contact mucositis, nausea, and diarrhea"
100,amitriptyline hydrochloride + chlordiazepoxide,moderate to severe depression associated with moderate to severe anxiety,anxiolytic,antihypertensive action of guanethidine,guanethidine,patients with hypersensitivity,adverse reactions
101,amitriptyline hydrochloride,indicated in- depressive illness: particularly where sedation is required,not fully elucidated,disulfirum and cimetidine inhibit the metabolism,disulfirum,"myocardial infarction, arrythmias",anticholinergic
102,amisulpride,amisulpride injection is indicated in adults,antipsychotic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pituitary gland prolactinomas and breast cancer,NO SPECIFIC DATA AVAILABLE
103,amiodarone hydrochloride,in patients refractory to other therapy,"broad spectrum"" antiarrhythmic medication",metabolism of dextromethorphan,dextromethorphan,patients with a known hypersensitivity,lungs
104,aminophylline,adults,increase in intracellular camp through inhibition of phosphodiesterase;,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to xanthines or ehylenediamine,"albuminuria, diuresis and hematuria"
105,kabid nawshadri,weakness of stomach and liver hepatitis,strengthens the liver,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been observed in therapeutic dosage
106,jouban satadal,increases the secretion of testosterone &amp;,aphrodisiac,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,not yet known
107,jogaraj guggulu,rheumatoid arthritis,exudates obtained in the form of oleogum resin,decrease the effectiveness of diltiazem,thyroid hormone pills,rare case,no severe side effects
108,jirakaddarista,digestive disturbances,antimicrobial effect,anticoagulant drugs,"anticoagulant drugs like warfarin, aspirin.",obstructive jaundice,no significant side effect
109,jinsin,anaemia immunodeficiency,an adaptogen and immunostimulant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in therapeutic dosage
110,jeerakaddarishta carminative,reactive arthritis,increase hydrochloric acid in the stomach,anticoagulant drugs,anticoagulant drugs,obstructive jaundice,no known significant side effect
111,jamani arka,"indigestion, dyspepsia",scientific manner,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no major contraindication,not yet known
112,"jadwar [denudatum, saffron, henbane]",chronic cold catarrh &amp; cough,aphrodisiac,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
113,ispaghula husk + sonapata,piles,inhibitor of water &amp,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,without water,"flatulence, stomach irritation &amp; intestinal obstruction"
114,ispaghula husk + mebeverine hydrochloride,all kinds of ibs,antispasmodic drug,"absorption of calcium, iron and zinc",other agents,"cases of intestinal obstruction, fecal impaction",safe
115,hingastak churna,"hyperacidity, peptic ulcer disease",antioxidant mechanism,not known,not known,cases of known allergy to plants,stomach irritation
116,herbal multivitamin,anaemia of pregnancy,non-alcoholic vitaminised herbal tonic of proven bioavailability,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper usage
117,herbal gastric preparation,hyperacidity,time-tested natural ingredients,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed
118,herbal cough syrup [vasakarista],"asthma, smokers cough and throat hoarseness",mucolytic and expectorant action,drug interactions,drug,patients who are hypersensitive,rare
119,herbal cough syrup [tulsi],",",NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,cardiac patient
120,artemether + lumefantrine,malaria infections,inhibition of nucleic acid - protein synthesis within the malarial parasites,no such result is available,no such result is available,patients taking any drug which is metabolized by the cytochrome enzyme,mild to moderate severity and duration
121,artemether,malaria,rapidly acting blood schizontocide,phenothiazines,phenothiazines,patients with hpersensitivity toartemether,"first degree heart block, transient increase in serum transaminases"
122,armodafinil,adult patients,indirect dopamine receptor agonist,mao inhibitors,mao inhibitors,patients with known hypersensitivity,rash
123,aripiprazole,schizophrenia schizoaffective disorder,both dopamine and serotonin receptors activity,alcohol,alcohol,hypersensitive to it or to any component of this product,"vomiting, coughing, abdominal pain."
124,arformoterol tartrate,important limitations of use: arformoterol ... read more,NO SPECIFIC DATA AVAILABLE,potassium,"mao inhibitors, tricyclic antidepressants",NO SPECIFIC DATA AVAILABLE>,arformoterol can cause serious side effects
125,arabinoxylan,"patients who are attacked by cancer, virus, bacteria",reducing the amount of sugar,diabetes medications,diabetes medications,NO SPECIFIC DATA AVAILABLE,no adverse or toxic side-effects
126,aprepitant,prevention of postoperative nausea and vomiting,selective high affinity antagonist,alternative or back-up methods of contraception,drugs,patients who are hypersensitive to any component of the product,pyrexia
127,apremilast,moderate to severe plaque psoriasis,increases intracellular levels of camp,cytochrome p450 enzyme inducers,cytochrome p450 enzyme inducers,patients with a known hypersensitivity,"nausea, diarrhea and headache"
128,apixaban,in patients with nonvalvular atrial fibrillation,inhibiting coagulation,risk of bleeding,cyp3a4 and p-gp,active pathological bleeding. severe hypersensitivity reaction,skin rash or severe allergic reaction
129,apis mellifica + gelsemium sempervirens + gnaphalium,100% safe to use between the toes non-greasy formula,"no added dyes, no petroleum or mineral oils",<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>
130,antioxidants and micronutrients,protection,sperm concentration co-enzyme q10,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE
131,antihemophilic factor [factor viii],haemophilia a,it activates factor x in conjunction with activated factor ix,allergic reactions,vomiting,anaphylactic or severe systemic reaction,allergic reactions
132,anti-thymocyte globulin,use in conjunction with concomitant immunosuppression,not fully understood,drug interaction studies,drug,active acute or chronic infections,low counts of platelets and white blood cells
133,antazoline + tetryzoline,adults and children above 2 years of age,sympathomimetic with alpha-adrenergic activity,contraindicated,alcohol,excipients,burning/stinging
134,anidulafungin,limitations of use,antifungal activity,no dosage adjustment,amphotericin b liposome for injection,patients with known hypersensitivity,"hypoglycemia, epistaxis, and rash"
135,nabayas louha herbal haematinic,iron deficiency anemia,laxative,drug interactions,drug,patients who are hypertensive,not known to have any side effects
136,"mustakarista [cyperus, zingiber, piper nigrum]",dyspepsia,it refreshes entire human body,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,NO SPECIFIC DATA AVAILABLE
137,mumshik,physical &amp;,aphrodisiac capsule,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in therapeutic dosage
138,"mudir [aloe, saffron, ferrus sulphate]",amenorrhoea,synergistically acting natural ingredients,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in the therapeutic dosage
139,monjistha [rubia cordifolia],"dysmenorrhoea, oligomenorrhea",it stimulates and cleanses the uterus,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,during pregnancy,not known
140,menthol + camphor + methyl salicylate + oleoresin capsicum,"muscle pain sprains, strains and sports injuries",binds and stimulates the trpm-8 receptor protein,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,allergies to aspirin,<NO SPECIFIC DATA AVAILABLE>
141,menthol + camphor + eucalyptus oil + mint oil,cream,topically used as a pain reliever,not known,not known,not recommended for infant &amp; young children,not known
142,mentha + cinnamomum + gaultheria + capsicum,effective,capsicum,no data available,no data available,contraindication,not yet known
143,marwareedi,general debility nervous debility,general tonic &amp; nervine tonic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
144,marine collagen,cozen,cell activation and growth,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with hypersensitivity,no significant side effects have been observed in therapeutic dosage
145,marham kharish,indicated in- scabies itching pustular piles,"antiseptic, anti-inflammatory and anti-microbial",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
146,malus sylvestris,-,-,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>
147,mahadrakkharist [grape extract],pulmonary fibrosis pulmonary tuberculosis,inhibition of l-kb kinase,anticoagulants,grape seed may increase the risk of bleeding,NO SPECIFIC DATA AVAILABLE,no side effects
148,lutein + zeaxanthin,cataracts retinitis pigmentosa,immunostimulant and photoprotectant properties,drugs,proton-pump inhibitors and lipid lowering drugs,no toxicities,no adverse side effects have been reported
149,liquorice + cascara sagrada + belladona,spermatorrhoea painful micturations nocturnal emission enuresis,preparation,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,contraindication,no significant side effect has been observed in proper dosage
150,azelastine hydrochloride (eye drop),12 years and older,antiallergics,high oral doses,systemic,hypersensitivity,NO SPECIFIC DATA AVAILABLE
151,azelaic acid,mild to moderate inflammatory acne vulgaris,inhibition of microbial cellular protein synthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,individuals who have shown hypersensitivity to any of its components,skin irritation
152,azathioprine,cannot be recommended,incorporation of thiopurine analogues into the dna structure,reduces the neuromuscular blockade,succinylcholine,pregnant women,pancreatitis
153,axitinib,failure of one priorsystemic therapy,inhibit receptortyrosinekinases,strong cyp3a4/5 inducers,grapefruit or grapefruit juice,none,"dizziness (9%),"
154,avanafil,erectile dysfunction,selective phosphodiesterase 5 (pde5) enzyme inhibitor,cyp3a4 inhibitors,alcohol,patients using any form of organic nitrate,"nasal congestion, nasopharyngitis, and back pain"
155,atropine sulfate,"non ulcer dyspepsia, irritable bowel syndrome",anticholinergic effects,antihistamines,antihistamines,.,may progress to circulatory failure and resp depression
156,atracurium besilate,"facilitate mechanical ventilation in intensive care, muscle relaxant in general anaesthesia",acetylcholine,"halothane), certain antibiotics",general anaesth,patients known to be hypersensitive,potentially fatal
157,atosiban acetate,indicated to delay imminent pre-term birth,it acts as an antagonist of gq coupling,inhibit the drug metabolising cytochrome p450 enzymes,labetalol and betamethasone,gestational age below 24 or over 33 completed weeks,high blood sugar
158,atorvastatin calcium,adjunct to diet,selective inhibitor of hmg-coa reductase,antihypertensives or hypoglycemic agents,antihypertensives or hypoglycemic agents,liver disease or unexplained persistent elevations of serum transaminases,"constipation, flatulence, dyspepsia"
159,atorvastatin + ezetimibe,lipid-altering agents,complementary to that of statins,cholestyramine,fenofibrates,hypersensitivity,NO SPECIFIC DATA AVAILABLE
160,atomoxetine hydrochloride,attention deficit hyperactivity disorder (adhd).,unknown,antihypertensive agents,albuterol,history of pheochromocytoma,decreased appetite; headache; nausea
161,atezolizumab,locally advanced or metastatic urothelial carcinoma,leaves the pd-l2/pd-1 interaction intact,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity,NO SPECIFIC DATA AVAILABLE
162,atenolol + chlorthalidone,hypertension,no interference with bioavailability,bradycardia,catecholamine depletor,hypersensitivity,chlorthalidone
163,atenolol,for the long-term management of patients with angina pectoris,no membranestability activity and no partial agonist activity,hypotension and/or marked bradycardia,a catecholamine depletor,those patients with a history of hypersensitivity,"fever, combined with aching and sore throat"
164,astaxanthin,cancer,dual mode of action,absorption rate,"mineral oil, orlistat",known allergies,no severe side effects have been reported yet
165,red clover isoflavones,menopausal women,interact with the human estrogen receptor,anti-coagulants,"contraceptives, estrogen",during therapy with reproductive hormones,no adverse reactions are known at the recommended dosage
166,"qurs mulayin [scammony, lavender, fennel]",qurs mulayin helps to relieve irritable bowel syndrome,stimulates peristalsis,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in therapeutic dosage
167,pumpkin [cucurbita pepo],commonly used by mouth for symptoms of benign prostatic hyperplasia,chemicals in pumpkin seed cause an increase in urination,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,rare
168,psyllium [ispaghula husk] + senna extract,constipation hemorrhoids or piles bowel regulation,laxative effect,potassium deficiency which may increase the effectiveness of cardiac glycosides,cardiac glycosides,contraindicated for children under 12 years old,allergic reaction
169,probiotic combination [4 billion],antibiotic associated diarrhea,chelation of metal ions,none well documented,none well documented,patients at risk of opportunistic infections,no known toxicity or side-effects
170,probiotic combination [3.2 billion],indigestion,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
171,probiotic combination [2.3 billion],urinary tract infection,lactobacillus reuteri rc-14,drug interaction,drug,known hypersensitivity to any component of the formulation,no clinically significant adverse reactions have been observed in therapeutic dosage
172,probiotic combination [2 billion],lactobacillus reuteri ncimb 30242,over-the-counter probiotic supplement,clinically signif icant drug interaction,drug,persons with a hypersensitivity to lactose or milk,no clinically signif icant adverse reactions have been observed
173,proanthocyanidins,amp,antioxidant,drug interaction,drugs,contraindications,no serious side effects have been reported
174,prasarani sandhan,rheumatoid arthritis,anti-inflammatory (antiphlogistic) and astringent activities,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,not reported,no side effect or adverse effect
175,peppermint oil,irritable bowel syndrome,"it is carminative, antibacterial, mucolytic",antacids,antacids,patients with achlorhydria,NO SPECIFIC DATA AVAILABLE
176,penitab,loss of memory dementia,acts as the food for the brain,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been observed
177,pechish,indicated,synergistic action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
178,patrangasav,low back pain,anti-fungal activity in experimental and clinical studies,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no health hazards or side effects are known
179,panax ginseng,primary uses- adaptogen and general tonic,pharmacological,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no known contraindications,no serious side effects or drug interactions have been reported
180,beclomethasone dipropionate + chloramphenicol + clotrimazole + lidocaine,shows excellent pain reduction of lidocaine to treat acute otitis media,amp; lidocaine,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE,amp; clotrimazole ear drops
181,beclomethasone dipropionate (nasal spray),nasal polyps,anti-inflammatory and vasoconstrictor effects,none is known,none is known,infections,dryness and irritation of the nose and throat
182,beclomethasone dipropionate (inhaler),250,unknown,<NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with active or quiescent pulmonary tuberculosis,systemic effects of inhaled corticosteroids
183,beclometasone dipropionate + formoterol fumarate,asthma,glucocorticoid,beta-blockers,eye drops,patients with hypersensitivity,dihydrate
184,basiliximab,some cases oflichen planushave,inhibiting il-2 binding,concomitant admin,concomitant admin,known hypersensitivity,"pain or burning when you urinate easy bruising or bleeding,"
185,barium sulfate,radiopaque contrast media,increases the absorption of x-rays,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known or suspected obstruction of the colon,severe stomach pain
186,baricitinib,limitation of use: use of baricitinib in combination with other,janus kinase (jak) inhibitor,strong organic anion transporter 3 (oat3) inhibitors,strong organic anion transporter 3 (oat3) inhibitors,patients with hemoglobin less than 8 g/dl,not known if baricitinib will harm an unborn baby
187,bambuterol hydrochloride,"bronchial asthma, chronic bronchitis, emphysema",adrenergic 2 receptor agonist,inhibit the effect of -blockers,xanthine,"hepatic impairment, liver cirrhosis or severely impaired liver function","fatigue, nausea, palpitation, headache, dizziness"
188,baloxavir marboxil,treatment of acute uncomplicated influenza,selective inhibitor of influenza cap-dependent endonuclease,dairy products,dairy products,patients with a history of hypersensitivity,"diarrhea (3%), bronchitis (3%)"
189,balanced salt solution,isotonic solution for use in irrigating tissues of the eyes,action potential excitation threshold to facilitate nerve and muscle performance,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity to the products,not been established
190,baclofen,spasticity,stimulating the gaba b receptors,magnesium sulphate or other neuromuscular blocking agents,magnesium sulphate,patients with hypersensitivity,"transient drowsiness, daytime sedation, dizziness, weakness and fatigue"
191,bacitracin zinc + polymyxin b sulfate,pre and post operatively,inhibiting bacterial cell wall development,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,cross sensitizing substances,"allergic reaction, eye irritation, eye redness, itching, swelling"
192,bacillus clausii spores,restores the equilibrium of the intestinal flora changed during diarrhoea,probiotic,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,no side effects have been reported
193,aztreonam,infections caused by susceptible aerobic gram-negative micro-organisms,it inhibits bacterial cell wall synthesis,serum levels of aztreonam,probenecid or furosemide,patients with known hypersensitivity,"anaphylaxis, angioedema"
194,azithromycin dihydrate (ophthalmic),bacterial conjunctivitis,biliary excretion,drug,drug,hypersensitivity,eye irritation
195,stevia rebaudiana,everyone including children who wants to reduce calorie intake,glycosides,not yet known,not yet known,NO SPECIFIC DATA AVAILABLE,no known side effects are found
196,st. johns wort,depression insomnia seasonal affective disorder,unknown,"dry mouth, dizziness and diarrhea",diarrhea,NO SPECIFIC DATA AVAILABLE,"dry mouth, dizziness, constipation and diarrhea"
197,spirulina,"malnutrition, diabetes, arthritis, asthma",high digestibility,conventional medication,medication,those who are hypersensitive to any component of this product,"occasional diarrhea, gastrointestinal discomfort, such as nausea"
198,silymarin [milk thistle],indicated for the treatment and prevention of- liver disease,biologically active component,lipid peroxidation,butyrophenones or phenothiazines,hypersensitivity,mild laxative effect
199,sharbat musaffi,blood purifier,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
200,sharbat amla,vitamin c deficiency diseases,NO SPECIFIC DATA AVAILABLE,no report,no report,patients who are hypersensitive to any of its ingredient,no significant side effects have been observed in therapeutic dosage
201,saw palmetto (500 mg),urination problems in benign prostatic hyperplasia,<NO SPECIFIC DATA AVAILABLE,hormones,"hormones, hormone-like drugs or adrenergic drugs",no absolute contraindications,stomach problems
202,saw palmetto (160 mg),zinc,inhibits action of 5-reductase,estrogen,birth control pills,frst ruling out prostate cancer,hypertension
203,saribadyarista,skin diseases,properties,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,not yet known
204,sanoon babla,pyorrhoea gingivitis toothache,natural ingredients,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper usage
205,sanjivani rasayan,stress,antidepressant and nutritive properties,<,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,no significant side effect
206,sana + revand chini + neem + chirata + tulsi,blood,purifies blood and cures almost every skin disease.,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in therapeutic dosage
207,salep + coconut + poppy seeds + almond,general debility nervous debility,unique combination,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,contraindication,no significant side effect has been observed in the therapeutic dosage
208,"salajeet [mineral pitch, red sage]",polyuria leucorrhoea,antioxidant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no known contraindication,no significant side effect has been observed in proper dosage
209,saffron + sand lizard + nutmeg fruit,sexual debility loss of libido premature ejaculation fatigue,unique preparation,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,children,no significant side effect has been observed in proper dosage
210,betamethasone + calcipotriol,topical suspension,non-steroidal antipsoriatic agent,additive adverse effects,steroids,patients with a history of hypersensitivity to any of the components,folliculitis and burning sensation of skin
211,betamethasone,asthma severe allergic reactions rheumatoid arthritis,short duration of action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,if you have an infection,changing how you act or having feelings of being alone
212,betahistine mesylate,vertigo and dizziness,increasing the blood flow in the inner ear,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,"pheochromocytoma, peptic ulcer",hypersensitivity: hypersensitivity reactions
213,betahistine dihydrochloride,meniere's disease,multifactorial,antihistamines,antihistamines,pheochromocytoma,there is no known serious adverse effects
214,betacarotene + vitamin c + vitamin e,carotene,vitamin a,impair intestinal absorption of vitamins a and k,"oestrogen, tetracycline and aspirin",patients with hypersensitivity,vitamin e
215,besifloxacin,fewer than 10 infections,inhibition of both bacterial dna gyrase and topoisomerase iv,topical ophthalmic,topical ophthalmic,hypersensitivity,"blurred vision, eye pain, eye irritation, eye pruritus and headache"
216,bepotastine besilate,itching associated with signs and symptoms of allergic conjunctivitis,direct h1-receptor antagonist,no drug interactions,drug,patients with a history of hypersensitivity reactions,"eye irritation, headache, and nasopharyngitis"
217,benzyl penicillin,pneumonia,bactericidal,bacteriostatic antibacterials,bacteriostatic antibacterials,hypersensitivity,"nausea, vomiting, stomatitis"
218,benzyl benzoate,indicated for scabies,unknown,allergic dermatitis reactions,"mucous membranes, allergic dermatitis reactions, drying effects in the elderly",broken or irritated skin; neonates; pregnancy,"allergic dermatitis reactions, drying effects in the elderly"
219,benzyl alcohol,6 months of age and older,inhibits lice from closing their respiratory spiracles,drug,no formal drug interaction studies to date.,hypersensitivity to any of the active ingredients.,"irritation, itching, redness, tingling, or numbness"
220,benzydamine hydrochloride,mouthwash,different mechanism of action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients allergic,generally minor
221,benzoyl peroxide,acne vulgaris.,release of free-radical oxygen which oxidizes bacterial protein,"drugs with desquamative, irritant and drying effects",gel,hypersensitivity to benzoyl peroxide,irritation of the skin
222,benzoic acid + salicylic acid,amp,potent keratolytic action,topical drugs,topical drugs,hypersensitivity,"irritation, sensitivity, excessive drying"
223,benzocaine + camphor + methanol + phenol,"sore throat, toothaches, gum pain, canker sores",the underlying molecular mechanism of camphor action is not understood,drug interactions,drug,if you have a history of allergy,"slight burning, tingling, or stinging"
224,benzocaine + butamben + tetracaine hydrochloride,all accessible mucous membrane except the eyes,reversibly blocking nerve conduction,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients who are hypersensitive,aminobenzoate anesthetic
225,-sitosterol,burn leg ulcer surgical wound obstetric wound cracked nipple,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,rare allergic reactions to sesame oil
226,yohimbine hydrochloride,erectile dysfunction,antidopaminergic properties,inadequate blood pressure control,yohimbe,patients with liver and kidney diseases,"tachycardia, tremor, mania and vomiting"
227,white damar + acacia + bole rubra,diarrhoea gastric ulcer duodenal ulcer,valuable natural ingredients,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,there is no known contra-indication,no significant side effect has been observed in therapeutic dosage
228,vitamin e [alpha tocopherol acetate],nutritional deficiency states,antioxidant,impair the absorption of vitamin a &amp,vitamin e,no known contraindications found,"hypertension, fatigue, diarrhea and myopathy"
229,vitamin d3 + vitamin k1 + vitamin k2,normal blood clotting contribute to the maintenance of normal bones,vitamin k2 is necessary for the activation of osteocalcin,co-administration of anticonvulsants,co-administration of anticonvulsants,patients with known hypersensitivity to any of the ingredients,well tolerated in recommended dose
230,vaskar laban [piper + zingiber + cinnamomum],"loss of appetite, indigestion",cinnamomum zeylanicum,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,not yet known
231,valerian root,insomnia,anti-inflammatory and muscle relaxant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,no significant side effect has been observed in therapeutic dosage
232,tocotrienol + tocopherol,antioxidant,alpha-tocopherol,cholesterol-lowering medication,cholesterol-lowering medication,patients with known hypersensitivity to any of the ingredients,well tolerated in recommended dose
233,"tila jadeed [madar, mace arillus, nutmeg nut]",male organ,increases the elasticity of male organ,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,no known contraindication,no significant side effect has been observed in proper dosage
234,tart cherry,gout hyperuricemia,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known hypersensitivity,occasionally may cause gastrointestinal discomfort
235,tabkheer,gastroesophageal reflux disorders,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been reported
236,"suzark [chir pine, chickpea, pearl]",gonorrhea burning sensation during urination urinary tract infection,special preparation,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
237,suranjan,gout rheumatoid arthritis,rheumatism,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
238,steviol glycoside,everyone,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
239,benzocaine,temporary relief of pain due to minor injury or irritation of the mouth,blocks the initiation and conduction of nerve impulses,anticholinesterases,anticholinesterases,epiglottis,"allergies, swelling in the mouth or throatetc"
240,benzathine penicillin,prophylaxis of penicillin-sensitive secondary infections especially in children,binding proteins,potentially hazardous interactions,no potentially hazardous interactions have been described.,hypersensitivity,"moderate burning discomfort, local pain, and deep muscle soreness and tenderness"
241,bisacodyl,constipation,colon to stimulate peristalsis and on the small bowel and colon,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,severe dehydration,free of side effects
242,biphasic insulin aspart [rdna],adults and children,blood glucose lowering agent with an earlier onset and an intermediate duration of action,alcohol,alcohol,during episodes of hypoglycemia,"hypoglycemia, lipodystrophy"
243,bimatoprost + timolol,mono-therapy,beta-adrenergic receptor antagonist,thiseye drops,digitalis glycosides,patients with known hypersensitivity,"decreased visual acuity, eye discomfort"
244,bimatoprost,ocular hypertension,mimicking the action of a naturally-occuring prostaglandin,drug interactions,drug,known hypersensitivity,"increased sensitivity to light, dizziness"
245,bilastine,allergic rhino-conjunctivitis,histamine antagonist,lorazepam,alcohol,patients with hypersensitivity,"headache, dizziness, somnolence and fatigue"
246,bicarbonate component [hco3 hemodialysis solution],"renal failure, chronic renal failure and haemodialysis",neutralises the hydrogen ion concentration,toxicity,sodium bicarbonate,known hypersensitivity to any of the ingredients,<NO SPECIFIC DATA AVAILABLE
247,bicalutamide,not approvedfor use alone or with other treatments,it competitively inhibits the action of androgens,increased adverse effects when used with drugs that may inhibit oxidation,increased adverse effects when used with drugs that may inhibit oxidation,"females, children, pregnancy and lactation","cough, pharyngitis, bronchitis, pneumonia"
248,betrixaban,adult patients,factor xa inhibitor that selectively blocks the active site of factor xa,p-gp inducers,p-gp inducers,patients with active pathological bleeding,"most common adverse reaction is bleeding, epidural or spinal hematoma"
249,bevacizumab,indiated for - metastatic colorectal cancer,binds vegf and prevents the interaction of vegf to its receptors,irinotecan,irinotecan,manufacturers labeling,"jaw pain/swelling/numbness, loose teeth, or gum infection."
250,betaxolol hydrochloride,alone or in combination with other intraocular pressure-lowering medication,reduction of aqueous production,elevated intraocular pressure,a miotic,patients with a history of overt cardiac failure,"bradycardia, heart block, congestive heart failure"
251,betamethasone valerate,children and adults,slight degree of mineral corticosteroidactivity,significant drug interactions,cream/ointment,hypersensitivity to any of the ingredients in the preparation,"dryness, itching, burning, skin thinning, local irritation"
252,betamethasone sodium phosphate,steroid responsive,it is rapidly hydrolyzed to betamethasone,drug,drug,NO SPECIFIC DATA AVAILABLE,reduced visual acuity
253,betamethasone dipropionate + salicylic acid,scalp preparation,keratolytic properties,side effects,scalp preparation,fungal or bacterial skin infections,topical corticosteroids
254,betamethasone dipropionate,resistant or severe corticosteroid-responsive dermatoses,topical corticosteroid,no evidence of any kind of interaction,no evidence of any kind of interaction,viral infections of the skin,mild to moderate
255,betamethasone + neomycin sulphate (topical),burns,broad-spectrum bactericidal amino-glycoside,significant drug interactions,cream/ointment,skin lesions caused by infection with viruses and fungi,"acne, thinning and dilatation of blood vessels"
256,betamethasone + phenylephrine + lignocaine,local anorectal conditions,lidocaine,not known,not known,primarily infected skin lesions caused by viral infections,systemic absorption
257,betamethasone + neomycin sulphate (e/e),ear : otitis externa,betamethasone has a 16-methyl group,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,when the ear drum is perforated,cataract
258,betamethasone + gentamicin,"wet, oozing primary infections, and greasy, secondary infections",broad spectrum anti-bacterial effect,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,corticosteroid therapy
259,betamethasone + clotrimazole,topical treatment of inflammatory dermal infections,the exact mechanism of action of corticosteroids is not clearly known,no information is available of drug interaction,drug,bacterial or viral infections,paresthesia
260,betamethasone + clotrimazole + gentamicin,corticosteroid,broad spectrum antifungal activity,toxicity,nephrotoxic drugs,patients with a history of sensitivity reactions to any of its components,adverse reactions
261,benzalkonium chloride,eye-drops,quaternary ammonium antiseptic and disinfectant,hyaluronic acid,skin preparation before injections of viscoelastic solutions,incompatible with soaps and other anionic surfactants,nausea and vomiting
262,bendamustine,has not been established,unknown,tobacco smoking,tobacco smoking,anaphylaxis and anaphylactoid reactions,neutropenia
263,saffron + mace arillus + nutmeg fruit,amp,aphrodisiac,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,children,no significant side effect has been observed in proper dosage
264,bempedoic acid,heterozygous familial hypercholesterolemia,adenosine triphosphate-citrate lyase,simvastatin,simvastatin,NO SPECIFIC DATA AVAILABLE,elevated liver enzymes
265,saccharomyces boulardii,read,the production of intestinal polyamines,reduce the effectiveness,medications,patients with a history of hypersensitivity,it can cause gas in some people
266,rohitakarista,jaundice,antibacterial activities,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,not yet known
267,rhubarb + ginger,heart burn abdominal pain due to gases nausea,improves the activity of digestive system,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in therapeutic dosage
268,rehmin,leucorrhoea weakness of uterus,"astringent, anti-inflammatory and emmenagogue",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
269,azithromycin dihydrate,sexually,binding to the 50s ribosomal subunit of susceptible microorganisms,ergotism,antacid,patients with hepatic diseases,"nausea, vomiting, abdominal discomfort"
270,azilsartan medoxomil + chlorthalidone,arb monotherapy,diuretic,nsaids increase risk of renal dysfunction,nsaids,patients with anuria,fetal toxicity hypotension in volume- or salt-depleted patients
271,bromhexine hydrochloride,respiratory tract disorders associated with productive cough,oral mucolytic agent,significant interactions with other drugs,drugs,hypersensitivity,"headache, vertigo (dizziness) and allergic reactions"
272,bromfenac sodium,patients who have undergone cataract extraction,inhibiting cyclooxygenase 1 and 2,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity to any ingredients of the formulation,"abnormal sensation in eye, conjunctival hyperemia, eye irritation"
273,bromelain + trypsin,"inflammatory pains, soft tissue inflammation, edema associated with trauma and surgery",protease enzymes,drug,drug,hypersensitivity,pain and burning
274,bromazepam,bromazepam is indicated in- emotional disturbances,bromazepam binds to the gaba-a receptor,alcohol,alcohol,patients with known hypersensitivity to bromazepam,"fatigue, drowsiness, muscle weakness, numbed muscle"
275,brivaracetam,only in adult patients,not known,added therapeutic benefit,levetiracetam,hypersensitivity,"somnolence/sedation, dizziness, fatigue, and nausea"
276,brinzolamide + brimonidine tartrate,open-angle glaucoma or ocular hypertension,alpha 2 adrenergic receptor agonist,drug interactions,high-dose salicylate therapy,hypersensitivity,"blurred vision, eye irritation, bad taste and dry mouth"
277,brinzolamide + timolol,monotherapy,the exact mechanism whereby timolol reduces ocular pressure is still not known,oral ca-channel blockers,oral ca-channel blockers,severe allergic rhinitis,"irritation, foreign body sensation"
278,brinzolamide,"monotherapy, or as adjunctive therapy to beta-blockers",inhibits aqueous humor formation and reduces elevated intraocular pressure,drug interactions,oral carbonic anhydrase inhibitors,patients who are hypersensitive,blepharitis
279,brimonidine tartrate + timolol maleate,glaucoma or ocular hypertension,dual mechanism of action,specific drug interaction studies,drug,patients with hypersensitivity,allergic conjunctivitis
280,brimonidine tartrate,chronic open-angle glaucoma or ocular hypertension,dual mechanism of action,circulating catecholamines,beta-blockers,patients with hypersensitivity,ocular allergic reactions
281,brigatinib,patients with anaplastic lymphoma kinase,tyrosine kinase inhibitor,strong cyp3a inducers,grapefruit or grapefruit juice,patients with known hypersensitivity,hypertension
282,brexpiprazole,use as an adjunctive therapy to antidepressants,unknown,<,NO SPECIFIC DATA AVAILABLE,hypersensitivity,<
283,bortezomib,treatment of patients with multiple myeloma,26s proteasome,toxicities or reduced efficacy,melphalan-prednisone,patients with hypersensitivity,most commonly reported adverse reactions
284,bosentan monohydrate,functional class ill,dual endothelin receptor antagonist,inhibitors,rifampicin,pregnancy,"anaemia, haemoglobin decrease"
285,bleomycin sulfate,squamous cell carcinoma : head and neck,unknown,may reduce the absorption of phenytoin,may reduce the absorption of phenytoin,acute pulmonary infection or greatly reduced lung function,injection site reactions
286,bivalirudin,patients undergoing ptca/pci or pci with hits/hitts,directly inhibits thrombin,risks of major bleeding events,heparin,active major bleeding &amp; hypersensitivity,"fever,infection, sepsis"
287,bisoprolol hemifumarate,not recommended for the emergency treatment of hypertensive crises,selectively blocks 1 adrenergic receptor,not be combined with other -blocking agents,other -blocking agents,patients with cardiogenic shock,doctor informed
288,bisoprolol fumarate + hydrochlorothiazide,hypertension,antihypertensive effects of these agents are additive,excessive reduction of sympathetic activity,calcium antagonists,"cardiogenic shock, overt cardiac failure",mild and transient
289,bisoprolol fumarate + amlodipine besilate,concurrently at the same dose level as in the combination,dihydropyridine calcium antagonist,combinations,eye drops,hypersensitivity,asthma
290,bismuth subsalicylate,upset stomach indigestion heartburn nausea and diarrhea,antacid action,drugs to thin the blood,oral therapy for diabetes,hypersensitive,black stool and black tongue
291,azilsartan medoxomil,either alone or in combination with other antihypertensive agents,selective at1 subtype angiotensin ii receptor antagonist,drug interactions,amlodipine,patients with diabetes,"nausea, asthenia"
292,azelastine hydrochloride + fluticasone propionate,6 years of age and older,not known,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,"dysgeusia, epistaxis, and headache"
293,azelastine hydrochloride (nasal spray),adults and pediatric patients 5 years and older,histamine h1 receptor antagonist activity,alcohol,alcohol,patients with a known hypersensitivity,"headache, dizziness, sneezing, nosebleed, nausea"
294,nux-vomica + black pepper + long pepper,rheumatoid arthritis,effective natural ingredients,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in the therapeutic dosage
295,nimbadi churna,skin diseases,antibacterial,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,not yet known,no known side effect
296,nigella sativa [black seed oil],"(ldl, tg) (hdl",", , , - , , , , , , , , , ,",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,","
297,neem,viral skin infections,"antiseptic, astringent, anthelmintic",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindication,no significant side effect
298,natural medicine for diabetes,tablet,unani formulation,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,there is no known contraindication,no significant side effect has been observed in proper dosage
299,aspirin + dipyridamole,antiplatelet agent,anti-platelet agents,cholinesterase inhibitors,cholinesterase inhibitors,children or teenagers with viral infections,nausea and diarrhea
300,aspirin,prophylaxis against arterial occlusive events,anti-inflammatory and antipyretic properties,salicylates,salicylates,breast-feeding and active peptic ulcer,mild
301,calcipotriol monohydrate,chronic stable plaque type psoriasis vulgaris in adult patients,non-steroidal antipsoriatic agent,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known disorders of calcium metabolism,allergic reactions
302,calamine + zinc oxide + glycerine,plants,mild astringent and antipruritic,drug interactions,drug,history of hypersensitivity to any of the components.,"severe dizziness, trouble breathing"
303,caffeine citrate,apnea of prematurity,not known,concurrent use of these drugs is not recommended,drugs which are reported to decrease caffeine elimination,NO SPECIFIC DATA AVAILABLE,"rash, skin breakdown, kidney failure"
304,cabozantinib,hepatocellular carcinoma,metabolism,st. john's wort,grapefruit or grapefruit juice,patients with known hypersensitivity,proteinuria osteonecrosis of the jaw wound complications
305,cabergoline,either idiopathic or due to pituitary adenomas,reducing the amount of prolactin,d2-antagonists,d2-antagonists,uncontrolled hypertension or known hypersensitivity,"pathological gambling, increased libido, and hypersexuality"
306,cabazitaxel,patients with hormone refractory metastatic prostate cancer,inhibiting disassembly,vaccination with a live attenuated vaccine,vaccination with a live attenuated vaccine,yellow fever vaccine,diarrhea
307,butoconazole nitrate,non-pregnant women,unknown,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a history of hypersensitivity,adverse events
308,butenafine hydrochloride,superficial dermatophytosis,the exact mechanism of action has not been established,drug interactions,cream,individuals who have known or suspected sensitivity to this cream or any of its components,hypersensitivity reactions
309,butamirate citrate,acute cough of any etiology,antitussive action,expectorants,expectorants,hypersensitivity to the active ingredient,"rash,nausea,diarrhoea and vertigo"
310,busulfan,chronic myeloid leukaemia,alkylation,decreased clearance,paracetamol,patient with chronic myelogenous leukemia whose disease was resistant to prior therapy,cns effects including convulsions.
311,bupropion hydrochloride,smoking cessation,noradrenergic and/or dopaminergic mechanisms,alcohol,alcohol,patients who have shown an allergic response to bupropion,"fever, dry mouth, headache or migraine"
312,bupivacaine hydrochloride + dextrose,amp,amp; dextrosehas a rapid onset of action and long duration,toxic effects,drugs,patients with a known hypersensitivity to it,nerve block
313,bupivacaine hydrochloride,procedures,route and dose-dependent): 1-17 min,toxic effects,lidocaine,intravenous regional anaesthesia;,anaphylactoid reactions
314,bumetanide,renal disease including the nephrotic syndrome,inhibits the sodium-potassium atpase pump,blood uric acid,blood uric acid,severe hypokalaemia,"headache, dizziness, fatigue, postural hypotension"
315,budesonide + formoterol fumarate,long-acting bronchodilators,formoterol fumarate dihydrate,cyp3a4 inhibitors,potent cyp3a4 inhibitors,lactose,"tremor, palpitations, and headache"
316,budesonide (tablet),mild to moderate ulcerative colitis,glucocorticoid activity and weak mineralocorticoid activity,cytochrome p450 3a4 inhibitors,grapefruit juice,NO SPECIFIC DATA AVAILABLE,"headache, nausea, upper abdominal pain"
317,budesonide (nebuliser suspension),maintenance treatment and as prophylactic therapy of asthma,topical anti-inflammatory potency,drug interactions,drug,hypersensitivity,"sneezing, headache, sore throat, dry mouth, nausea"
318,budesonide (nasal spray),nasal polyposis. prevention against nasal polyps after polypectomy,anti-inflammatory potency,drug interaction,drug,NO SPECIFIC DATA AVAILABLE,"sneezing, headache, sore throat, dry mouth, nausea"
319,budesonide (inhaler),not indicated for the relief of acute bronchospasm,corticosteroid,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,primary treatment of status asthmaticus or other acute episodes of asthma,"headache, flu-like syndrome"
320,bromocriptine mesylate,prolactin secreting adenomas,dopamine receptor agonist,ergot alkaloids,ergot alkaloids,in patients being treated for hyperprolactinemia,"nausea, headache, dizziness, fatigue, lightheadedness, vomiting"
321,aspartame,diet supplement,metabolized as a protein,drug,drug,"complete biliary obstruction, hypersensitivity",increased bleeding tendency
322,articaine hydrochloride + epinephrine,both simple and complex dental procedures,vasoconstrictor,concurrent use,phenothiazines and butyrophenones,patients who are hypersensitive to products containing sulfites,positive blood aspiration into syringe
323,artesunate,both adults and children,metabolized to the active dha,artemisinin drugs,antimalarial drugs,hypersensitivity to artemisinin and its derivatives or its inactive ingredients,no adverse effects have been reported
324,licorice + yellow silk cotton + mastic tree,hyperacidity gastric ulcer duodenal ulcer,cochiospermum religiosum) and other precious natural ingredients,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
325,licorice + vasaka + basil + peppermint,influenza,medicinal plants of time tested proven efficacy,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
326,lavendar [lavendula stoechas],chronic catarrh headache,it strengthens the brain,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
327,kusta qalyee [calcined stannum],spermatorrhoea oligospermia,"unani medicine, prepared with the valuable natural ingredients",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no known contraindication,no significant side effect has been observed in proper dosage
328,khakshi,in- fever influenza,immunostimulant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
329,anastrozole,hormone receptor positive post-menopausal women,selective and competitive inhibition of the aromatase enzyme,tamoxifen and/or other therapies containing estrogen,tamoxifen,NO SPECIFIC DATA AVAILABLE,"hair thinning, allergic reactions"
330,ampicillin sodium,infections of thegastrointestinal tract,binding to 1 or more of the penicillin-binding proteins,bacteriostatic antibacterials,chloroquine,hypersensitivity,moderate and transient increase in transaminases
331,amphotericin b,refractory,disruption of membrane integrity and ultimately cell death,azole antifungals,azole antifungals,hypersensitivity,"fever, chills, convulsions, malaise"
332,calcium orotate,"arthritis, psoriasis, lupus, spondylitis",facilitating the intracellular uptake of calcium,osteoporosis,mineral oil,"incomplete or infrequent bowel movements, kidney stone, kidney disease","loss of appetite, upset stomach, constipation, nausea, vomiting"
333,calcium lactate gluconate + coral calcium + vitamin c + vitamin d3,housebound and hospitalized elderly subjects,vitamin d3,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>
334,calcium lactate gluconate + calcium carbonate + vitamin d3,prevention and treatment of osteoporosis,calcium and vitamin d,consultations,calcium supplements,hypercalcemia and hyperparathyroidism,"nausea, vomiting, decreased appetite dry mouth and drowsiness, skin rash"
335,calcium lactate gluconate + calcium carbonate + vitamin c + vitamin d3,housebound and hospitalized elderly subjects,neutralizing hydrochloric acid in gastric secretions,hypercalcemia,"oxalic acid, phosphate or phytinic acid",severe renal failure and hypersensitivity to any of the tablet ingredients,occasional skin rash has been reported
336,calcium lactate gluconate + calcium carbonate + vitamin c,adjuvant in colds and influenza.,reducing agent,milk-alkali syndrome and hypercalcaemia,milk,"hyperparathyroidism, vitamin-d overdosage",urinary tract
337,calcium lactate,"heartburn, calcium supplement, calcium deficiencies",enzymatic reactions,increased risk of hypercalcaemia,atenolol,hypercalcaemia and hypercalciuria,milk-alkali syndrome
338,calcium gluconate,severe hypermagnesaemia,helps facilitate nerve and muscle performance as well as normal cardiac function,decreases effects of calcium-channel blockers,milk,patients with calcium renal calculi or history of renal calculi,"chalky taste, hot flushes and peripheral vasodilation"
339,calcium folinate [folinic acid],to treat the megaloblastic anemia due to folate deficiency,co-enzyme for nucleic acid synthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known hypersensitivity,fits and fainting
340,calcium dobesilate + lidocaine + dexamethasone,in cases of hemorrhoidectomy,anti-inflammatory and antipruritic actions,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,hypersensitivity reactions
341,calcium dobesilate,hemorrhoidal syndrome,capillary fragility,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pregnancy and lactation,reversible after treatment withdrawal
342,calcium carbonate + vitamin d3 + multimineral,lactation deficiency state,macronutrients for bone,interaction,aluminium or magnesium containing antacids &amp; other calcium supplements,"hypercalcaemia, hyperthyroidism",micronutrient are rare
343,calcium carbonate [elemental source] + vitamin d3,phosphate binder in chronic renal failure,calcium carbonate and vitamin d3,magnesium,aluminium or magnesium containing antacids &amp; other calcium supplements,"hypercalcaemia, hyperthyroidism",constipation
344,calcium carbonate [eggshell source] + vitamin d3,rickets,vitamin d3 helps the body to absorb calcium,consultations,"spinach, milk and milk products",severe renal insufficiencies concomitant digoxin therapy,eggshell calcium is safe for long-term use
345,calcium carbonate [coral source] + vitamin d3,"childhood diet, rickets, pregnancy &amp; lactation, elderly patients",aids in the absorption of calcium from gi tract,spinach,"spinach, cereals, milk",hyperparathyroidism,hypercalcaemia
346,calcium carbonate [algae source] + vitamin d3,deficiency,amp; vitamin d3,increased risk of hypercalcemia,thiazides,metastatic calcification hypersensitivity,vitamin d3
347,calcium carbonate,increasingly often to treat hyperphosphataemia in chronic renal failure,chemical reaction,hypercalcaemia,vitamin d therapy,"patients with sarcoidosis, renal or cardiac disease",irritating to the gi tract. it may also cause constipation
348,calcium acetate,hyperphosphatemia in end stage renal disease (esrd),combines with dietary phosphate to form insoluble calcium phosphate,bioavailability of tetracycline,calcium acetate,patients with hypercalcemia,vascular or soft-tissue calcification
349,calcium + vitamin d3 + vitamin c + vitamin e + multimineral,post-menopausal osteoporosis,antioxidant,calcium salts may reduce the absorption of fluoride,thiazide diuretics,mild to moderate renal failure or mild hypercalciuria,micronutrients are rare
350,calcitriol + calcium citrate,amp; calcium,increasing serum calcium levels,decreased absorption with corticosteroids,milk,pregnancy &amp; lactation,ectopic calcification; hypertension
351,calcitriol,post-menopausal osteoporosis,promotes intestinal absorption of calcium and regulates bone mineralization,hypercalcemia,magnesium containing drugs,patients with known hypersensitivity to any of its ingredients,"dystrophy, fever, polyuria, dehydration"
352,amoxicillin trihydrate,lansoprazole,inhibition of biosynthesis of cell wall,estrogen reabsorption,gut flora,penicillin hypersensitive patients,"diarrhoea, indigestion or occasionally rash"
353,amoxicillin + clavulanic acid,co-amoxiclav,(3-lactamase inhibitor,allergic skin reactions,co-amoxiclav. in common with other broad-spectrum antibiotics,penicillin-associated cholestatic jaundice,uncommon and mainly of a mild and transitory nature
354,herbal cough syrup [glycyrrhiza glabra],indicated in- cough,licorice,<,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
355,herbal cough syrup [adhatoda vasica],all types of cough,relieves cough &amp; bronchial spasm,no report,no report,patients who are hypersensitive,"in high dose diarrhea, vomiting may occur"
356,hazmina,digestive and carminative,tones up the digestive system,no report,no report,contraindication,no significant side effect has been observed in proper dosages
357,habb-e-nishat,erectile dysfunction,aphrodisiac,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
358,guggul + barberry + chebulic myrobalan,haemorrhoid,synergistically acting,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,there is no known contra-indication,no significant side effect has been observed in therapeutic dosage
359,aminocaproic acid,orally or intravenously,inhibition of plasminogen activators,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,when there is evidence of an active intravascular clotting process,"nausea, vomiting, stomach pain, diarrhea"
360,amino acid keto analogues,chronic kidney disease,intake of essential amino acids while minimizing the amino-nitrogen intake,disturbed absorption of the active substances,estramustine,hypercalcaemia,reduced
361,amino acid + glucose + electrolytes,adult and pediatric patients needing iv nutrition,total parenteral nutrition,interact with other medicaments,solution,"patients with inborn errors of amino acids metabolism, severe liver damage &amp",hypertonic infusion solution
362,amino acid + dextrose + eloctrolytes,glucose and electrolytes in adult and pediatric patients needing iv nutrition,NO SPECIFIC DATA AVAILABLE,interact with other medicaments,amino acid,patients with hyperosmolar nonketotic diabetic coma,thrombophlebitis may occur when peripheral veins are used
363,carboxymethylcellulose sodium,lubricant,ocular lubricant,not known,not known,patients with known hypersensitivity to any ingredient of the product,"burning, eye irritation or pruritus, visual disturbance, ocular discharge"
364,carboprost tromethamine,contraindicated,myometrial contractions,concomitant use with other oxytocic agents,concomitant use with other oxytocic agents is not recommended,"patients with active cardiac, pulmonary, renal or hepatic disease","vomiting, nausea, diarrhea and pyrexia"
365,carboplatin,one,it modifies the cell cycle by interfering with dna structure and function,liver vaccine,liver vaccine,patients with severe bone marrow depression or significant bleeding,"bone marrow suppression, gastrointestinal effects"
366,carbonyl iron + folic acid + zinc sulfate + vitamin b complex + vitamin c,this capsule,vitamin b complex is required for the growth and development of unborn babies,carbonyl iron decreases the absorption of tetracycline antibiotics,carbonyl iron decreases the absorption of tetracycline antibiotics,haemolytic anaemia,allergic sensitization
367,carbonyl iron + folic acid + zinc sulfate,"iron, folic acid and zinc deficiency especially during pregnancy and lactation","carbonyl iron, folic acid and zinc sulphate monohydrate",absorption of tetracycline antibiotics,carbonyl iron decreases the absorption of tetracycline antibiotics,hypersensitivity to any of its component or those with iron overload,rarely there may be allergic reactions
368,carbonyl iron + folic acid,megaloblastic anemias,producing red blood cells as well as transporting oxygen in the body,alcohol,alcohol,"hypersensitivity, intolerance to the drug",constipation diarrhea stomach cramps upset stomach allergic reactions
369,carbocisteine,"acute bronchitis, chronic bronchitis, bronchial asthma",mucolytic action happens in several mechanisms,hazardous nor therapeutically useful interactions,therapeutically,active peptic ulceration and in patients with hypersensitivity,"headache, heartburn and skin rash"
370,carbimazole,thyroidectomy,antithyroid action,iodine or iodine excess,iodine or iodine excess,hypersensitivity,nausea
371,carbetocin,following delivery of the infant,similar to that of oxytocin,drug interactions,drug,hypersensitivity to oxytocin or carbetocin,"back pain, dizziness, metallic taste, anaemia"
372,carbamazepine,partial and secondary generalized tonic-clonic seizures,unknown mechanisms,metabolism,metabolism,allergic to one or any of its ingredients,"dizziness, drowsiness, ataxia, dry mouth"
373,captopril,cardopril is effective alone or in combination,competitively inhibits the conversion of angiotensin i,k supplements,k supplements,pregnancy,"neutropenia, anaemia and thrombocytopenia"
374,capsaicin,"rheumatoid arthritis, osteoarthritis",not fully understood,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,transient burning on application
375,caprylic + capric triglyceride,"repairs, restores &amp; protects dry skin &amp",physiological lipids to protect &amp; maintain healthy skin,drug interactions,drug,hypersensitivity,"rash, redness and itchiness"
376,capecitabine,adjuvant colon cancer,thymidine phosphorylase,food,food,pregnant or breast-feeding,"fever, infection, chest pain"
377,candesartan cilexetil + hydrochlorothiazide,hypertension,combines an angiotensin ii receptor blocker,oral contraceptives,oral contraceptives,patients who are hypersensitive to any component of this product,"headache, upper respiratory tract infection, back pain, influenza-like symptoms"
378,candesartan cilexetil,"hypertension, heart failure with impaired left ventricular systolic function",angiotensin ii receptor (type at1) antagonist,significant drug interactions,oral contraceptives,"pregnancy, breast-feeding, cholestasis",mild
379,canagliflozin hemihydrate,adults with type 2 diabetes mellitus,subtype-2 sodium-glucose co-transport protein,ugt inducers,ugt inducers,on dialysis patients,"low blood pressure, increases potassium blood levels"
380,camphor + menthol + oil clove + oil eucalyptus + oil turpentine,headache,eucalyptus oil acts as a cough suppressant,drug interactions,drug,history of convulsion,"redness, irritation, rash or pruritis"
381,calcium polystyrene sulfonate,hyperkalemia due to acute and chronic renal failure,removing potassium ions which are excreted in the feces,"sorbitol, digitalis drugs, cation donating agents",sorbitol,neonates,acute bronchitis and bronchopneumonia have been reported
382,calcium pantothenate,burning feet syndrome,enzymatic reactions,drug interactions,drug,patients with hypercalcaemia,irritation
383,amino acid + d-sorbitol + electrolytes,intravenous nutrition,"electrolytes, which are necessary as the nitrogen source for parenteral nutrition",interact with other medicaments,amino acid,patients with hyperosmolar nonketotic diabetic coma,hypertonic infusion solutions
384,dinar,jaundice hepatitis,prebiotic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,there is no known contraindication,no significant side effect has been observed in proper dosage
385,devils cotton + ashoka bark + aswagandha,leucorrhoea metritis anaemia,solely on female reproductive system,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,children,no significant side effect has been observed in proper dosage
386,devil's claw,2400 mg/day,chemicals,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"nausea, vomiting, abdominal pain, headaches, ringing in the ears"
387,datura + rhubarb + ginger,tablet,analgesic,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
388,date palm + betel nut + acacia,weakness of uterus leucorrhoea,medicinal plants,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in proper dosage
389,alpha lipoic acid,tablet,antioxidant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,people receiving treatment for diabetes,NO SPECIFIC DATA AVAILABLE
390,alogliptin benzoate,adults with type-2 diabetes mellitus,dpp-4 inhibitor,significant drug-drug interactions,renally excreted drugs,"anaphylaxis, angioedema","nasopharyngitis, headache and upper respiratory tract infection"
391,almotriptan,12 to 17 years of age,almotriptan binds to specific serotonin receptors,selective serotonin reuptake inhibitors,selective serotonin reuptake inhibitors,"patients with a history, symptoms or signs of ischaemic heart disease","cardiac reactions, including myocardial infarction"
392,almitrine bismesylate + raubasine,amp,amp,not to be used concurrently with other almitrine-containing preparations,monoamine oxidase inhibitor,severe hepatic impairment,"weight loss, nausea, sensations of heaviness or burning in the stomach"
393,allylestrenol,threatened abortion,no oestrogenic or androgenic properties,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,undiagnosed vaginal bleeding toxaemia of pregnancy,"vomiting, nausea, and sometimes epigastric discomfort"
394,cefprozil,mild to moderate infections caused by susceptible strains,in vitro against both gram positive and gram negative bacteria,probenecid doubled the auc,probenecid doubled the auc,hypersensitivity,"diarrhea, nausea, vomiting, abdominal pain"
395,cefpodoxime proxetil + clavulanic acid,infections,clavulanic acid is a natural inhibitor of beta lactamase,h2 blockers,antacids or h2 blockers,patients with known hypersensitivity to cephalosporins,"diarrhea, vomiting and abdominal pain"
396,cefpodoxime proxetil,infections caused by susceptible microorganism,prodrug,h2 blockers reduces peak plasma levels,high doses of antacids,patients with known allergy to cephalosporins,few
397,cefpirome sulphate,severe infections,inhibiting biosynthesis and arresting cell wall assembly,drug interactions,drug,patients with known allergy to the cephalosporin group of antibiotics,there are no predictable life threatening effects
398,cefoxitin,patients with pelvic inflammatory disease,binding to 1 or more of the penicillin-binding proteins,nephrotoxic agents,nephrotoxic agents,hypersensitivity,"nausea, vomiting, diarrhoea"
399,cefotaxime,infections,binds to 1 or more of the penicillin binding proteins,increased nephrotoxicity,aminoglycoside antibiotics,patients who have shown hypersensitivity,"candidiasis, rashes, fever"
400,cefoperazone sodium,infections when caused by susceptible organisms,inhibition of bacterial cell wall synthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known allergy to the cephalosporin,hypersensitivity
401,cefixime trihydrate,uncomplicated urinary tract infections,it kills bacteria by interfering in the synthesis of bacterial cell wall,prothrombin time,warfarin,hypersensitivity,"nausea, abdominal pain"
402,cefepime hydrochloride,febrile neutropenic patients,bactericidal,nephrotoxicity,aminoglycosides,patients who have shown immediate hypersensitivity reactions,contraindicated in patients who have shown immediate hypersensitivity reactions
403,cefditoren,mild to moderate infections in adults and adolescents,prodrug which is hydrolyzed by esterases during absorption,ethinyl estradiol,intravenous,patients with milk protein hypersensitivity,"diarrhea, nausea, headache, abdominal pain"
404,cefdinir,community acquired pneumonia,binds to 1 or more of the penicillin-binding proteins,probencid,iron supplement,patients with known allergy to the cephalosporin class of antibiotics,"vomiting, headache, rash"
405,cefazolin sodium,infections,inhibiting transpeptidase enzyme,renal tubular secretion,probenecid,patients with known allergy to the cephalosporin group of antibiotics,injection site reactions
406,cefadroxil monohydrate,bacteria,binding to 1 or more of the penicillin-binding proteins,drug interaction with other drugs,drug interaction with other drugs,patients with a history of hypersensitivity,gastrointestinal disturbances and hypersensitivity phenomena
407,cefaclor monohydrate,"otitis media, lower respiratory tract infections",stability against b-lactamase inactivation,aminoglycoside antibiotics,aminoglycoside antibiotics,patients with known allergy to the cephalosporin group of antibiotics,"allergic reactions such as eruptions, pruritis and urticaria"
408,casirivimab + imdevimab,treatment of covid-19,unmodified in the fc regions,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity to the active substances,NO SPECIFIC DATA AVAILABLE>
409,carvedilol,in patients unable to tolerate an ace inhibitor,non-selective antagonism of -adrenergic receptors,adverse effects,warfarin,patients with decompensated heart failure,reported
410,carmellose sodium,dry eye,NO SPECIFIC DATA AVAILABLE,eye drops,eye drops,hypersensitive,eye irritation
411,carisoprodol,used as an adjunct in physical therapy in injuries,it has no direct action on muscle itself,cns depressants,alcohol,patients with a history of acute intermittent porphyria,"drowsiness, dizziness and headache"
412,carboxymethylcellulose sodium + hypromellose,this medication,polymer in nature,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known sensitivity or allergy,"blurred vision, matting or stickiness of eyelashes"
413,carboxymethylcellulose sodium + glycerin,sterile eye drops,lubricating and hydrating protective shield,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,minor burning/ stinging/ irritation
414,bitter melon [korola],natural source of vitamin c,numerous reddishbrown or white seeds encased in scarlet arils,antidiabetic agent,antidiabetic agent,no absolute contraindication,no significant side effect
415,biotin,dermatitis,carboxylation of pyruvate and acetyl-coa,excessive consumption of raw egg whites,raw egg whites,patients with known hypersensitivity to any of the ingredients,no biotin toxicity
416,bilberry fruit [vaccinium myrtillus l],retinopathy,inhibits enzymatic cleavage of collagen,may interact with warfarin or other antiplatelet drugs,antiplatelet drugs,none known,none known
417,belgiri [bael fruit + connessi bark],diarrhoea amoebiasis,pathogenic microbes,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no known contraindication,no significant side effect has been observed in the therapeutic dosage
418,barsina,vitiligo or leucoderma,valuable natural ingredients,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been reported
419,adhatoda vasica + centella asiatica,this syrup,the soothing action of vasac,data,no data available,patients known to have hypersensitivity,there is no data available
420,adenosine,intravenous,nonpyrogenic solution for rapid bolus intravenous injection,additive or synergistic depressant effects,verapamil,second- or third-degree a-v block,"prolonged asystole, ventricular tachycardia"
421,adefovir dipivoxil,adults with evidence of active viral replication,diester prodrug of adefovir,urinary recovery,urinary recovery,patients with previously demonstrated hypersensitivity to any of the components,"weakness, headache, stomach pain and nausea"
422,adapalene + benzoyl peroxide,amp,amp,irritancy effect,"peeling, desquamating, or abrasive agents",hypersensitive,dry skin
423,adapalene,acne vulgaris,retinoid receptors,"sulfur, resorcinol or salicylic acid",salicylic acid,individuals who are hypersensitive,usually lessen with continued use of the medication
424,aloe + black pepper + henbane,constipation flatulence anorexia colic obesity,synergistic action,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,contraindication,no significant side effect has been observed in proper dosage
425,chloramphenicol + lidocaine hydrochloride,acute bacterial ear infections,bacteriostatic and bactericidal,drugs that depress bone marrow function,drugs that depress bone marrow function,perforated ear drum,ototoxicity
426,chloramphenicol (oral),both are suggested by in vitro studies to be effective against a specific pathogen,interference or inhibition of protein synthesis in intact cells and cell-free systems,"clindamycin, or erythromycin","clindamycin, or erythromycin","colds, viral influenza, infections of the throat",NO SPECIFIC DATA AVAILABLE
427,chloramphenicol (ophthalmic),ocular infections involving the conjunctiva and/or cornea,inhibition of bacterial protein synthesis,chymotrypsin,chloramphenicol,individuals with a history of hypersensitivity,"burning, stinging, conjunctival hyperemia"
428,chlorambucil,macroglobulinaemia.,not yet completely understood,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pregnancy (1st trimester) &amp; lactation,drug fever
429,cetuximab,k-ras,it binds specifically to the epidermal growth factor receptor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"weakness, bone pain"
430,cetrorelix acetate,assisted reproductive technologies,gonadorelin antagonist,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pregnancy and lactation,"nausea, headache, ovarian hyperstimulation syndrome"
431,cetirizine hydrochloride (ophthalmic),ocular itching associated with allergic conjunctivitis,selective inhibition of h1 histamine receptors,<NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE,"ocular hyperemia, instillation site pain and visual acuity reduction"
432,cetirizine hydrochloride,asthma,without any significant anticholinergic and antiserotonic effects,drug interactions,drugs,patients with a history of hypersensitivity,somnolence
433,cetalkonium chloride + choline salicylate,orthodontic device,inhibition of prostaglandin production,inhibit the action of uricosurics,salicylates may enhance the effect of anticoagulants,if allergic to salicylates,asthma attacks
434,ceritinib,adult patients with metastatic non-small cell lung cancer,kinase inhibitor,concurrent use of strong cyp3a inducers,grapefruit and grapefruit juice,patients with known hypersensitivity,gastrointestinal adverse reactions
435,cephalexin,infections when caused by susceptible organisms,it kills bacteria by interfering in the synthesis of the bacterial cell wall,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,"nausea, vomiting, diarrhoea and abdominal discomfort"
436,cephradine,infections caused by sensitive gram-positive and gram-negative bacteria,the cell wall of bacteria,risk of kidney damage,diuretics,patients with known or suspected hypersensitivity to cephalosporins,hypersensitivity phenomena
437,celiprolol hydrochloride,it is used to treat high blood pressure,partial beta-2 agonist activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,allergic,"dizziness or light headedness, weakness, or fainting"
438,celecoxib,for the relief of the signs and symptoms of osteoarthritis,inhibition of prostaglandin synthesis,aluminium and magnesium-containingantacid,aluminium and magnesium-containingantacid,aspirin or other nsaids,allergy aggravated
439,cefuroxime axetil + clavulanic acid,switch therapy,cefuroxime inhibits bacterial cell wall synthesis,effect of postprandial absorption,probenecid,patients with known allergy to cephalosporin &amp,"nausea, vomiting, diarrhea, abdominal discomfort or pain"
440,cefuroxime axetil,it is indicated for the treatment of infections caused by sensitive bacteria,antibacterial agent,potentially hazardous interactions,hazardous interactions,patients with known allergy to cephalosporins,rashes and gastrointestinal disturbances
441,ceftriaxone sodium,lower respiratory tract infections,beta lactamases,drug interactions,drug,hypersensitivity to cephalosporin antibiotics,"diarrhea, nausea and vomiting, stomatitis and glossitis"
442,ceftibuten dihydrate,mild-to-moderate infections,bactericidal,ranitidine,ranitidine,patients with known allergy to the cephalosporin group of antibiotics,vomiting
443,ceftazidime pentahydrate,infections caused by susceptible strains of the designated organisms,inhibition of enzymes responsible for cell-wall synthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients who have shown hypersensitivity,local reactions following iv injection and allergic and gastrointestinal reactions
444,ceftazidime + avibactam,antibacterial agents,"non -lactam, -lactamase inhibitor",<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,"anaphylactic reaction, severe skin reaction",do not take medicines that stop or slow bowel movement
445,almond + coconut + edible pine + salep,spermatorrhoea oligospermia,enhances retentive power and relieves oligospermia,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,contraindication,no significant side effect has been observed in the therapeutic dosage
446,acacia + dates + asparagus + edible pine,sexual debility,formulation,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindication,no significant side effect has been observed in the therapeutic dosage
447,abhayarista,haemorrhoid bleeding piles,"cooling, tonic, and carminative",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no absolute contraindications,no significant side effect
448,23 herb formula to increase breast milk,15,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE
449,acarbose,adults with type 2diabetes mellitus,different,loss of blood glucose control,insulin,patients with known hypersensitivity to the drug,tell your doctor or pharmacist promptly
450,acalabrutinib,at least one prior therapy,small-molecule inhibitor of btk,gastric acid reducing agents: avoid co-administration with proton pump,gastric acid reducing agents,NO SPECIFIC DATA AVAILABLE,"headache, diarrhea, and musculoskeletal pain"
451,abiraterone acetate,metastatic castration-resistant prostate cancer,covalent binding mechanism,strong cyp3a4 inducers,strong cyp3a4 inducers,hypersensitivity,headache
452,abemaciclib,in combination with endocrine therapy,inhibitor of cyclin-dependent kinases 4 and 6,strong and moderate cyp3a inhibitors,strong and moderate cyp3a inhibitors,NO SPECIFIC DATA AVAILABLE>,"anemia, leukopenia"
453,abacavir + lamivudine + zidovudine,combination with other antiretrovirals,phosphorylated,sorbitol-containing medicines,sorbitol,patients,"nausea, headache, malaise and fatigue, and nausea and vomiting"
454,ciclopirox olamine (nail lacquer),mild to moderate onychomycosis,poorly understood,systemic antifungal agents,topical solution,individuals who have shown hypersensitivity to any of its components,allergic reaction to ciclopirox is rare
455,ciclopirox olamine (cream),mild to moderate inflammatory fungal infections,broad spectrum of antifungal action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,individuals who have shown hypersensitivity to any of its components,low incidence of adverse reactions
456,ciclesonide (nasal spray),patients aged 6 years and older,aqueous suspension,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,fewer side effects are seen
457,ciclesonide (inhalation aerosol),asthma,hydrolyzation by endogenous esterases,the risk of clinical adverse effect,nelfinavir,hypersensitivity,rash and eczema. systemic effects of inhaled corticosteroids
458,choriogonadotropin alpha,only if enrolled in anin vitrofertilization program,binds to the lh/hcg receptor,significant drug interactions,drug,prior hypersensitivity to hcg preparations,injection
459,cholera saline,in cholera,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"fever, ongoing cough"
460,chlorthalidone,edema associated with congestive heart failure,thiazide-type diuretic- antihypertensive,glucose tolerance,glucose tolerance,patients with renal disease or with impaired hepatic function,rise in blood lipids
461,chlorpromazine hydrochloride,mania and hypomania,slight ganglion-blocking activity,adverse drug reaction,alcohol,circulatory collapse. cns depression,"cardiovascular: postural hypotension, ecg changes."
462,chlorpheniramine maleate,urticaria sensitivity reactions,blocking h1-receptor competitively,calcium chloride,meglumine adipiodone,newborn or premature infants,well-tolerated
463,chloroxylenol + triclosan,"insect bites, sunburn, cuts, scratches, abrasions",chlorinated bisphenol antiseptic,drug interactions,drug,hypersensitivity,reversible brown staining of the teeth
464,chloroxylenol,antiseptic lubricant for vaginal examinations and on forceps,disinfection,drug interactions,drug,hypersensitivity,reversible brown staining of the teeth
465,chloroquine phosphate,treatment of malaria prophylaxis and suppression of malaria,interferes with the nucleoprotein synthesis of the patient,cimetidine,cimetidine,there is no absolute contraindication,headache and gastrointestinal disturbances
466,chlorhexidine hydrochloride + nystatin,it is used to treat skin infections,poorly absorbed from the gastrointestinal tract,drug interactions,drug,those with a history of possible chlorhexidine-related allergic reactions,allergic skin reactions
467,chlorhexidine hydrochloride + cetrimide,amp,antimicrobial agent,drug interactions,drug,"eye, ear, mucous membrane or body cavities",skin irritation
468,chlorhexidine gluconate + isopropyl alcohol,pre-operative surgical hand disinfection,bacteriostatic and bactericidal,soaps and other anionic agents,hypochlorite bleaches,chlorhexidine,irritative skin reactions
469,chlorhexidine gluconate + cetrimide,for cleansing and irrigating the skin and dirty wounds,cationic surfactants,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,"brain, meninges, eyes or perforated eardrum",cetrimide may have a prolonging effect on the wound healing process
470,chlorhexidine gluconate [7.1%],omphalitis (infection of the umbilical cord) in newborn,both bacteriostatic and bactericidal action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE
471,chlorhexidine gluconate [4%],surgical hand scrub,both bacteriostatic and bactericidal,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,allergic,NO SPECIFIC DATA AVAILABLE
472,chlorhexidine gluconate [1%],antiseptic cream,both bacteriostatic and bactericidal,brown stains,fabrics,patients who are hypersensitive to chlorhexidine,allergic reactions
473,chlorhexidine gluconate [0.2%],"following oral surgery, in mentally or physically handicapped patients",bacteriostatic and bactericidal depending on its concentration,sulfates,"soaps, other anionic agents",hypersensitivity,transient taste disturbance; parotid gland swelling
474,clascoterone,12 years of age and older,potent antagonist at ars,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,local skin reactions
475,clarithromycin,streptococcal pharyngitis sinusitis,inhibiting microsomal protein synthesis in susceptible organisms,serum theophylline concentrations,terfenadine,patients receiving terfenadine,"nausea, vomiting, diarrhoea and abdominal pain"
476,citric acid monohydrate,dry cough,reduce the dry cough and soothes the throat from any related discomfort and pain,drug-drug interaction,drug-drug,hypersensitivity,no known side effects
477,citicoline sodium,cerebrovascular disease,inhibits the activation of phospholipase a2,meclophenoxate,meclophenoxate,patients with hypertonic of the parasympathetic nervous system.,discrete hypotensive effect
478,citalopram hydrobromide,obsessive-compulsive disorder and social phobia,antidepressant,metabolism,omeprazole,patients with a hypersensitivity,gastro-intestinal effects
479,cisplatin,advanced and metastatic ovarian carcinoma,cells are killed at all stages,myelosuppression,cytotoxic drugs,"myelosuppressed patients, or patients with hearing impairment","kidneys, bone marrows and ears"
480,ciprofloxacin + hydrocortisone acetate,steroid responsive inflammatory ocular conditions,hydrocortisone is a corticosteroid,increased toxicity,ethanol,newborn babies,steroid
481,ciprofloxacin + dexamethasone,anti-infective component,interference with the enzyme dna gyrase,specific drug interaction,ophthalmic,newborn babies,adverse reactions
482,ciprofloxacin (ophthalmic),prophylaxis in otic surgeries such as mastoid surgery,bactericidal action,drug interaction studies,drug,hypersensitivity,hyperemia
483,ciprofloxacin,"respiratory tract infections,urinary tract infections, pelvic inflammatory diseases",it inhibits bacterial dna synthesis,magnesium or aluminum containing antacids or sucralfate,calcium,patients who have known hypersensitivity,"headache, dizziness, joint pain and skin rashes"
484,ciprofibrate,hypertriglyceridemia with or without low hdl cholesterol,it also increases levels of hdl cholesterol,oral anticoagulant therapy,oral anticoagulants,pregnancy and lactation or when pregnancy is suspected concurrent use with another fibrate,"headache, dizziness, somnolence, vertigo, nausea, vomiting"
485,cinnarizine + dimenhydrinate,prophylaxis of motion sickness,calcium antagonists,drugs,alcohol,"patients with angle-closure glaucoma, convulsions","impaired vision, allergic reactions, light sensitivity, and difficulty in urinating"
486,cinnarizine,labyrinthine arteriosclerosis,"selective calcium antagonist, inhibiting the influx of ca 2+ intracellularly",drug interactions,anticoagulants or hypoglycaemics,hypotensive patients,somnolence and gastrointestinal disturbances are extremely rare
487,cinchocaine hydrochloride,surface anaesthesia,decrease of permeability of the nerve cell to sodium ions,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,application to inflamed or infected tissues,cardiac arrest
488,cinchocaine + hydrocortisone + neomycin + esculin,application,anti-inflammatory and anti-pruritic agent,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitive to any component of the product,side effects which have been reported for individual constituents
489,cinchocaine + hydrocortisone + framycetin + esculin,application to relieve pain and discomfort,skin protective action,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,"herpes simplex, vaccinia or varicella",children
490,cinacalcet,secondary hyperparathyroidism in patients with chronic kidney disease on dialysis,calcimimetic agent,serum concentrations of tacrolimus,tacrolimus,patients with hypersensitivity,"nausea, vomiting, anorexia"
491,cilostazol,intermittent claudication,specifically inhibit cellular phosphodiesterase iii,major metabolites,diltiazem,patients with known or suspected hypersensitivity to any of its components,"headache, diarrhoea, vomiting, leg cramps, rash"
492,cilnidipine,patients with chronic kidney disease,dihydropyridine calcium-channel blocker,antipsychotics,antipsychotics,patients with known sensitivity to cilnidipine,dizziness; flushing; headache;
493,ciclopirox olamine (shampoo),seborrheic dermatitis,antifungal action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,individuals who have shown hypersensitivity to any of its components,low incidence of adverse reactions
494,clostridium botulinum toxin type a neurotoxin,indicated,blocks the signals between the nerve &amp; its muscle,drug interactions,drug,prior history of severe reaction to other human immunoglobulin preparations,skin rash
495,clopidogrel bisulphate,"recent mi, recent stroke, or established peripheral arterial disease",irreversible binding,plasma concentrations of repaglinide,omeprazole or esomeprazole repaglinide,hypersensitivity to the drug substance or any component of the product,"bleeding, diarrhoea, gastrointestinal discomfort"
496,clopidogrel + aspirin,"recent mi, recent stroke, or established peripheral arterial disease",aspirin,bleeding,"valproic acid, varicella vaccine",hypersensitivity,generally well tolerated
497,clonidine hydrochloride,"anxiety, cancer pain, generalized anxiety disorder",clonidine stimulates 2 -adrenoceptors,nsaids,nsaids,2nd- or 3rd-degree av block or sick sinus syndrome,"heart failure, hallucinations"
498,clonazepam,has not been systematically studied in controlled clinical trials,anxiolytic effects,metabolism of other drugs,metabolism of other drugs,patients with clinical or biochemical evidence of significant liver disease,cns depression
499,clomipramine hydrochloride,"depression, obsessions and phobias","either by increasing the amount of chemical ""messengers"" in the brain",monoamine oxidase inhibitors,medicines for depression called monoamine oxidase inhibitors,acute and recovery stages of myocardial infarction,increase in appetite and weight gain
500,clomiphene citrate,ovulatory failure in female patients who wish to become pregnant,unknown but is believed to be related to its antiestrogenic properties,drug interaction,drug,patients with liver diseases,all these effects disappear promptly after the treatment is discontinued
501,clobetasone butyrate,eczema and dermatitis,can cause cutaneous atrophy if grossly misused,potentially hazardous interactions,potentially hazardous interactions,pregnancy,"amenorrhoea, hyperhidrosis, skin thinning"
502,clobetasol propionate + salicylic acid,this ointment,high potency corticosteroid,topical medicines on the same area of skin,skin,patients displaying salicylate hyersensitivity,"possible sensitivity reactions, drying and irritation"
503,clobetasol propionate + ofloxacin + ornidazole + terbinafine,this cream,clobetasol,hazardous interactions,hazardous interactions,hypersensitive,"burning, itching, irritation, dry skin"
504,clobetasol propionate + neomycin sulphate + nystatin,less active steroids,unclear,hazardous interactions,nystatin,"rosacea, acne vulgaris and perioral dermatitis",hypercortisolism
505,clobetasol propionate (topical preparation),"adults, elderly and children",multiple mechanisms,inhibit the metabolism of corticosteroids,"ritonavir, itraconazole","rosacea, acne vulgaris, perioral dermatitis",burning and stinging sensation
506,clobetasol propionate (scalp preparation),psoriasis and seborrheic dermatitis,multiple mechanisms,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,dermatoses in children under one year of age,application should be stopped immediately
507,clobazam,only in conjunction with adequate concomitant treatment,increases the duration of time for which the chloride ionopore is open,lithium,lithium,patients with hypersensitivity to clobazam,drug tolerance
508,clioquinol + flumetasone pivalate,external ear inflammation and infections,bacteriostatic action,protein-bound iodine,protein,"punctured eardrum, pre-existing tuberculosis of the skin",treatment should be discontinued if severe irritation
509,clindamycin + tretinoin,acne vulgaris,retinoid tretinoin,irritating,erythromycin,hypersensitive,common side effects
510,clindamycin + benzoyl peroxide,acne vulgaris.,both active against propionibacterium acnes,increased coagulation tests,increased coagulation tests,"history of regional enteritis, ulcerative colitis","application site pain, application site exfoliation, application site irritation"
511,clindamycin (vaginal cream),non pregnant women and pregnant women during the second and third trimester,inhibits bacterial protein synthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,children under 12 years of age,"genital tract: vaginitis, vulvo-vaginal irritation"
512,clindamycin (lotion),skin infections,antiacne and antibacterial activity,"neuromuscular blocking agents. therefore, it should be used with caution",neuromuscular blocking agents,NO SPECIFIC DATA AVAILABLE,rare
513,clindamycin,"upper respiratory infections, lower respiratory infections, skin",NO SPECIFIC DATA AVAILABLE,"neuromuscular blocking agents. therefore, it should be used with caution",neuromuscular blocking agents,patients previously found to be sensitive,abdominal pain
514,conjugated estrogen + bazedoxifene,an estrogen agonist/antagonist,binding to and activating estrogen receptors,risk of endometrial hyperplasia,cyp3a4 inhibitors,"pregnancy, women who may become pregnant, and nursing mothers","muscle spasms, nausea, diarrhea, dyspepsia"
515,conjugated estrogen (tablet),conjugated estrogens with or without progestins,binding to nuclear receptors in estrogen-responsive tissues,anticonvulsants,anti-infectives,hypersensitivity,blood clots in the blood vessels.
516,conjugated estrogen (cream),moderate-to-severe vasomotor symptoms associated with estrogen deficiency,estrogen replacement therapy,rifampin,hepatic,hypersensitivity,"vaginal burning, irritation and itching"
517,colistimethate sodium,not indicated for infections due to proteus or neisseria,it interacts with the bacterial cytoplasmic membrane,sodium cephalothin,sodium cephalothin,patients with a history of sensitivity to the drug or any of its components,"gastrointestinal upset, tingling of extremities and tongue"
518,colecalciferol [vitamin d3],patients with vitamin d3 deficiency,reabsorption of calcium &amp; phosphorous,antifungal agents,liquid paraffin,patients with known hypersensitivity,"hypercalcaemia, hypercalciuria"
519,colchicine,in adults and children 4 years or older,inhibits the phagocytosis of uric acid by leukocytes,inhibitors,p-gp and/or cyp3a4 inhibitors,patients with renal or hepatic impairment,diarrhea and pharyngolaryngeal pain
520,cod liver oil,pregnant women,omega-3 fatty acids,anti-convulsants,barbiturates or anti-convulsants,"hypervitaminosis of vitamin a, d or e",these may disappear on discontinuation of supplementation
521,coal tar solution,natural tars to clear scales,it moisturises and nourishes the skin,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,"eye irritation, hair loss, itchy and redskin"
522,coal tar + precipitated sulphur + salicylic acid,ointment,reduction,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,local infections,photosensitivity of the skin
523,coal tar,psoriasis,it slows down excessive epidermal cell turnover,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,folliculitis and acne vulgaris,acne-like eruptions of the skin
524,coagulation factor viia [eptacog alfa],bleeding episodes in patients with haemophilia,extrinsic pathway of the coagulation cascade,increased risk of thromboembolism,non-activated prothrombin complex concentrate,hypersensitivity,anaphylaxis
525,clozapine,schizophrenia,antagonist,adrenaline,adrenaline,drug intoxication; coma or severe cns depression,"increased watering of mouth, nausea or vomiting"
526,cloxacillin sodium,"infected wounds), (infected burns), (protection for skin grafts",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitive,indigestion
527,clove oil,bad breath,"clove oil is effective, safe and well tolerated for all age groups",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,irritating to mucosal tissues
528,clotrimazole + hydrocortisone,all dermatomycoses,hydrocortisone is a glucocorticoid,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,hypersensitivity reactions
529,clotrimazole (vaginal tablet),"in vaginal itching, burning and discharge",membrane damage unrelated to sterol synthesis,no information is available,no information is available,patients with known hypersensitivity to any of the components of this product,no systemic effect is expected
530,clotrimazole (vaginal suppository),candidal vaginitis,membrane damage unrelated to sterol synthesis,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitive to clotrimazole,occasional skin irritation or burning sensation
531,clotrimazole (topical),yeasts (candida species).,antimycotic activities,no information is available,no information is available,hypersensitivity,well tolerated
532,clotrimazole (eye ointment),fungal keratitis,stopping the production of ergosterol,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,individuals sensitive to its components,rarely patients may experience burning or irritation
533,clotrimazole (ear drop),fungal infections,stopping the production of ergosterol,heat reaction,sofradex drops,individuals who have hypersensitivity,"erythema, stinging, edema, pruritus and general irritation"
534,dacomitinib,first-line treatment of patients with metastatic non-small cell lung cancer,irreversible inhibitor of the kinase activity,proton pump inhibitors,proton pump inhibitors,NO SPECIFIC DATA AVAILABLE,"decreased appetite, dry skin, decreased weight"
535,daclatasvir + sofosbuvir,daclatasvir is a direct-acting antiviral agent,directly inhibiting hcv protein ns5a,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE
536,daclatasvir,adults,inhibitor of ns5a,adverse reaction,breast cancer resistance protein,in combination with drugs that strongly induce cyp3a,fainting or near-fainting
537,dacarbazine,in combination with other effective agents,unclear,increased metabolism,enzyme inducers,patients who have demonstrated a hypersensitivity to it in the past,"rarely, dacarbazine for injection has caused diarrhea"
538,dabigatran etexilate mesylate,patients who have been previously treated,prolongs the coagulation markers,deep venous thrombosis and pulmonary embolism,p-gp inducers,active pathological bleeding,increased risk of thrombotic events
539,d-chiro-inositol,polycystic ovary syndrome,improves glucose tolerance and reduces circulating insulin,toxicity,digoxin,hypersensitivity,well tolerated
540,cytarabine,leukaemic meningitis,antiviral and immunosuppressant activity,neurotoxicity,intrathecal,patient with active meningeal infection,"thrombocytopenia, fatigue"
541,cyproterone acetate + ethinyl estradiol,oral antibiotic,increases levels of sex hormone binding globulin (shbg),pregnancy,vitamin c,previous or existing liver tumors,"bleeding, dizziness, depression, weight gain, headache"
542,cyclosporine (ophthalmic),emulsion,partial immunomodulator,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with active ocular infections,eye pain
543,cyclosporine,transplantation,not known,drugs that decrease cyclosporine levels,oral,hypersensitivity,allergic rashes
544,cyclophosphamide,concurrently or sequentially with otherantineoplasticdrugs,any stage of the cell cycle,depolarising muscle relaxants,depolarising muscle relaxants,pregnancy,"alopecia, skin and nails hyperpigmentation, nausea and vomiting"
545,cyclopentolate hydrochloride,diagnostic purposes,anticholinergic agent,antagonize miosis and ciliary body contraction,anticholinergic agents,children,systemic effects
546,cyclobenzaprine hydrochloride,adjunct to rest and physical therapy,centrally-acting skeletal muscle relaxant,brimonidine,sibutramine,"recent mi, arrhythmias, severe liver disease","drowsiness, dry mouth and dizziness"
547,cyclizine hydrochloride,adults and children aged 6 years and over,NO SPECIFIC DATA AVAILABLE>,alcohol,alcohol,if you are allergic to cyclizine hydrochloride,"skin rashes or itching, drowsiness, lack of coordination"
548,cyanocobalamin,pernicious anemia,coenzyme,k salts,k salts,tobacco amblyopia,polycythemia vera
549,crotamiton,itching and skin irritation,relieves itching by producing what is called a counter-irritation,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,in or around the eyes,irritation of the skin or contact allergy
550,crizotinib,patients with- metastatic non-small cell lung cancer,inhibitor of receptor tyrosine kinases,strong cyp3a inhibitors,st. johns wort,NO SPECIFIC DATA AVAILABLE,"upper respiratory infection, dizziness, and neuropathy"
551,crisaborole,pediatric patients 3 months of age and older,phosphodiesterase 4b,inhibit cytochrome p450,metabolite 1 are not expected to inhibit cytochrome p450,NO SPECIFIC DATA AVAILABLE>,application site pain
552,covid vaccine,corona virus,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
553,copper peptide + procapil + niacinamide + biotin + l-arginine,substantial hair growth,"boosts the hair growth, health &amp; appearance",<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,hypersensitivity,<NO SPECIFIC DATA AVAILABLE
554,desloratadine,chronic idiopathic urticaria,non-sedating; long acting tricyclic histamine antagonist,drug,drug,patients having hypersensitivity,"headache, nausea, fatigue, dizziness, pharyngitis"
555,dequalinium chloride,fluomizin,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,if you are allergic to the active substance dequalinium chloride,vaginal discharge; vaginal itching or vaginal burning
556,denosumab,patients,binds to receptor activator of nuclear factor kappa-b ligand,midazolam,midazolam,hypersensitivity,osteonecrosis of the jaw (onj).
557,delafloxacin,only,concentration-dependent bacteriocidal activity,multivalent cations,pediatric powder for oral solution,patients with known hypersensitivity,"nausea, diarrhea, headache, transaminase elevations, and vomiting"
558,dehydroepiandrosterone,lacking,antagonist of gamma-aminobutyric acid (gaba) receptors,progesterone assays,dhea,breast or prostate cancer,mania and hypomania
559,degarelix acetate,adult male patients with advanced hormone-dependent prostate cancer,selective gonadotrophin releasing-hormone (gnrh) antagonist,not a substrate for the human cyp450 system,medicinal products able to induce torsades de pointes,hypersensitivity,testosterone suppression
560,deflazacort,"anaphylaxis, asthma, severe hypersensitivity reactions",anti-inflammatory action by inhibiting phospholipase a2 enzyme,liver enzymes,drugs which are liver enzyme inducers are co-administered,hypersensitivity,susceptible to infection
561,deferoxamine mesylate,acute iron intoxication,"ferrioxamine, a stable complex which is eliminated via the kidneys",impairment of consciousness,erythropoietin,hypersensitive,NO SPECIFIC DATA AVAILABLE
562,deferiprone,iron overload patients with thalassemia,chelating agent,aluminium containing antacids,aluminium containing antacids,hypersensitivity,arthralgia and increased liver enzymes
563,deferasirox,adult and paediatric patients,orally active chelator,decreased exposure with colestyramine and potent inducers of ugt enzymes,"hormonal contraceptives, simvastatin",high risk myelodysplastic syndrome,serum creatinine
564,daunorubicin,acute nonlymphocytic leukemia,simple glycosidic cleavage,doxorubicin or daunorubicin,daunorubicin,patients with known hypersensitivity,dose-limiting toxicity
565,dasatinib,philadelphia chromosome-positiveacute lymphoblastic leukemia,inhibits the following kinases,narrow therapeutic index,narrow therapeutic index,pregnancy,acne
566,darifenacin,overactive bladder,"potent, competitive and selective muscarinic receptor antagonist",anticholinergic agents,dry mouth,"patient with urinary retention, gastric retention","abnormal vision, back pain, dry skin, hypertension"
567,darbepoetin alfa,including patients ondialysisand patients not on dialysis,endogenous erythropoietin,ethanol,ethanol,uncontrolled hypertension,hypertension; seizures; serious allergic reaction; severecutaneousreactions
568,dapsone,12 years of age and older,both anti-infammatory and antimicrobial properties,benzoyl peroxide,topical benzoyl peroxide,those who are hypersensitive,application site dryness and pruritus
569,dapoxetine hydrochloride,indicated for the treatment of premature ejaculation,inhibition of neuronal reuptake of serotonin,alcohol,alcohol,maois or thioridazine,hypertension
570,dapagliflozin propanediol,withtype 2 diabetesmellitus,reversible inhibitor of sodium-glucose cotransporter 2,increase in cmax &amp; auc with mefenamic acid,rifampin,moderate to severe renal impairment; end-stage renal disease; active bladder cancer,"renal impairment, female genital mycotic infections"
571,dantrolene sodium,tion,probably by interfering with the release of ca ++,cns depressants,cns depressants,hepatitis and cirrhosis,"drowsiness, dizziness, weakness, general malaise"
572,danazol,endometriosis,unknown,migraine,carbamazepin,hypersensitivity to danazol.,elevated lft values
573,dalteparin sodium,extracorporeal circulation,antithrombotic agent,increased risk of haemorrhage,etacrynic acid,severe hypertension,"elevated serum transaminase levels (ast and alt), allergic reactions"
574,dextromethorphan + pseudoephedrine + triprolidine,this preparation,central action on the cough centre in the medulla,avoid taking isocarboxazid,tranylcypromine,patients with liver disease or asthmatic patients,no apparent evidence of physical dependence of the morphine
575,dextromethorphan + phenylephrine + triprolidine,upper respiratory allergies,central action on the cough centre in the medulla,avoid taking isocarboxazid,tranylcypromine,asthma,no apparent evidence of physical dependence of the morphine
576,dextran + sodium chloride,moderate- to high-risk patients undergoing surgery,dextran produce expansion of plasma volume,lithium,lithium,pregnancy,raised liver enzyme values; alopecia; bone marrow suppression
577,dextran + hypromellose,keratoconjunctivitis,dextran &amp; hypromellose,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,when soft contact lenses are being worn,there are no known side effects
578,dextran + dextrose,thromboembolic disorders,inhibits sludging or aggregation of red blood cells,enzyme inducers,enzyme inducers,NO SPECIFIC DATA AVAILABLE,injection site infection/phlebitis
579,dexpanthenol,prevention and treatment of diaper rash in infants,enzymatically,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,you may not suffer from any of them
580,dexmedetomidine hydrochloride,non-intubated patients,terminate the propagation of pain signals,reducing dosage,co-administered drug,none,"hypotension, respiratory depression, and bradycardia"
581,dexlansoprazole,healing of erosive esophagitis,proton pump inhibitor,food,food,patients with known hypersensitivity to any component of the formulation,"diarrhea, abdominal pain, nausea, vomiting"
582,dexketoprofen,amp,anti-inflammatory,drugs,any of the following drugs,allergic,unwanted effects
583,dexibuprofen,osteoarthritis,analgesic action,anticoagulant,anticoagulant,patients with previous history of hypersensitivity,"dyspepsia, diarrhea, fatigue, and headache"
584,dexamethasone + tobramycin,corticosteroid,inhibit the phospholipase a2,combination eye drops,topical ophthalmic medicines,hypersensitivity,topical ocular tobramycin
585,dexamethasone + neomycin sulphate + polymyxin b sulphate,antimicrobial,anti-infective component,drug interactions,drug,uncomplicated removal of a corneal foreign body,adverse reactions
586,dexamethasone + chloramphenicol,post-operative inflammation and any other ocular inflammation associated with infection,chloramphenicol,phenobarbital,phenobarbital,hypersensitivity,allergic sensitization
587,dexamethasone (ophthalmic),dexamethasone phosphate,it suppresses normal immune response,none relevant,none relevant to topical use.,perforation of a drum membrane,"rarely, stinging and burning may occur."
588,dexamethasone,selected cases may require low-dose maintenance therapy,it suppresses normal immune response,oral anti-coagulants,oral anti-coagulants,hypersensitivity to corticosteroids,glucocorticoid
589,desvenlafaxine,adult outpatients,the exact mechanism is unknown,anticoagulants,aspirin,"maois (e.g. linezolid, iv methylene blue","nausea, dizziness, insomnia, hyperhidrosis"
590,desoximetasone,corticosteroid,uncertain,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a history of hypersensitivity,NO SPECIFIC DATA AVAILABLE
591,desonide,mild to moderate atopic dermatitis,unclear,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to any of the components of the preparation,"burning, rash and pruritus"
592,desogestrel,alternative for women who have a weak tolerance levels for the estrogen hormones,NO SPECIFIC DATA AVAILABLE,charcoal,charcoal,hypersensitivity to ingredients,decreased libido
593,desmopressin acetate,primary nocturnal enuresis nocturia and central diabetes insipidus,mimicking the actions of endogenous adh,urine production and osmolality,27% fat meal,cardiac insufficiency and other conditions requiring treatment with diuretic agents,"headache, stomach pain and nausea"
594,difluprednate,inflammation and pain associated with ocular surgery,structurally similar to other corticosteroids,drug interaction,0.05% ophthalmic emulsion,most active viral diseases,corneal edema
595,diflorasone diacetate,corticosteroid-responsive dermatoses,anti-inflammatory,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,those patients with a history of hypersensitivity to the preparation,"burning, itching, irritation, dryness"
596,diethylcarbamazine citrate,"filariasis, lymphatic filariasis",sensitizing the microfilariae to phagocytosis,drug interactions,drug,"pregnancy, hypersensitivity; lactation","fever, headache, vomiting, dizziness, drowsiness, nausea"
597,dienogest + estradiol valerate,progestin,cervical mucus changes that inhibit sperm penetration,contraception,drugs or herbal products,breast cancer,natazia
598,dienogest,endometriosis,it is an antagonist at androgen receptors,adverse reactions,progestogens,active venous thromboembolic disorder,undesirable effects
599,dicycloverine hydrochloride,functional bowel/irritable bowel syndrome,antispasmodic and anticholinergic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"increased ocular tension, urinary hesitancy"
600,diclofenac sodium + misoprostol,high risk of developing nsaid,not completely understood,antacids,antacids,patients with hypersensitivity,"abdominal pain, diarrhea and other gi symptoms"
601,diclofenac sodium + methyl salicylate + linseed oil + menthol,indicated,anti-inflammatory agent,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,known hypersensitivity to any part of the preparation,extremely low frequency of hypersensitivity reactions
602,diclofenac sodium + lidocaine hydrochloride,diclofenac sodium,inhibition of prostaglandin synthesis,influencing their clinical effect,lithium,in patients with adams-stokes syndrome,mild and transient
603,diclofenac sodium (ophthalmic),in- inhibition of miosis during cataract surgery,non-steroidal anti-inflammatory drug with analgesic property,drug interaction,steroid,"attacks of asthma, urticaria or acute rhinitis","sensitivity to light, bad taste, feeling of pressure, allergic reactions"
604,diclofenac sodium,surgery,inhibiting prostaglandin biosynthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,asthmatic patient,"mild, rare and transient"
605,diclofenac potassium,"severe painful inflammatory infections of the ear, nose, or throat",inhibition of cyclooxygenase,unwanted effects,anticoagulant therapy,patients with known hypersensitivity to diclofenac,mild and transient
606,diclofenac diethylamine + mephenesin + menthol + methyl salicylate + turpentine oil,topical gel,reducing pain and delayed onset muscle soreness,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,children less than 12 years old cuts infected skin,gel
607,diazoxide,orally,enhancing cell membrane permeability to potassium ions,phenytoin,oral,all cases which are amenable to surgery or other specific therapy,adverse reactions
608,diazepam,hospitalized patients,attaches to the specific site on the gaba receptor,omeprazole and isoniazide,omeprazole,"myasthenia gravis, pulmonary insufficiency","dizziness, light headedness, confusion and ataxia."
609,diabasic sodium phosphate + monobasic sodium phosphate,bowel cleansing is required,saline laxative,no other sodium phosphate preparations,no other sodium phosphate preparations including sodium phosphate oral solution or tablets,"congestive heart failure, impairment of renal function",adverse events possibly associated with the use of phosphate enema
610,dextrose & hartmann's solution,electrolytes and calories or as an alkalinizing agent,intravenous administration,drug interactions,drug,patients with known allergy to corn or corn products,"coughing, sneezing, and/or difficulty with breathing"
611,dextrose,when there is no significant loss of electrolytes,replace lost fluids and provide carbohydrates to the body,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,allergic to dextrose,"fever, ongoing cough"
612,dextromethorphan hydrobromide + guaifenesin,preparation provides relief from all the symptoms associated with common cold,guaifenesin and dextromethorphan hbr.,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,"hypersensitivity, rash, nausea &amp; vomiting"
613,dextromethorphan hydrobromide,chronic dry cough or unproductive cough,nmda receptor antagonist and acts as a non-competitive channel blocker,cns depressants and monoamine oxidase (mao) inhibitors,cns depressants and monoamine oxidase (mao) inhibitors,hypersensitivity,no analgesia or addiction and little or no cns depression
614,donepezil hydrochloride,mild to moderate dementia,inhibiting hydrolysis of acetylcholine,drugs with anticholinergic properties and which cross into the brain,drugs,patients with known hypersensitivity,less frequent
615,domperidone maleate,parkinson's disease,gastroprokinetic,mao (monoamine oxidase) inhibitors,mao (monoamine oxidase) inhibitors,neonates,"galactorrhea, breast enlargement, and soreness"
616,docusate sodium (oral),abdominal radiological procedures,allowing more water to be absorbed by the stool,mineral oil,mineral oil,patients with hypersensitivity,"diarrhea, nausea, abdominal cramps or skin rash"
617,docusate sodium (ear drop),indicated as an aid in the removal of ear wax,low surface tension and miscibility,interaction with other medicinal products,medicinal,perforation of the eardrum or inflammation of the ear,transient stinging or irritation
618,docetaxel trihydrate,doxorubicin and cyclophosphamide,inhibiting their disassembly,compounds,compounds,neutrophil counts of &lt;1500 cells/mm 3,infections
619,dobutamine,inotropic support is required for the treatment of patients,stimulating 1-adrenergic receptors,b-adrenergic receptor antagonists,folic acid,patients who have shown previous manifestations of hypersensitivity,mild reduction in serumpotassiumconcentration
620,dithranol + boric acid + salicylic acid,-,"atp , keratinocytes : keratolytic agent",increase your risk for side-effects or cause your drug not to work properly,ointment,acute or actively inflamed psoriatic eruptions,ointment
621,disopyramide phosphate,ventricular arrhythmias,not act as a blocking agent for beta or alpha adrenergic receptors,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"pre-existing a-v heart block, shock, glaucoma","dry mouth/ nose/ eye, nausea, vomiting"
622,dipyridamole,secondary prophylaxis of stroke or transient ischaemic attack,inhibiting platelet aggregation,thromboembolism,aspirin,hypersensitivity. peptic ulcer,large doses may lower bp
623,"diphtheria, tetanus, pertussis, poliomyelitis vaccine",prevention,<NO SPECIFIC DATA AVAILABLE,haemophilus influenzae type b conjugate vaccine,haemophilus influenzae type b conjugate vaccine,febrile or acute disease,"injection-site reactions, abnormal crying, loss of appetite and irritability"
624,"diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis, influenzae vaccine",primary and booster vaccination,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,history of an anaphylactic reaction,"prolonged crying, diarrhoea, induration"
625,diphtheria + pertussis + tetanus [dpt],immunization,vaccine,do not mix this vaccine with any other vaccine,influenza vaccine,amp; tetanus vaccine,headache
626,diphenhydramine hydrochloride + zinc acetate,cream,blocking the releases of histamine at its sources,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,individuals with a known allergy to its components,contact dermatitis
627,diphenhydramine hydrochloride,"seasonal, perennial, vasomotor rhinitis urticaria",antihistamine with anticholinergic and sedative effects,absorption of the antituberculous agent,gastrointestinal tract,impaired hepatic or renal function,"sedation, dizziness, tinnitus"
628,diphenhydramine + levomenthol,cough,levomenthol has decongestant and anti-inflammatory properties,mao inhibitors,alcohol,patients currently receiving monoamine oxidase inhibitors,diphenhydramine
629,diphenhydramine + dextromethorphan + levomenthol,syrup,diphenhydramine hydrochloride,monoamine oxidase inhibitors,monoamine oxidase inhibitors,at risk of developing respiratory failure,this syrup
630,diltiazem hydrochloride (sr tablet),prophylaxis and treatment of angina pectoris,calcium channel antagonist,drugs,short-or long-acting nitrates,patients with known hypersensitivity,reported
631,diltiazem hydrochloride (fc tablet),alone or in combination in the management of hypertension,interferes with the influx of calcium ions through the channels of active cell membranes,lithium &amp; carbamazepine,lithium &amp; carbamazepine,"severe bradycardia, sick sinus syndrome, pregnancy","headache, ankle oedema, hypertension"
632,diloxanide furoate,intestinal amoebiasis,"hydrolysed in the gut, thus releasing the free diloxanide",drug,drug,hypersensitivity,"flatulence, itching, urticaria, vomiting"
633,digoxin,heart failure,direct action on vascular smooth muscle,antacids,antacids,hypersensitivity,pregnancy
634,eflornithine hydrochloride,limited to these areas of involvement,suicide inhibition) to ornithine decarboxylase,interaction,drug,patients with a history of sensitivity to any components of the preparation,"acne, barbae, pseudofolliculitis"
635,efavirenz,there are no results from controlled trials evaluating long term suppression of hivrna,it blocks the rna- and dna-dependent polymerase activities,voriconazole,voriconazole,concomitant admin with terfenadine,autoimmune disorders
636,econazole nitrate + triamcinolone acetonide,amp,<NO SPECIFIC DATA AVAILABLE>,lowering of plasma salicylates levels,warfarin &amp; acenocoumarol,individuals who have shown hypersensitivity to any of its ingredients,minimal allergenic effect
637,econazole nitrate,"tinea cruris, and tinea corporis",interferes with fungal oxidative enzymes,systemic absorption,genital application,individuals who have shown hypersensitivity to any of its ingredients,"burning, itching, stinging, and erythema"
638,ebastine,seasonal and perennial allergic rhinitis. chronic idiopathic urticaria,selective h1-histamine receptor antagonist,alcohol,alcohol,patients with a known hypersensitivity,"abdominal pain, dyspepsia, nausea and insomnia"
639,dydrogesterone,treatment of threatened miscarriage treatment of habitual miscarriage,endogenous progesterone deficiency,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known or suspected progestogen dependent neoplasms,"migraines/headache, nausea, menstrual disorders"
640,dutasteride,in men with an enlarged prostate,dual inhibitor of 5-reductase,inhibit the in vitro metabolism,chronic cyp3a4 inhibitors,women who are pregnant or may be pregnant,testicle pain or swelling increased breast size breast tenderness
641,duloxetine hydrochloride,serotonin and norepinephrine reuptake inhibitor,selective serotonin and norepinephrine reuptake inhibitor,ciprofloxacin and enoxacin,quinolone antimicrobials,patients with substantial alcohol use or evidence of chronic liver disease,"nausea, dizziness, dry mouth, constipation"
642,dulaglutide,adults with type 2 diabetes mellitus,dulaglutide activates the glp-1 receptor,oral medications,oral medications,patients with a prior serious hypersensitivity reaction,"nausea, diarrhea, vomiting, abdominal pain, and decreased appetite"
643,drotaverine,uterine tetanus,inhibition of phosphodiesterase-iv,analgesics,additive,patients with known hypersensitivity to the products and its constituents,"headache, dizziness, rhinitis, sinusitis"
644,drospirenone,oral contraception,antiandrogenic activity,"enzymes (for example, cyp3a4) may decrease the effectiveness",drugs or herbal products,undiagnosed abnormal uterine bleeding,hyperkalemia bleeding irregularities and amenorrhea
645,doxylamine succinate,hypersensitivity reactions,antimuscarinic and pronounced sedative effects,enhance effects of cns depressants,alcohol,premature infants or full-term neonates,antimuscarinic effects
646,doxycycline hydrochloride,infections,primarily a bacteriostatic antibiotic,penicillin,penicillin,pregnant women and to the lactating mothers,"nausea, vomiting, diarrhoea, skin rashes"
647,doxorubicin hydrochloride,patients who have not previously received bortezomib,binding to dna and inhibition of nucleic acid synthesis,antibiotics,antibiotics,"cardiac disease, neonates, pregnancy and lactation","blurred vision, headache, seizures, paraesthesia"
648,doxophylline,bronchial asthma bronchospasm,selectively inhibits phosphodiesterase 4,together with other xanthine derivatives,xanthine derivatives,"patients with hypotension, in lactating women &amp","nausea, vomiting, headache, upset stomach and heartburn"
649,doxepin (topical),adult patients with atopic dermatitis,unknown,mao inhibitors,cream,individuals who have shown previous sensitivity to any of its components,antimuscarinic
650,doxepin (oral),3 months,unknown,alcohol,alcohol,maois or has used maois within the past two weeks,suicide
651,dorzolamide + timolol,beta blockers,intraocular pressure reduction,concurrent use,cyp2d6 inhibitors,patients who are hypersensitive,"mild burning, ocular hyperemia, blurred vision"
652,doripenem,only,binding to several penicillin-binding proteins,seizures,valproic acid,hypersensitivity,"thrombocytopenia, neutropenia"
653,dopamine hydrochloride,after open heart surgery,"can stimulate , and dopamine receptors",ergot alkaloids,ergot alkaloids,patients with known hypersensitivity to dopamine,elevated blood pressure
654,eptifibatide,patients with acute coronary syndrome,reversibly inhibits platelet aggregation,potentially additive pharmacologic effects,gp iib/iiia,severe hypertension,allergic reactions and hypotension
655,epoetin beta,patients on dialysis,identical in its amino acid and carbohydrate composition,myelotoxicity,cytostatic medicinal products,poorly controlled hypertension,"headaches, pain in the limbs, malaise and/or bone pain"
656,eplerenone,hypertension,blocks the binding of aldosterone,cyp3a4 inhibitors,hypotensive effect of 1-blockers,hyperkalaemia severe renal impairment,"rash, itching, swelling, severe dizziness, trouble breathing"
657,epirubicin hydrochloride,patients with evidence of axillary node tumor involvement,generates cytotoxic free radicals,radiation,radiation,"urinary infections, bladder inflammation or catheterisation problems",drops
658,epinastine hydrochloride,allergic conditions,does not penetrate the blood-brain barrier,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients who are hypersensitive,upper respiratory infections
659,ephedrine hydrochloride,little value in hypotensive crisis,action toward both alpha and beta receptors,volatile anaesthetics,volatile anaesthetics,coronary thrombosis,"nausea, vomiting, anorexia"
660,eperisone hydrochloride,lumbago,centrally-acting skeletal muscle relaxant,methocarbamol,methocarbamol,patients with a history of hypersensitivity,"excessive relaxation, stomachache, nausea, vertigo"
661,epalrestat,diabetic peripheral neuropathy,may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms,drug interactions,drug,if you are pregnant or breastfeeding,"abdominal pain, nausea, rash"
662,entecavir,adults and pediatric patients 2 years of age and older,inhibits all three activities of the hbv polymerase,adverse events,lamivudine or adefovir dipivoxil,patients with previously demonstrated hypersensitivity to entecavir,"headache, fatigue, dizziness and nausea"
663,entacapone,levodopa,inhibition of comt enzyme leading to an increased levodopa concentration,additive sedative effects with other cns depressants,additive sedative effects with other cns depressants,concomitant use w/ non-selective maois,increased liver enzymes
664,enoxaparin sodium,concurrently with aspirin,primarily metabolised in the liver.,agents which affect hemostasis,strictly indicated,patients with active major bleeding,spinal/epidural anesthesia
665,encephalitis vaccine,"adults, adolescents, children and infants aged 2 months and older",not well understood,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,persons with acute severe febrile conditions,"nausea, influenza like illness, fever, other injection site reactions"
666,enalapril maleate,all grades of essential hypertension and renovascular hypertension,inhibits angiotensin converting enzyme (ace),supervision,concomitant propranolol,peripheral vascular disease or generalized atherosclerosis,less than 2% of patients
667,empagliflozin + metformin hydrochloride,separate tablets,antihyperglycemic drug,hypoglycemia,alcohol,"lactic acidosis, diabetic ketoacidosis",metformin (&gt
668,empagliflozin + linagliptin,linagliptin,linagliptin,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,urinary tract infection
669,empagliflozin,adults with type 2 diabetes mellitus,sodium glucose co-transporter-2 (sglt-2) inhibitor,risk for hypoglycemia,insulin or insulin secretagogues,"severe renal impairment, end-stage renal disease, or dialysis","dehydration, hypotension"
670,emollient [cepalin+allantoin],relief of dry skin,softens and hydrates skin. it is also a mild cleanser,drug interactions,drug,acne or greasy skin,skin irritation
671,eluxadoline,adults,delta opioid receptor antagonist,oral contraceptive,oral contraceptive,pancreatitis,"constipation, nausea and abdominal pain"
672,eltrombopag olamine,chronic immune (idiopathic) thrombocytopenia,uncovered mechanism of action,polyvalent cations,calcium-rich foods,no contraindications,"nausea, diarrhea, upper respiratory tract infection, vomiting, increased alt"
673,elagolix,moderate to severe pain associated with endometriosis,gnrh) receptor antagonist,estrogen-containing contraceptives,estrogen,women: who are pregnant,"headache, nausea, insomnia, amenorrhea"
674,estriol (oral),tablet,rapidly and almost completely absorbed from the gastrointestinal tract,activated charcoal,activated charcoal,pregnancy,"breast enlargement, vaginal candidiasis, change in vaginal"
675,estradiol valerate,ovulation induction intrauterine insemination in vitro fertilization,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,anticonvulsants,.
676,estradiol,advancing age,NO SPECIFIC DATA AVAILABLE,glucose tolerance,sex steroids,"otosclerosis with deterioration during pregnancy, severe diabetes with vascular changes",NO SPECIFIC DATA AVAILABLE
677,esomeprazole + amoxicillin + clarithromycin,"active chronic gastric, duodenal and gastric ulcers",inhibition of cell wall biosynthesis,interactions,terfenadine,patients with known hypersensitivity,diarrhoea and nausea
678,esomeprazole (mups tablet),gastro-esophageal reflux disease,single optical isomer,gastric acid secretion,"diazepam, phenytoin, or quinidine",patient with known hypersensitivity,"headache, diarrhoea, nausea, flatulence, abdominal pain"
679,esmolol hydrochloride,short-term treatment,no significant intrinsic sympathomimetic or membrane stabilizing activity,avoid concomitant use,substances,pulmonary hypertension,adverse reactions
680,esomeprazole,duodenal ulcer disease,proton pump inhibitor,gastric acid secretion,oral contraceptives,hypersensitivity,"headache, diarrhoea, nausea, flatulence"
681,eslicarbazepine acetate,partial seizure,blocking voltage-gated sodium channels,contraception,phenytoin,hypersensitivity,adverse reactions
682,escitalopram oxalate,treatment of major depressive episodes,selective serotonin reuptake inhibitor,ssri or related antidepressants,fluoxetine,patients with known hypersensitivity,ssris
683,erythropoietin alfa,in patients on dialysis and not on dialysis,NO SPECIFIC DATA AVAILABLE,significant drug interactions,haematinic agent such as ferrous sulphate,patients who develop pure red cell aplasia,adverse reactions
684,erythropoietin,including patients on dialysis and patients not on dialysis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,uncontrolled hypertension,palpitations
685,erythromycin (lotion),bacterial skin infections susceptible to erythromycin.,unknown,clindamycin,clindamycin,hypersensitivity,"erythema, desquamation, burning sensation, eye irritation"
686,erythromycin (oral),clinical infections,500 mg. of the base of stearate,toxicity,theophylline,known hypersensitivity,"abdominal discomfort after oral administration, sometimes with nausea and vomiting"
687,ertugliflozin,adults with type 2 diabetes mellitus,an inhibitor of sglt2,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients on dialysis,insulin secretagogues
688,ertapenem,adult patients and pediatric patients,ertapenem binding to penicillin binding proteins,renal excretion,valproic acid/divalproex sodium,patients with a known hypersensitivity to local anesthetics,"diarrhea, nausea, headache and infused vein complication"
689,erlotinib,maintenance,NO SPECIFIC DATA AVAILABLE,dose modifications,gastric ph,NO SPECIFIC DATA AVAILABLE,the most common adverse reactions
690,eribulin mesylate,two,tubulin-based antimitotic mechanism,no drug-drug interactions,without ketoconazole,NO SPECIFIC DATA AVAILABLE,"nausea, and constipation"
691,ergotamine tartrate + caffeine,vascular headache,cranial vasoconstrictor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,sepsis,extrapyramidal effects
692,ergometrine maleate,"excessive uterine bleeding,postpartum and post-abortion bleeding",contraction of the uterine muscle,halothane,halothane,"preeclampsia, eclampsia or threatened spontaneous abortion","nausea, vomiting, abdominal pain, diarrhoea"
693,erdosteine,improves the symptoms associated with short episodes of chronic bronchitis,reducing the viscosity of mucus and purulent sputum,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"25 ml/min, or with severe liver failure","headache, cold, taste alterations, nausea, vomiting, diarrhea"
694,ethyl butylacetylaminopropionate,over 30 years,no killing action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
695,etodolac,acute and long-term,inhibition of the enzyme cycooxygenase,increased adverse effects,aspirin,"patients who have experienced asthma, urticaria or other allergic type reactions","abdominal pain, constipation, diarrhea"
696,ethyl alcohol + hydrogen peroxide + glycerol,pre-operative surgical hand disinfection,glycerol,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>
697,ethosuximide,indicated for the control of absence (petit mal)epilepsy,suppresses the paroxysmal three cycle per second spike and wave activity,"antipsychotics, antidepressants",isoniazid,pregnancy and lactation,"increased libido, myopia, vag bleeding"
698,ethinyl estradiol + lynestrenol (0.05 mg),<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,", - , ; ; - - , -",","
699,ethinyl estradiol + lynestrenol (0.0375 mg),<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,",",",",-,","
700,ethinyl estradiol + levonorgestrel + ferrous fumarate,except smoker and who use tobacco regularly,cervical mucus changes that inhibit sperm penetration,caffeine,"caffeine, dairy foods, phytic acid",hypersensitivity,"headache, nausea, mood changes"
701,ethinyl estradiol + gestodene,this pill is indicated for the prevention of pregnancy,progesterone,non hormonal back-up method of contraception,amp,<NO SPECIFIC DATA AVAILABLE>,2-3 months
702,ethinyl estradiol + drospirenone + levomefolate,premenstrual dysphoric disorder,<NO SPECIFIC DATA AVAILABLE>,contraception,drugs or herbal products,liver tumors or liver disease pregnancy,contraception
703,ethinyl estradiol + drospirenone (hrt),hormone replacement therapy,synthetic progestogen,ne,alcohol,endometrial cancer,breast pain
704,ethinyl estradiol + drospirenone (24 tablet),moderate acne vulgaris,inhibit ovulation by suppressing gonadotropin release,non hormonal back-up method of contraception,non hormonal back-up method of contraception,known or suspected pregnancy if you have heart disease,oral contraceptive
705,ethinyl estradiol + drospirenone (21 tablet),oral contraception,antimineralocorticoid and antiandrogenic properties,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,if any of the conditions appear for the first time during their use,contraceptives some undesirable effects may have seen with this tablet
706,ethinyl estradiol + desogestrel + ferrous fumarate,contraception,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>
707,ethinyl estradiol + desogestrel (0.03 mg),oral contraceptives are a very effective method of birth control,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,do not use the combined pill if you have any of the conditions listed below,"breast tenderness, pain and secretion"
708,ethinyl estradiol + desogestrel (0.02 mg),if used correctly it does not interrupt sex,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,allergy,"nausea, vomiting"
709,ethanol + isopropyl alcohol,rubbing alcohol,disinfectant properties,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
710,ethambutol,at least one other antituberculous drug,it is active against susceptible bacteria only when they are undergoing cell division,aluminium hydroxide,aluminium hydroxide,patients who are known to be hypersensitive,"retinal haemorrhage, hypersensitivity reactions"
711,etanercept,moderately to severely active rheumatoid arthritis,tumor necrosis factor (tnf) blocker,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with serious active infections,allergic reactions
712,eszopiclone,first sedative approved long-term use,allosterically coupled to benzodiazepine receptors,alcohol (which causes sedation) and drugs that have sedating effects,alcohol,having thoughts of suicide,few side effects
713,estriol (vaginal),at least 12 months since their last natural period,slowly released and absorbed into the surrounding area and into the bloodstream,irregular bleeding,st john's wort,vaginal cancer,cream
714,ferrous ascorbate + folic acid + zinc sulfate,prophylaxis,three nutritional supplements,antibiotics,meals,patients with haemolytic anaemia,mild and transient
715,ferrous ascorbate,iron deficiency anemia,iron replenishes the iron stores in your body,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"hemosiderosis, hemochromatosis",slightly increased
716,ferric pyrophosphate citrate,adult patients with hemodialysis-dependent chronic kidney disease,NO SPECIFIC DATA AVAILABLE,drug interaction studies,drug,NO SPECIFIC DATA AVAILABLE,"headache, peripheral edema, asthenia"
717,ferric derisomaltose,adult patients,releases iron,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a history of serious hypersensitivity,rash and nausea
718,ferric citrate,not on dialysis,by binding phosphate in the gi tract and decreasing absorption,blood levels of the concomitant medication,monitoring clinical responses or blood levels of the concomitant medication,patients with iron overload syndromes,discolored feces
719,ferric carboxymaltose,ofiron deficiency anemiain adult patients,a carbohydrate polymer that releases iron,drug,drug,hypersensitivity,"nausea, hypertension, flushing, decreased blood phosphorus"
720,fenticonazole nitrate [vaginal tablet],genital candidiasis,inhibiting the biosynthesis of ergosterol,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,no systemic effects should occur
721,fenticonazole nitrate [vaginal cream],vulvovaginal candidiasis,antibacterial action,interactions with other drugs,systemic absorption of fenticonazole,hypersensitivity,"slight transient burning may occasionally occur, which usually disappears rapidly."
722,fentanyl citrate,week or longer,analgesia and sedation,adverse drug effects,grapefruit juice,patients with known intolerance or hypersensitivity,respiratory depression
723,fenofibrate,hyperlipidemias,rapidly hydrolyzed after oral ingestion,hmg-coa reductase inhibitors,hmg-coa reductase inhibitors,patients with hypersensitivity to fenofibrate,"headache, dizziness, vertigo, fatigue, hair loss"
724,febuxostat,patients with gout,"non-purine, selective xanthine oxidase",toxicity,"azathioprine, mercaptopurine or theophylline",patients being treated,"liver function abnormalities, nausea, arthralgia, and rash"
725,favipiravir,cases in which other influenza antiviral drugs are ineffective or not sufficiently effective,different from that of the existing influenza antiviral drugs,toxicity,humans,pregnant women and women who may possibly be pregnant,diarrhea and increase of blood uric acid levels
726,famotidine,zollinger-ellison syndrome,completely inhibits the action of histamine on h2- receptors,clinically important drug interactions,cytochrome p450-linked drug,known hypersensitivity,rarely occur
727,famciclovir,hiv-infected patients,biotransformation,active metabolite,raloxifen,hypersensitivity to famciclovir and penciclovir,"abnormal leukocyte counts, purpura, angioedema"
728,ezetimibe,homozygous familial hypercholesterolaemia,inhibits absorption of cholesterol,fibrates,fibrates,patients with active liver disease,alone or with an hmg-coa reductase inhibitor
729,everolimus,"advanced hormone receptor-positive, her2-negative breast cancer",proliferation signal inhibitor,vaccines,grapefruit juice &amp; live vaccines,with or without respiratory impairment,"stomatitis, constipation"
730,eucalyptol+ menthol + thymol,amp; thymol mouthwash,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,diminish the effects of the mouthwash
731,eucalyptol + menthol + methyl salicylate + thymol + sodium fluoride,dental cavities,local anesthetic action,drug interactions,drug,hypersensitivity,"local irritation of mouth, nausea &amp; vomiting"
732,etoricoxib,acute gouty arthritis,"specific inhibitor within, and significantly above, the clinical dose range",meals,take without regards to meals,allergic-type reactions,"influenza-like symptoms, ecchymosis"
733,etoposide,"testicular cancer,small cell lung cancer",inhibits dna synthesis resulting in the arrest of the cell cycle,drugs that inhibit phosphatase activity,cyclosporin a,"hypersensitivity, pregnancy, lactation","leukopenia, nausea and vomiting"
734,fluocinolone acetonide,eczema and dermatitis,hydrocortisone derivative,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,primary infections,"rare, but as with all topical corticosteroids"
735,flunarizine,prophylaxis,selective calcium channel antagonist,metabolism,hepatic enzyme inducers,patients with a history of depressive illness,depression
736,fludrocortisone acetate,primary and secondary adrenocortical insufficiency,raisesextracellular fluid volume and blood pressure and lowers potassium levels,oral contraceptives and ketoconazole,oral,"systemic fungal infection, hypersensitivity",unwanted effects
737,fludarabine phosphate,previously untreated or non-refractorypatients,inhibitingdna polymerasealpha,adenosine uptake inhibitors,cytarabine,pregnancy and lactation. concomitant use of live vaccines,progressive encephalopathy and blindness (high doses).
738,fluconazole (ophthalmic),fungal corneal ulcers/ keratitis.,fungistatic,alter pharmacokinetics of certain drugs undergoing hepatic metabolism,hepatic metabolism,patients with hypersensitivity to azoles,eosinophillia
739,fluconazole,"vaginal candidiasis, oropharyngeal &amp;",potent inhibitor of fungal cytochrome p-450 dependent enzymes,rifampicin level,amp,patients with known hypersensitivity,"nausea, vomiting, abdominal pain"
740,flucloxacillin sodium,during major surgical procedures,inhibiting the formation of cell wall of bacteria,increased level of flucloxacillin in blood,blood,penicillin hypersensitive patients,"nausea, vomiting, diarrhoea, dyspepsia"
741,flibanserin,premenopausal women,5-ht1a and 5-ht2a receptors,cyp3a4 inducers,cyp3a4 inducers,patients with hepatic impairment,"nausea, fatigue, insomnia, dry mouth"
742,flavoxate hydrochloride,cystitis,anticholinergic-parasympatholytic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pyloric or duodenal obstruction,"increased ocular tension, blurred vision, disturbance in eye accommodation"
743,finerenone,adult patients,"nonsteroidal, selective antagonist of the mineralocorticoid receptor",strong or moderate cyp3a4 inducers,grapefruit or grapefruit juice,with adrenal insufficiency,hyperkalemia
744,finasteride [for b.p.h.],treatment and control of benign prostatic hyperplasia,competitive inhibitor of the 5 reductase enzyme,clinically important drug interactions,cytochrome p450 linked drug,women and paediatric patient,"impotence (3.7%), decreased libido"
745,finasteride [for androgenic alopecia],only,no androgenic or antiandrogenic effects,drug interactions,drug,women and paediatric patient,"decreased libido (1.8%), erectile dysfunction"
746,filgrastim,cancer patients receiving myelosuppressive chemotherapy,glycoprotein,drugs which may potentiate the release of neutrophils,lithium should be used with caution,hypersensitive,"transient decrease in blood glucose, raised uric acid"
747,fexofenadine hydrochloride,adults and children,selective peripheral h1-receptor antagonist activity,aluminium and magnesium hydroxide containing antacid reduces the absorption,erythromycin or ketoconazole,patients with known hypersensitivity,"headache, fatigue, drowsiness, nausea"
748,ferrous sulfate + folic acid + zinc sulfate,zinc deficiency especially during pregnancy and lactation,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,those with iron overload,zinc may also produce a gastrointestinal upset
749,ferrous sulfate + folic acid,iron,folic acid is an important factor in cell division,magnesium,magnesium trisilicate-containing antacid,patients receiving repeated blood transfusions or in patients with anaemias,nausea and epigastric pain
750,ferrous sulfate,routine administration of iron is necessary,NO SPECIFIC DATA AVAILABLE,antacids,tea,haemachromatosis and haemosiderosis,side effects can be reduced by taking it with or immediately after food
751,ferrous gluconate,iron-deficiency anemia,it also allows transportation of oxygen via haemoglobin,"absorption of levodopa, methyldopa and penicillamine",quinolones or tetracyclines,"haemochromatosis, haemolytic anemia",gi symptoms
752,ferrous fumarate + folic acid,concomitant folic acid deficiency in adults,arresting the anaemia process,absorption of both drugs are reduced,tetracycline,magnesium trisillicate and antacid containing carbonate,"gastric distress, abdominal cramps, diarrhoea, allergic reaction"
753,ferrous fumarate,prevent or treat iron deficiency anaemia,prevention and treatment of iron deficiency,reduce the absorption of ferrous fumarate from the gi tract,gi tract,hemochroma,diarrhoea or constipation
754,fluticasone propionate (nasal spray),nasal mucosa without detectable systemic activity,unknown,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a hypersensitivity to any of its ingredients,fewer side effects
755,fluticasone propionate (inhaler),patients aged 4 years and older,anti-inflammatory activity,systemic corticosteroid adverse effects,not recommended,primary treatment of status asthmaticus or other acute episodes of asthma,headache
756,fluticasone furoate,once-daily,wide range of actions on multiple cell types,coadministration of ritonavir,coadministration of ritonavir,patients with a hypersensitivity to any of its ingredients,fewer side effects are seen
757,flutamide,in combination with lhrh agonists,by blocking androgen uptake,increased prothrombin time,warfarin,"hypersensitivity, severe hepatic impairment, pregnancy and lactation","nausea, vomiting, diarrhoea"
758,flurbiprofen,individual patient treatment goals,potent inhibitor of platelet aggregation,reduced antihypertensive effect of ace inhibitors,"glyburide, metformin","asthma, urticaria, or allergic-type reactions",rash
759,flurazepam,acute or chronic medical situations requiring restful sleep,binds to an allosteric site on gaba-a receptors,cns depressants,alcohol,patients with known hypersensitivity to benzodiazepines,"severe sedation, lethargy, disorientation and coma"
760,fluphenazine decanoate,long-term management,dopaminergic d1 and d2 receptors,lithium toxicity,alcohol,patients with hypersensitivity to the drug,"tardive dyskinesia, sedation, mental confusion"
761,fluphenazine + nortriptyline,mild to moderate,piperazine side chain,central depressants,alcohol,younger children,agranulocytosis
762,flupentixol + melitracen,anxiety depression,not seem to influence the pharmacokinetic properties of the individual compounds,mao-inhibitors may cause hypertensive crises,tablet,excitable or overactive patients,rare
763,flupentixol,"psychoses,depression with or without anxiety",blocking postsynaptic dopamine receptors,dopamine,tcas. reduced efficacy of levodopa,mania; porphyria; coma; preexisting cns depression,potentially fatal: neuroleptic malignant syndrome
764,fluoxetine hydrochloride,fluoxetine,selectively inhibit the reuptake of serotonin,cns active drugs,cns active drugs,patients known to be hypersensitive to it,"excessive sweating, pruritus, skin rashes"
765,fluorouracil,alone or in combination,inhibiting the enzyme thymidylate kinase,reduced hepatic blood flow,intravenous,pregnant or breastfeeding women,elopathy
766,fluorometholone acetate,acute and chronic non-infectious conjunctivitis,immunosuppressive,drug,drug,infections,suppression of host immunity
767,fluorometholone + tetrahydrozoline,post-operative conditions,tetrahydrozoline is an alpha agonist,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,infectious conjunctivitis or keratitis,systemic effects
768,fluorometholone + gentamicin,postoperative infection,anti-inflammatory effect,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,viral infections,delay wound healing
769,fluormetholone + neomycin sulphate,before and after surgery,ocular corticosteroids,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,if you are hypersensitive,increased eye pressure
770,fluorescein sodium,diagnostic examinations,responds to electromagnetic radiation and light between the wavelengths of 465- 490 nm,none known,none known,acute necrotising pancreatitis,"staining of the skin, clothing and soft contact lenses"
771,fluocinolone acetonide + neomycin sulfate,eczema and dermatitis,neomycin sulfate actively transported across the bacterial cell membrane,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,primary infections,topical corticosteroids
772,fluocinolone acetonide + hydroquinone + tretinoin,use a sunscreen,unknown,medications with photosensitizing effects,alcohol,"hypersensitivity, allergy or intolerance","mild to moderate redness, peeling, burning, dryness or itching"
773,fluocinolone acetonide + clioquinol,inflammatory skin conditions,antifungal and antibacterial actions,mixing on the skin,mixing on the skin,children under one year of age,skin irritation
774,fusidic acid (ophthalmic),superficial bacterial infections,prolonged contact with the conjunctival sac,antistaphylococcal penicillin,antistaphylococcal penicillin,patients who are hypersensitive to any component of this preparation,very few adverse effects
775,furosemide + spironolactone,in- essential hypertension,complementary,indomethacin,sucralfate,hypersensitive,"ataxia, mental confusion, and skin rashes"
776,furosemide,fluid retention associated with chronic congestive cardiac failure,acid-base balance changes,toxic effects of nephrotoxic antibiotics,toxic effects of nephrotoxic antibiotics,"anuria, electrolyte deficiency and pre-comatose states",hyperglycemia and glycosuria
777,fucidic acid + betamethasone,eczematous dermatoses,fusidic acid is a potent topical antibacterial agent,increased hyperglycaemia,thiazide diuretics,"tb or syphilis, perioral dermatitis and rosacea",rarely
778,fructose,may be used in diabetic patients,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,methyl alcohol poisoning,"facial flushing, abdominal pain and sweating"
779,fosfomycin trometamol,only for the treatment of uncomplicated urinary tract infections,inactivation of the enzyme enolpyruvyl transferase,lowers the serum concentration,metoclopramide,patients with known hypersensitivity,"sgpt increased, skin disorder, somnolence, and vomiting"
780,formoterol fumarate + glycopyrrolate + budesonide,asthma,inhaled long-acting beta2-adrenergic agonist,anticholinergics,anticholinergics,patients who have demonstrated hypersensitivity,asthma
781,formoterol fumarate,may be clinically indicated in patients who do not have persistent asthma,inhibitor of the release ofmast cellmediators,beta-adrenergic blockers,beta-adrenergic blockers,hypersensitivity,"viral infection, bronchitis, chest infection"
782,fondaparinux sodium,conjunction with warfarin sodium,selective inhibitor of activated factor x,increased risk of bleeding,lmwh,"clinically significant bleeding, acute bacterial endocarditis",treatment of venous thromboembolism
783,follitropin beta,anovulatory infertile patients,it stimulates ovarian follicular growth,drug-drug interaction studies,drug-drug,uncontrolled thyroid or adrenal dysfunction,mild systemic allergic reactions
784,follitropin alfa + lutropin alfa,injection,recombinant dna technology,active substances,mixture with other medicinal products,hypersensitivity to the active substances,NO SPECIFIC DATA AVAILABLE>
785,follitropin alfa,theanovulatoryinfertilepatient,it stimulates ovarian follicular growth,ovarian response,gnrh agonist-induced pituitary desensitisation,"pregnancy, lactation",mild systemic allergic reactions
786,follicle stimulating hormone [urofollitropin],hcg,in vivo biological activity,drug/drug interaction studies,drug/drug,pregnancy or lactation,"headache, vaginal bleeding, nausea, and hot flashes"
787,folic acid + zinc sulfate monohydrate,tablet,amp,drug interactions,calcium,untreated cobalamine deficiency,zinc
788,folic acid,"pregnancy, infancy, or childhood",receptor-mediated endocytosis,none has been reported,none has been reported,patients who have shown previous intolerance to the drug,gastro-intestinal disturbances may occur
789,fluvoxamine maleate,maprotiline hydrochloride,not been fully determined,cytochrome p450 isoenzymes,tricyclic antidepressants,linezolid or intravenous methylene blue,"decreased libido, dry mouth, rhinitis"
790,fluvastatin,lipid-altering agents,competitively inhibiting hmg-coa reductase,hiv protease inhibitors,niacin (nicotinic acid,pregnancy and lactation,increased blood creatinine phosphokinase
791,fluticasone propionate + formoterol fumarate,adults only,formoterol fumarate dihydrate,co-administration with such drugs,co-administration of strong cyp 3a4 inhibitors,asymptomatic,undesirable effects
792,fluticasone propionate (topical),corticosteroid responsive eczema/dermatitis,anti-inflammatorypotency,no information is available,no information is available,"rosacea, acne vulgaris, perioral dermatitis",local burning and pruritus
793,fluticasone propionate (nebuliser suspension),high dose inhaled or oral corticosteroid therapy,unknown,drug interactions,drug,patients with a history of hypersensitivity to any component of the preparation,"cataract, glaucoma"
794,glibenclamide,ineffective in completely pancreatectomized patients,it stimulates the mobilization of endogenous insulin,hypoglycemic effect,alcohol,pregnancy,"nausea, vomiting, epigastric pain"
795,glecaprevir + pibrentasvir,not both,inhibits the assembly of proteins and production of mature hcv particles,coadministration of carbamazepine,st. johns wort,patients with severe hepatic impairment,headache and fatigue
796,gentian violet,topical antiseptic,free-radical mechanism,drug,drug,ulcerative lesion,"redness, irritation, swelling or pain"
797,gentamicin sulfate (topical),minor surgical wounds,bactericidal antibiotic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pregnancy and myasthenia gravis,irritation
798,gentamicin sulfate (ophthalmic),mastoidectomy or tympanoplasty,eye drops,eye/ear drops,eye/ear drops,individuals with a history of sensitivity reaction to any of its components,eye/ear drop
799,gentamicin sulfate (injection),"septicaemia, meningitis, respiratory tract infections",cell death results,potentially nephrotoxic or ototoxic drug substances,potent diuretics,NO SPECIFIC DATA AVAILABLE,adverse renal effects
800,gentamicin + hydrocortisone acetate,surgery to infected mastoid cavities,corticosteroid,hyperglycaemia and hypokalaemia,ethanol,pregnancy; hepatic impairment,allergic
801,gemifloxacin,acute bacterial exacerbation of chronic bronchitis,inhibiting dna synthesis,aluminium or magnesium containing antacids and iron salts,sucralfate administration,children under 18 years of age,fungal overgrowth in body
802,gemfibrozil,hyperlipoproteinemia,anti-lipemic agent,risks,lovastatin,"alcoholism, hepatic impairment, gallstone, and pregnancy","pruritus, rash, headache, dizziness, blurred vision"
803,gemcitabine,previously treated with 5-fu,inhibiting dna polymerase and ribonucleotide reductase,anticoagulant effect of warfarin,warfarin,"pregnancy, lactation; hypersensitivity",mild gi effects
804,gefitinib,limitation of use: safety and efficacy,atp)-binding site of the enzyme,cyp3a4 inducers,cyp3a4 inducers,hypersensitivity. lactation,elevations in blood creatinine
805,gatifloxacin + dexamethasone,sterile eye drops,inhibits bacterial dna gyrase and topoisomerase iv,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,individuals hypersensitive,"mild burning, chemosis, redness may occur."
806,gatifloxacin (oral),infections,inhibition of both dna gyrase,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity of gatifloxacin,mild
807,gatifloxacin (ophthalmic),bacterial conjunctivitis,fluoroquinolones,specific drug interaction studies,eye drops,hypersensitivity to gatifloxacin,conjunctival irritation
808,ganciclovir (ophthalmic),acute herpetic keratitis,phosphorylation,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,"blurred vision (60%), eye irritation"
809,gadoversetamide,intravenous,paramagnetic agent,contrast agents,contrast agents,prior hypersensitivity reactions,nausea and paresthesia
810,gadodiamide,mri,does not cross the intact blood-brain barrier,drug,drug,"chronic, severe kidney disease","nephrogenic systemic fibrosis, hypersensitivity reactions"
811,gabapentin,partial seizure and secondary generalized seizure,activity of parent compound,oral contraceptive preparations,oral contraceptive preparations,patients who have known hypersensitivity to the drug,"fatigue, dizziness, ataxia, weight gain, peripheral edema"
812,fusidic acid + hydrocortisone,seborrhoeic dermatitis,anti-inflammatory &amp; anti-pruritic effects,hazardous drug interactions,hydrocortisone acetate,patients with hypersensitivity,generally local
813,fusidic acid + betamethasone,eczema and dermatitis with secondary infections,inhibition of bacterial protein synthesis,corticosteroids,skin-applied) medications,viral tuberculosis and fungal skin infections,allergic reactions
814,glycopyrronium bromide (oral solution),3 to 16 years,competitive inhibitor of acetylcholine receptors,dose reduction,digoxin tablets,patients with medical conditions that preclude anticholinergic therapy,"increased viscosity of bronchial secretion, nasal congestion"
815,glycopyrronium bromide (injection),anesthesia,quaternary ammonium antimuscarinic with peripheral effects,failure to dissolve under the tongue owing to dry mouth,tricyclic antidepressants,NO SPECIFIC DATA AVAILABLE,rarely
816,glycopyrronium bromide (inhalation capsule),maintenance bronchodilator,inhibition of m3-receptors at the smooth muscle results in relaxation,without clinical evidence of drug interactions,inhaled steroids,hypersensitivity,"dehydration, dry mouth, constipation"
817,glycine,irrigating fluid of choice,amino acid and a non-electrolyte,do not store,"additives, use aseptic technique, mix thoroughly and do not store",patients with anuria,electrolyte loss
818,glycerol + liquid sugar,glycerol &amp; liquid sugar,osmosis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity or intolerance,allergic to the ingredients
819,glycerol + hypromellose + polyethylene glycol 400,keratoconjunctivitis sicca,greater muco-adhesive properties,an interval of at least 5 minutes between each application,medicines,patients with known hypersensitivity to any ingredient of the product,blurred vision after application
820,glycerol,latex condoms,NO SPECIFIC DATA AVAILABLE,drug,drug,persons with a known hypersensitivity,no common side effects have been reported
821,glycerin + hypromellose + polyethylene glycol + tetrahydrozoline + zinc sulfate,temporary relief of burning and irritation due to exposure to wind or sun,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,stop use and ask a doctor if you feel eye pain,"temporary stinging or burning; redness, itching and watering of the eye"
822,glycerin,occasional constipation,hyperosmotic laxative,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,constipated,rectal discomfort or a burning sensation
823,glucose 19% + vamin 18 novum + intralipid 20%,parenteral nutrition,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,contra-indications to infusion therapy,transient increases in liver enzymes during intravenous nutrition
824,glucose 11% + vamin 18 novum + intralipid 20%,parenteral nutrition,<NO SPECIFIC DATA AVAILABLE,soybean oil,soybean oil,contra-indications to infusion therapy,transient increases in liver enzymes during intravenous nutrition
825,glucosamine sulfate + diacerein,osteoarthritis rheumatoid arthritis,"analgesic, antipyretic and anti-inflammatory activity",decrease absorption,aluminium,hypersensitivity,no serious adverse effect has been reported
826,glucosamine sulfate + chondroitin + camphor + peppermint oil,topically,chemically manufactured from turpentine oil,not known to interact significantly with other medicines,this medicine,<NO SPECIFIC DATA AVAILABLE,there are no known systemic side effects
827,glucosamine sulfate + chondroitin,dietary supplement,synergistic effect,antibiotics,nitrates,allergic to shellfish or sulfur,amp
828,glucosamine hydrochloride,dietary supplement,prodrug for glucosamine,antibiotics,nitrates,proven hypersensitivity,rarely occurring side effects
829,glipizide + metformin hydrochloride,amp; metformin,sulfonylurea,alcohol,alcohol,"pregnancy, breast-feeding",amp; metformin
830,glipizide,certain patients who are receiving insulin,dependent upon functioning beta cells,hypoglycaemia,protein bound,patients who are hypersensitive,"dose related, transient, and responded to dose reduction or withdrawal of the medication"
831,glimepiride + metformin,replacement,metformin hydrochloride,alcohol and alcohol-containing medications iodinated contrast agents,alcohol and alcohol-containing medications iodinated contrast agents,patients with severe impairment of liver function and in dialysis patients,weight gain
832,glimepiride,concomitantly with metformin,stimulating the release of insulin from functioning pancreatic beta cells,attenuate the hypoglycaemic action,acute and chronic aicohol intake,patients hypersensitive to glimepiride,"hypoglycaemia, temporary visual impairment"
833,gliclazide,certain form of diabetes (type 2 diabetes mellitus) in adults,decreases hepatic glucose output,drinking alcohol,drinking alcohol,if you are allergic to gliclazide or to other medicines,"gliclazide can cause side effects, although not everybody gets them"
834,hepatitis b vaccine [rdna],all known subtypes of hepatitis b virus,<NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with previous hypersensitivity,generally well tolerated
835,hepatitis b immune globulin,in case of accidental exposure in non-immunised subjects,NO SPECIFIC DATA AVAILABLE,mixed with other medicinal products,hepatitis b immune globulin must not be mixed with other medicinal products,allergic reactions,"hypersensitivity, anaphylactic shock"
836,hepatitis a vaccine,12 months of age and older,the presence of antibodies to hav confers protection against hepatitis a infection,reduced response to vaccination,corticosteroids or antineoplastics,patients with hypersensitivity reactions to egg,"transient soreness, erythema, induration at inj site."
837,heparin sodium,patients undergoing major abdomino-thoracicsurgery,multiple sites in the normal coagulation system,increased risk of hyperkalaemia,activated protein c,elective surgical procedures,"increased serum concentrations of ast and alt, prolonged prothrombin time"
838,hartmann's solution,metabolic acidosis associated with dehydration,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with diabetes mellitus,"nausea, vomiting, headache"
839,halothane,all types of surgery and in patients of all ages,"anaesthetic agents, is unknown",muscle relaxants,ketamine,history of unexplained jaundice and pyrexia,"depression, hypotension, skeletal muscle relaxation, bradycardia"
840,haloperidol,"psychomotor agitation in mania, dementia, acute and chronic schizophrenia",12 hours after one single administration,slower excretion rate,methyldopa,dyskinesias,"headache, vertigo, insomnia"
841,halobetasol propionate + tazarotene,plaque psoriasis in adults,cosyntropin,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,pregnancy,rash
842,halobetasol propionate,"not recommended, and the total dosage should not exceed 50 gm/week","anti-inflammatory, antipruritic and vasoconstrictive",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to any of the components of the preparation,"burning, itching, dryness"
843,halcinonide,corticosteroid-responsive dermatoses,unclear,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a history of hypersensitivity,mild depigmentation;
844,halazone,solution 4 mg,disinfecting,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
845,haemophilus influenzae type b vaccine [conjugated],2 months of age,predominantly stimulates b-cells to produce antibodies,different injection sites,"hepatitis b, or live attenuated measles",in case of any known hypersensitivity,adverse reactions
846,guaifenesin + levomenthol + diphenhydramine,syrup,mild local anesthetic and decongestant properties,"alcohol, and other cns depressants",alcohol,individuals with known hypersensitivity to the product or any of its components,"this syrup may cause drowsiness, dizziness, nausea and vomiting"
847,guaifenesin + dextromethorphan + menthol,fast &amp,dextromethorphan hydrobromide is a cough suppressant,reactions,codeine,ask a doctor or pharmacist,"dizziness, drowsiness;"
848,griseofulvin [microsize],not justified in minor or trivial infections,inhibits the growth of dermatophytes is not clear,efficacy of oral contraceptives,barbiturates,hypersensitivity to griseofulvin,oftherapyand
849,granisetron,the prevention and treatment of post operative nausea and vomiting,highly selective 5-ht3 receptor antagonist,serotonin syndrome with other serotonergic agents,phenobarbital,patients with known hypersensitivity to granisetron,application site reactions
850,gramacidin + neomycin + polymixin b,superficial infections of the external eye,gramicidin,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,those persons who have shown hypersensitivity to any of its components,anti-infective components of this product
851,golimumab,moderately to severely active rheumatoid arthritis,unknown,live vaccines/therapeutic infectious agents,live vaccines/therapeutic infectious agents,NO SPECIFIC DATA AVAILABLE,"upper respiratory tract infection, nasopharyngitis, injection site reactions"
852,glycopyrronium bromide + formoterol fumarate,maintenance treatment of patients with chronic obstructive pulmonary,rapid onset of action,anticholinergics,anticholinergics,hypersensitivity,possible side efects are sudden breathing problems
853,glycopyrronium bromide (respirator solution),long-term maintenance treatment for patients with chronic obstructive pulmonary disease,inhibition of m3 receptor at the smooth muscle leading to bronchodilation,unnecessary co-administration,anticholinergics,patients with a hypersensitivity to glycopyrrolate,adverse reactions
854,hydrogen peroxide,"theskinto prevent infection of minor cuts, scrapes, and burns.",oxidising agent with antibacterial and antiviral activity,"donot start, stop, or change the dosage of any medicine","donot start, stop, or change the dosage of any medicine",instillation of hydrogen peroxide into closed body cavities,"gas embolism, rupture of the colon"
855,hydrocortisone butyrate,<NO SPECIFIC DATA AVAILABLE>,", - - - -",<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,","
856,hydrocortisone acetate + neomycin sulphate,amp,aminoglycoside antibiotic,enhance the effect of non-depolarising muscle relaxants,aminoglycosides,bacterial infections,burning
857,hydrocortisone acetate + benzyl benzoate + bismuth subgallate + bismuth oxide + balsam peru + zinc oxide,comprehensive symptomatic treatment of internal and external hemorrhoids,hydrocortisone acetate has anti-inflammatory action,increase the likelihood of systemic effects,orally may increase the likelihood of systemic effects,"tubercular, fungal and most viral lesions",systemic corticosteroid effects
858,hydrocortisone acetate,primary irritant dermatitis contact allergic dermatitis eczema,cytosolic glucocorticoid receptor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,infections,if signs of hypersensitivity
859,hydrocortisone + neomycin sulphate + polymixin b,amp; polymixin b,antibiotics,increased neuromuscular blockade and possibly respiratory depression,additive toxicity,allergic,"become red, scaly and itchy"
860,hydrocortisone + lidocaine,anti-inflammatory,amide type local anesthesia,drugs that inhibit the metabolism of lidocaine,?-blockers,patients with a history of hypersensitivity,"rectal bleeding, swelling of the skin, adrenal suppression"
861,hydrocortisone,primary or secondary adrenocortical insufficiency,inhibiting the enzyme phospholipase a2,steroid toxicity,corticosteroid,severe systemic fungal infections,hydrocortisone is generally well tolerated except in prolonged high doses
862,hydrochlorothiazide + triamterene,potassiumlevels,triamterene directly inhibits the exchange of NO SPECIFIC DATA AVAILABLE for k and hydrogen,platinum compounds,platinum compounds,k supplements,"rarely, sle and photosensitivity"
863,hydrochlorothiazide,hypertension,the mechanism is not fully understood,pressor amines such as adrenaline may show decreased arterial responsiveness,gastrointestinal tract,"anuria, hypersensitivity",moderate to severe
864,hyaluronic acid,indicated in- relieve symptoms of knee osteoarthritis,all-natural ingredients,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no known side effects reported so far
865,human tetanus immunoglobulin,tetanus immunoglobulin should always be administered,interfering with the normal interaction of the toxoid with human tissue,may reduce the efficacy of live vaccines,may reduce the efficacy of live vaccines,deficiency or severe anaphylactic reactions to plasma products,rarely
866,"human papillomavirus quadrivalent (types 6, 11, 16, and 18)",genital warts,unknown,concomitantly,recombivax hb [hepatitis b vaccine,severe allergic reactions to yeast,1.0% and greater than aahs control or saline placebo
867,human papillomavirus bivalent (types 16 & 18),oncogenic,non-infectious vaccine produced by recombinant technology,vaccine,vaccine,patient suffering from an acute febrile illness,"injection site pain, erythema, and inflammation"
868,human milk based amino acid,parenteral nutrition,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
869,human menopausal gonadotrophin,hcg,gametotropic and steroidogenic effect,infertile males,hcg,tumors in the pituitary or in the hypothalamic glands,NO SPECIFIC DATA AVAILABLE
870,human immunoglobulin-g [igg],treatment of primary immunodeficiency for combined therapy with antibiotics,<NO SPECIFIC DATA AVAILABLE>,may interfere with the immune response,admin of the immunoglobulins,anaphylactic or severe systemic hypersensitivity reactions,renal failure
871,human chorionic gonadotrophin,cryptorchidism,lh activity,no interactions of clinical relevance,no interactions of clinical relevance,prostatic carcinoma or breast carcinoma in the male.,increased androgen production
872,human anti-d immunoglobulins,prevention of rhimmunizationin,antibodies to foetal rhesus-positive rbcs,live vaccines,live vaccines,splenectomised or rhesus-negative patients,"fever, chills, nausea, facial flushing, headache"
873,homatropine hydrobromide,sterile eye drops,tertiary amine antimuscarinic,antimuscarinic effect,maois or parasympathomimetics,patients with closed-angle glaucoma,hypersensitivity
874,ibuprofen,rheumatoid arthritis,both a peripheral and a central effect,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients who have shown the previous hypersensitivity to ibuprofen,"upset stomach, vomiting, heartburn, nausea"
875,ibrutinib,mantle cell lymphoma,small-molecule inhibitor of btk,if a moderate cyp3a inhibitor,cyp3a inducers,hypersensitivity,"diarrhea, visual disturbance"
876,ibandronic acid + calcium carbonate + vitamin d3,kit,vitamin-d aids in the absorption of calcium from gi tract,interfere with absorption of ibandronate,"spinach, cereals, milk","hypercalcemia, hyperparathyroidism",amp
877,ibandronic acid & calcium orotate,women (especially after menopause) &amp; men,NO SPECIFIC DATA AVAILABLE,aspirin,aspirin of nsnads,"kidney stone, kidney disease and lung disease",calcium orotate
878,ibandronic acid,postmenopausal osteoporosis,inhibition of bone resorption,unlikely to displace other drugs,calcium supplements,patients with known hypersensitivity,"dyspepsia, nausea, diarrhea, abdominal pain"
879,hypromellose + carbomer,substitute tear fluid,hypertonic tear fluid caused by dry eyes,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,"burning, stinging, allergic reactions or red eyes"
880,hypromellose,all patients with ocular discomfort,lubricant and artificial tear,compatibility study with lens material,no compatibility study,hypersensitivity,brief blurred vision or a slight stinging sensation
881,hyoscine hydrobromide,prevention and control of nausea and vomiting associated with motion sickness/travel sickness,antimuscarinic,reduced effects with acetylcholinesterase inhibitors,tacrine,glaucoma/blindness,"dry mouth, dizziness, blurred vision, difficulty with micturition."
882,hyoscine butylbromide,antispasmodic,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,giddiness)
883,hylan g-f 20,pain in osteoarthritis (oa) of the knee,helps to restore the shock-absorbing effect of the fluid within the knee,no information provided,no information provided,knee joint infections or skin diseases or infections in the area of the injection site,"pain in the injected knee, swelling in the injected knee"
884,hydroxyzine hydrochloride,4 months,h1 receptor antagonist,monoamine oxidase inhibitors,monoamine oxidase inhibitors,patients with a known hypersensitivity,mild and transitory in nature
885,hydroxyurea,resistantchronic myeloid leukemia,inactivating the enzyme,anticoagulants,oral anticoagulants,hypersensitivity,"pulmonary oedema, dermatological reactions, headache, dizziness"
886,hydroxypropyl methylcellulose,it maintains the depth of the anterior chamber during the whole surgical procedure,non pyrogenic viscoelastic solution that occupies space and protects tissue,drug interactions,drug,when used as recommended,extremely well tolerated
887,hydroxyprogesterone caproate,indicated,anti-inflammatory effect,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,undiagnosed abnormal vaginal bleeding unrelated to pregnancy,allergic reactions
888,hydroxyethyl starch + sodium chloride,children,NO SPECIFIC DATA AVAILABLE,mixed with other medicinal products,mixed with other medicinal products,suffer from severe generalized infection (sepsis) have a severe liver disease,does not cause pancreatitis
889,hydroxyethyl cellulose + glycerin,gloves and instruments,providing lubrication,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,people with prior history of sensitivity or allergic reaction,NO SPECIFIC DATA AVAILABLE
890,hydroxychloroquine sulphate,acute and chronic rheumatoid arthritis,it acts as an immunosuppressant,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"nausea, vomiting, stomach upset"
891,hydroxocobalamin,themouth,renally excreted,arsenic trioxide chloracol,hicon (sodium iodide-i-131) lodotope,hypersensitivity,pain after injection
892,hydroquinone + octyldimethyl + dioxybenzone + oxybenzone,cosmetics,octyldimethyl p-aminobenzoate,drug interactions,drug,sunburn or depilatory usage,hypersensitivity
893,hydroquinone,gradual bleaching,suppressing melanocyte metabolic processes,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity or allergic reaction,no systemic adverse reactions have been reported
894,inositol nicotinate,"hyperlipidemias, raynaud's disease",vasodilator and lipid-lowering agent,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,anyone is allergic to one or any of its ingredients,"headache, rash, paraesthesia"
895,infliximab,mission,unknown,increased risk of serious infections,anakinra or abatacept- increased risk of serious infections,previous severe hypersensitivity reaction,"headache, and abdominal pain"
896,indomethacin (rectal),"rheumatoid arthritis, ankylosing spondylitis",not related to the pituitary gland or the adrenals,anticoagulants,aspirin,previously hypersensitive patient,gastrointestinal reactions
897,indomethacin (oral),rheumatoid arthritis,"strong anti-inflammatory, analgesic, and antipyretic properties",antihypertensive drugs,sulfonylureas,"patients with ulcer, gastritis, active ulcerative colitis",minimize the frequency and the severity of these untoward effects
898,indapamide + perindopril arginine,essential hypertension,ace inhibitor,lithium toxicity,alcohol,pregnancy; lactation,"dry cough, dry mouth"
899,indapamide + amlodipine,concurrently at the same dose level,direct relaxant effect on vascular smooth muscle,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,severe renal failure,"somnolence, dizziness, headache, palpitations"
900,indapamide,patients with renal function impairment,extra-renal antihypertensive action,decrease arterial responsiveness to norepinephrine,norepinephrine,hypersensitivity to sulfonamides,"headache, anorexia, gastric irritation"
901,indacaterol maleate,airflow obstruction,NO SPECIFIC DATA AVAILABLE,monoamine oxidase inhibitors,monoamine oxidase inhibitors,hypersensitivity to indacaterol or to any of the ingredients,"cough, nasopharyngitis, headache, nausea"
902,indacaterol + glycopyrronium + mometasone furoate,inhaled corticosteroid,mometasone furoate,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitive,<NO SPECIFIC DATA AVAILABLE>
903,indacaterol + glycopyrronium,airflow obstruction,antimuscarinic agent,potassium,p-gp,<NO SPECIFIC DATA AVAILABLE,amp
904,inactivated polio vaccine,oral polio vaccine is contraindicated,neutralizing antibodies against each type of virus,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,subjects with known hypersensitivity,mild erythematous reaction and induration
905,inactivated influenza vaccine,should be based on official recommendations,NO SPECIFIC DATA AVAILABLE>,adverse reactions,immunosuppressant treatment,patients with febrile illness or acute infection,NO SPECIFIC DATA AVAILABLE
906,inactivated hepatitis a vaccine,active immunization of adults and children from 12 months of age,antibodies to hav confers protection against hepatitis a infection,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,people who are allergic,fever
907,imiquimod,external genital and perianal warts in adults,both the innate and acquired immune response,immunosuppressive medication,cream,patients with hypersensitivity,localised hypopigmentation and hyperpigmentation
908,imipramine hydrochloride,children,inhibiting the neuronal reuptake,reducing the dosage of imipramine,alcohol,patients with convulsive disorders or glaucoma,"nausea, vomiting, loss of appetite"
909,imipenem + cilastatin,amp,hydrolyzed by dehydropeptidase-i,increased risk of generalised seizures,ganciclovir,patients who have demonstrated hypersensitivity to this product,penicillin
910,imatinib mesylate,adjuvant treatment of adult patients following complete gross resection of kit,protein-tyrosine kinase inhibitor,grapefruit juice,grapefruit juice,NO SPECIFIC DATA AVAILABLE,impairments related to driving and using machinery renal toxicity
911,iloperidone,schizophrenia in adults. when deciding among the alternative treatments,high affinity for adrenergic receptors,drug,drug,hypersensitivity,ejaculation failure
912,ifosfamide,in combination with certain other approved antineoplastic agents,hepatic microsomal enzymes,serum levels,cyp2a6 inducers,"pregnancy, lactation","confusion, alopoecia, nausea, vomiting"
913,idoxuridine,"skin infection, eyes infection, infection of reproduction organs",identical in chemical structure to thymidine,corticosteroids,corticosteroids,hypersensitivity,"eye irritation or pain, redness, itching, swelling of the eye"
914,irbesartan,treatment of renal disease in patients with hypertension,angiotensin ii receptor antagonist,hypotension,non-steroidal anti- inflammatory drugs,pregnancy,"nausea, vomiting"
915,ipratropium bromide (nebuliser solution),maintenance,antagonising the action of acetylcholine,<NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity to atropine,allergic-type reactions
916,ipratropium bromide (inhaler),asthma,inhibits serous and seromucous gland secretions by nasal application,adverse drug reactions,without any adverse drug reactions,patients with a history of hypersensitivity to soya lecithin,bronchial secretion
917,iopamidol,"digital subtraction angiography, venography, urography",iopamidol blocks x-rays as they pass through the body,iopamidol may interfere with thyroid function,metformin,waldenstrom's macroglobulinemia,arrhythmias
918,iohexol,adults and children,subarachnoid injection,all iodinated contrast media may interfere with tests on thyroid function,all iodinated contrast media,manifest thyrotoxicosis. history of serious reaction,"hyperthyroidism, thyroid storm thyrotoxicosis"
919,iodixanol,intra-arterial procedures,opacifies vessels in the path of flow of the contrast agent,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,not indicated for intrathecal use,"discomfort, warmth, pain"
920,intravenous fat emulsion,parenteral nutrition indications,isotonic,drugs,insulin,severe liver damage and acute shock,"shivering, chills and nausea/vomiting"
921,interferon alfa-2a [recombinant],in patients with chronic hepatitis c diagnosed by hcv antibody,it inhibits replication of a wide range of rna and dna viruses,increased risk of renal failure,renal failure,patients with severe pre-existing cardiac disease or with any history of cardiac illness,bone marrow depression
922,insulin lispro protamine + insulin lispro,25% insulin lispro injection,intermediate-acting glucose-lowering agent,lithium,lithium,during episodes of hypoglycemia,hypoglycaemia
923,insulin lispro,without a longer-acting insulin,"rapid-acting, parenteral blood glucose-lowering agent",alcohol,alcohol,hypersensitivity,allergic reactions
924,insulin human [rdna] + isophane insulin human,treatment of all patients with type 1 diabetes,recombinant dna technology,the dosage of insulin should be reduced,oral contraceptive drug,patients who have allergic reaction,allergic
925,insulin human [long-acting],treatment of all patients with type 1 diabetes,insulatard,alcohol,alcohol,hypersensitivity,hypoglycemia
926,insulin human [fast-acting],treatment of all patients with type 1 diabetes,"within 1 hours, reaches a maximum effect within 4-12 hours",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,low blood sugar
927,insulin glulisine,adults and children,regulation of glucose metabolism,decreased insulin resistance,octreotide and lanreotide,during episodes of hypoglycemia,rash all over your body shortness of breath
928,insulin glargine [rdna],adults and children,parenteral blood glucose lowering agent,thyroid hormones,oral anti-diabetic products,hypersensitivity,"hypoglycemia, allergic reactions"
929,insulin detemir,"use intravenous, rapid acting or short-acting insulin instead.",through binding to insulin receptors,decreased insulin resistance,octreotide and lanreotide,patients with hypersensitivity,"pain, itching, hives, swelling and inflammation"
930,insulin degludec + insulin aspart premixed,diabetes mellitus,human insulin receptor,drug interactions,drug,hypersensitivity,"hypoglycemia, allergic reactions"
931,insulin degludec,once-daily,delayed absorption,decreased insulin resistance,octreotide and lanreotide,"hypoglycaemia, hyperglycaemia, eye disorder",injection site reactions
932,insulin aspart + insulin aspart protamine,diabetes mellitus,amp,thyroid hormones,alcohol,hypersensitivity to this drug or one of its excipients,"hypoglycemia, hypersensitivity and allergic reactions"
933,insulin aspart,adults and children,inhibiting the output of glucose from the liver,oral anti-diabetic products,oral anti-diabetic products,during episodes of hypoglycemia,"hypoglycemia, allergic reactions"
934,isotretinoin (topical),mild to moderate inflammatory and non-inflammatory acne vulgaris,unknown mechanism,preparations containing a peeling agent,abrasive cleansers,patients with known hypersensitivity to isotretinoin,"stinging, burning or irritation; erythema andpeeling"
935,isotretinoin (oral),topical therapy,unknown mechanism,increased risk of local irritation,topical keratolytic or exfoliative anti-acne agents,pregnant or breastfeeding,overdose
936,isosorbide mononitrate,aborting an acute anginal episode,pharmacological,phosphodiesterase inhibitors,riociguat,patients who are allergic to it,"headache, feelings of dizziness, hypotension"
937,isopropyl alcohol + hydrogen peroxide + glycerol,only 70% solution,disinfecting action is not known,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,"burning, stinging, or a cold feeling"
938,isopropyl alcohol,pre-operative surgical hand disinfection,not known,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
939,isopropamide + trifluoperazine,wide range of gastrointestinal disorders,trifluoperazine,reverses antihypertensive effect of guanethidine,lithium,nausea and vomiting are believed to be evidence of intestinal obstruction or brain tumor,anticholinergic
940,isoniazid,tuberculosis,inhibits the synthesis of mycoloic acids in susceptible bacteria,toxicity,increased metabolism of enflurane,hypersensitivity,"loss of appetite, nausea, vomiting, stomach pain"
941,isoflurane,not been developed to establish its application in obstetrical anesthesia.,all commonly used muscle relaxants,ace inhibitors,ace inhibitors,porphyria,"nausea, vomiting, shivering, dose-dependent hypotension"
942,irrigating solution,chlorinated water for washing the eye,daily or emergency eye cleansing,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no data available,NO SPECIFIC DATA AVAILABLE
943,iron sucrose injection [elemental iron],thisis,the sucrose component is eliminated mainly through urinary excretion,absorption of oral iron is reduced,oral,patients with evidence of iron overload,adverse reactions
944,iron polymaltose complex + vitamin b complex + zinc,zinc deficiencies,iron,ionic interaction,"phytates, oxalates, tannin",patients with a known hypersensitivity,oral iron preparations
945,iron polymaltose complex + folic acid + zinc sulfate,tablet,zinc keeps enzymes working and helps to metabolize proteins,ionic interaction,"phytates, oxalates, tannin",patients with a known hypersensitivity,"nausea, vomiting, constipation or diarrhoea"
946,iron polymaltose complex + folic acid + zinc + vitamin b-complex,"zinc, iron, folic acid, b-vitamins deficiency",b vitamins,drug interactions,drug,patients with a known hypersensitivity to any of the ingredients,allergic reactions
947,iron polymaltose complex,"before, during and after pregnancy and during lactation",it does not release any free radicals,ionic interactions,"phytates, oxalates, tannin",hypersensitivity,"nausea, vomiting, constipation or diarrhoea"
948,iron hydroxide polymaltose + folic acid + zinc sulfate monohydrate,zinc deficiencies,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE
949,iron + folic acid + vitamin b complex + vitamine c + zinc sulfate,prophylaxis,vitamin b complex,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,patients with a known hypersensitivity to any of the ingredients,allergic reactions
950,iron + folic acid + vitamin b complex + vitamin c,prophylaxis,conversion of folic acid to folinic acid,absorption of all these may be impaired,antacids and tetracycline,haemachromatosis and haemosiderosis,allergic reactions
951,iron + folic acid + vitamin a + vitamin c + zinc,bangladesh,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,"thalassemia, sickle cell anemia, and hiv/aids",no side effect
952,irinotecan hydrochloride,metastatic carcinoma of the colon or rectum,inhibits the action of topoisomerase i,st john's wort,st john's wort,patients with a known hypersensitivity to the drug or its excitements,vasodilation
953,irbesartan + hydrochlorothiazide,amp,hydrochlorothiazide,alcohol,alcohol,patients with diabetes,hydrochlorothiazide
954,l-lysine hydrochloride,"infection in cuts, wounds abrasion, surgical incisions and burns",promotes healing of wounds by active and controlled regeneration of in-situ cells,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to the amino acid,slight itching sensation
955,ketotifen fumarate (oral),prophylactic treatment of bronchial asthma,selective mast cell stabilizer administered by inhalation,platelet count,platelet count,pregnancy or when breast feeding,dry mouth and slight dizziness
956,ketotifen fumarate (ophthalmic),allergic conjunctivitis,non-competitive histamine (h1) receptor blocking property,an interval of at least 5 minutes between the two medications,eye drops,hypersensitivity,"dry eyes, eyelid disorder, conjunctivitis, eye pain"
957,ketorolac tromethamine (ophthalmic),ocular surgery,secondary to inhibition of prostaglandin biosynthesis,no information available,no information available,patients with previously demonstrated hypersensitivity,superficial ocular infections
958,ketorolac tromethamine,moderate to severe acute post-operative pain,inhibiting the cyclooxygenase enzyme system,side effects,nsaids or aspirin,children under 16 years of age,"nausea, vomiting, gastro-intestinal bleeding"
959,ketoprofen (topical),mild to moderate local pain,analgesic and antipyretic actions,serum concentrations,serum,eczema or acne; or in infected skin or open wounds,"nausea, abdominal pain, vomiting, and flatulence"
960,ketoprofen (oral & injection),regardless of the origin,analgesic and antipyretic actions,plasma clearance,plasma clearance,severe heart failure,"nausea, abdominal pain, vomiting"
961,ketoconazole (tablet),maintenance treatment to prevent recurrence in systemic mycotic infections,blocking fungal cyp450,reduced absorption,cyp3a4 substrates,pregnancy and in patients with acute liver pathology,nausea and itching may occasionally occur
962,ketoconazole (shampoo),infections,antifungal agent,no information,no information was found for the shampoo,patients with known hypersensitivity,"a local burning sensation, itching or contact dermatitis"
963,ketoconazole (cream),dermatophyte infections,interacts with 14--sterol demethylase,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with knownhypersensitivity to ketoconazole,"wereskin application site burning sensation, erythema and pruritus"
964,ketamine,diagnostic and surgical procedures that do not require skeletal muscle relaxation,cortex and limbic system,thyroid hormones,apnoea,patients with increased intraocular or csf pressure,"nausea, vomiting, lacrimation"
965,kanamycin,serious infections caused by bacteria,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
966,ivermectin (topical),6 months of age and older,glutamate-gated chloride channels,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,conjunctivitis ocular hyperemia eye irritation
967,ivermectin (tablet),1427 patients in onchocerciasis-endemic areas of west africa,death of the parasite,increased inr,warfarin,patients who are hypersensitive,hypotension
968,ivabradine,contra-indication to the use of beta-blockers,selective and specific inhibition of the cardiac pacemaker i f current,cardiovascular and non cardiovascular qt wave prolonging medicinal products,cardiovascular,"cardiogenic shock, acute myocardial infarction","headaches, and dizziness"
969,itraconazole,"tinea corporis, tinea cruris, tinea pedis",itraconazole inhibits cytochrome p-450 dependent enzymes,metabolism of cyclosporine and warfarin,midazolam,patients with a known history of hypersensitivity to it,raised liver enzymes
970,isradipine,concurrently with thiazide-type diuretics,dihydropyridine calciumchannel blocker,reduced plasma concentrations,concurrent admin with enzyme-inducing drugs,hypertensive crisis,"polyuria, fatigue, malaise"
971,ispaghula husk + ispaghula seed + tinnevelly senna pods,constipation,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>
972,ispaghula [psyllium] husk,in- constipation,<NO SPECIFIC DATA AVAILABLE>,no significant interaction has been observed with other medicine,medicine,patients with gastrointestinal tract obstruction or threatening obstruction of the bowel,"flatulence, abdominal distension, gastro-intestinal obstruction"
973,lanthanum carbonate,patients with end-stage renal disease,phosphate binder,do not administer such compounds,quinolone intake,"bowel obstruction, including ileus and fecal impaction","constipation, dyspepsia, allergic skin reactions"
974,lansoprazole + amoxicillin + clarithromycin,indicated for the eradication of h. pylori,inhibiting the synthesis of bacterial cell walls,interactions,terfenadine,patients with known hypersensitivity,adverse reactions
975,lansoprazole,short term treatment of active duodenal ulcer,block the final step of acid secretion,reduction in gastric acid,vitamin b12,patients with known hypersensitivity to any component of the formulation,rise in serum gastrin
976,lamotrigine,adults with bipolar disorder,not fully elucidated,oral contraceptives,oral,NO SPECIFIC DATA AVAILABLE>,"dizziness, tremor, headache, rash, blurred vision"
977,lamivudine + zidovudine + nevirapine,nevirapine 200 mg twice daily,amp,antiviral activity,stavudine may decrease antiviral activity; valproic acid,hypersensitivity,nevirapine
978,lamivudine + zidovudine,hiv-1 infection,intracellularly,intracellular phosphorylation of one another,zalcitabine,patients with low body weight,"chills, fever, pale skin; sore throat"
979,lamivudine [for hiv infection],lamivudine in combination with other antiretroviral agents,phosphorylated intracellularly,use of lamivudine in combination with zalcitabine,zalcitabine,hypersensitivity,blood and lymphatic systems disorders
980,lamivudine [for chronic hepatitis b],associated with evidence of hepatitis b viral replication and active liver inflammation,dna chain is terminated,higher doses of trimethoprim /sulfamethoxazole,trimethoprim,patients hypersensitive to any of the components of the product,post treatment exacerbations
981,lactulose,lactulose is only to be taken when these measures prove insufficient,minimally absorbed,drug interactions,drug,suspected intestinal obstruction,loss of electrolytes
982,lactobacillus rhamnosus gg,bowel problems (such asdiarrhea,NO SPECIFIC DATA AVAILABLE>,without your doctor's approval,"do not start, stop, or change the dosage of any medicines",NO SPECIFIC DATA AVAILABLE>,a very serious allergic reaction to this product is rare
983,lactitol monohydrate,acute and chronic portal systemic encephalopathy,it is absorbed only in minimal amounts,antacids,antacids,patients with known hypersensitivity,diminish or disappear
984,lactic acid + sodium pca,zinc oxide,keratolytic agent,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,no side effects
985,lactic acid + citric acid + potassium bitartrate,on-demand method of contraception,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,"dysuria, and vulvovaginal pain"
986,lactase,prevention of symptoms of lactose,hydrolysis and making dairy foods easier to digest,interactions,lactase,patients with known hypersensitivity,there are no major side effects reported
987,lacosamide,only in adult patients,inhibition of sodium channels,concomitant medications that prolong pr interval,beta-blockers and calcium channel blockers,none,"diplopia, headache, dizziness, nausea"
988,lacidipine,either alone or in combination with other antihypertensive agents,competitive inhibition of voltage-dependent calcium 'l' channels,no specific pharmacodynamic interaction problems,"digoxin, tolbutamide or warfarin",avoid within 1 month of myocardial infarction,"flushing, palpitation, edema, headache, dizziness"
989,labetalol hydrochloride (tablet),alone or in combination with other antihypertensive agents,intravenous administration,calcium antagonists,nitroglycerin,NO SPECIFIC DATA AVAILABLE,mild and transient and occur early in the course of treatment
990,labetalol hydrochloride (injection),hypertension,b-blocking action,class i antiarrhythmic agents,cimetidine,second or third degree heart block,liver damage
991,l-ornithine l-aspartate + pancreatin,improvement,not frequently used as there are still some reservations about its benefits,increase your risk for side-effects or cause your drug not to work properly,drugs or over the counter products,gastrectomy hypersensitivity pancreatectomy pregnant,nausea vomiting abdominal stomach pain bloating diarrhea
992,l-ornithine l-aspartate,adjunct to hepatotoxic drugs,endogenous amino acids,interactions,l-ornithine l-aspartate,NO SPECIFIC DATA AVAILABLE,nausea and vomiting occur
993,levodopa + benserazide,benserazide,peripheral decarboxylase inhibitor,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,<NO SPECIFIC DATA AVAILABLE
994,levocetirizine dihydrochloride,allergic conditions,rapid and long-acting action,interactions with other drugs,drugs,patients with severe renal impairment,"headache, dry mouth, fatigue and skin rash"
995,levocarnitine,chronic fatigue syndrome heart diseases,delivering substrate for oxidation and subsequent energy production,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"transient nausea and vomiting, abdominal cramps, and diarrhoea"
996,levobupivacaine hydrochloride,for the production of local or regional anesthesia,infiltration anaesthesia and regional nerve blocks including epidural block,plasma levels may be reduced when used with enzyme-inducing drugs,enzyme-inducing drugs,obstetrics,"restlessness, anxiety, dizziness, confusion, respiratory depression"
997,levobunolol,patients with chronicopen-angle glaucomaorocularhypertension,nonselective -adrenergic blocking agent,additive hypotensive effect with catecholamine,catecholamine,individuals with bronchial asthma,reduced corneal sensitivity and tearing
998,levetiracetam,"adults, adolescents, children and infants",NO SPECIFIC DATA AVAILABLE,alcohol,alcohol,hypersensitivity,"somnolence, asthenia, infection and dizziness"
999,levamisole,usually within 24 hours,paralysing susceptible intestinal worms,alcohol,alcohol,there is no absolute contra-indication,headache
1000,leuprorelin acetate,prostate cancer,reduces pituitary gonadotrophin secretion,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,undiagnosed abnormal vaginal bleeding,decreased testosterone
1001,letrozole,in post-menopausal women,letrozole had no effect on plasma androgen concentrations,significant drug reactions,cimetidine,"pregnancy, lactation and in pre-menopausal women",mild to moderate and rarely severe enough to require discontinuation
1002,lercanidipine hydrochloride,mild to moderate essential hypertension,direct relaxant effect on vascular smooth muscle,midazolam,midazolam,patients with left ventricular outflow tract obstruction,"flushing, peripheral edema, headache, dizziness and asthenia"
1003,lenvatinib mesylate,everolimus,kinase inhibitor,coadministration of lenvatinib with medicinal products,medicinal products,patients with known hypersensitivity,"impairment of thyroid stimulating hormone suppression/thyroid dysfunction, wound healing complications"
1004,lenograstim,autologous or allogeneic bone marrow transplantation,accelerates neutrophil recovery significantly after chemotherapy,pulmonary toxicity,bleomycin and cyclophosphamide,myeloid malignancies,toxic epidermal necrolysis
1005,lenalidomide,controlled clinical trials,without regard to food intake,risk of thrombosis,r- and s-warfarin,patients who have demonstrated severe hypersensitivity,hypersensitivity
1006,leflunomide,adults,anti-proliferative activity,risk of hepatotoxicity,charcoal,patients with known hypersensitivity to leflunomide,"diarrhea, nausea, vomiting"
1007,ledipasvir + sofosbuvir,adults,hcv ns5a inhibitor,p-gp inducers,p-gp inducers,patients with known hypersensitivity,fatigue and headache
1008,latanoprost + timolol,prostaglandins or other iop lowering agents,timolol is a non-selective adrenergic blocker,two topical -adrenergic blocking agents,epinephrine,patients with known hypersensitivity,irritation of the eye
1009,latanoprost,patients with open-angle glaucoma or ocular hypertension,increased uveoscleral outflow,precipitation,eye drops containing thimerosal,hypersensitivity,"blurred vision, burning and stinging"
1010,lasmiditan hemisuccinate,not indicated for the preventive treatment of migraine,unclear,drugs that are p-gp or bcrp substrates,drugs that are p-gp or bcrp substrates,NO SPECIFIC DATA AVAILABLE>,"dizziness, sleepiness, numbness, feeling tired, tingling"
1011,larotrectinib,adult and pediatric patients with solid tumors,binding is independent of drug concentrations,coadministration,grapefruit or grapefruit juice,patients with known hypersensitivity,"neurotoxicity, hepatotoxicity."
1012,lapatinib,capecitabine,it blocks the phosphorylation and activation of downstream 2nd messengers,cyp3a4 inducers,cyp3a4 inducers,hypersensitivity,hypersensitivity reactions including anaphylaxis.
1013,linagliptin,type 2 diabetes mellitus,inhibitor of dpp-4,oral contraceptives,oral contraceptives,hypersensitivity,hypoglycaemia
1014,light liquid paraffin + white soft paraffin + glycerine,moisturizing cream,occlusive film that reduces trans-epidermal water loss,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity to any of the ingredients.,no remarkable adverse effects have been reported
1015,lifitegrast,dry eye disease,not known,<,NO SPECIFIC DATA AVAILABLE,patients who are hypersensitive,"blurred vision, conjunctival hyperemia"
1016,lidocaine hydrochloride (spray),during general anesthesia,inhibiting sodium influx through sodium specific ion channels,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"myasthenia gravis, epilepsy","increased sweating, numbness"
1017,lidocaine hydrochloride (jelly),surface anaesthesia of the male and female urethra,inhibiting sodium influx through sodium specific ion channels,toxic effects,patients receiving antiarrhythmic drugs,hypersensitivity of local anaesthetics of the amide type,anaphylactic reactions
1018,lidocaine hydrochloride (injection),infiltration blockade and intravenous regional analgesia,inhibiting sodium influx through sodium specific ion channels,cimetidine,cimetidine,known hypersensitivity to anaesthetics,systemic effects occur involving the central nervous system and/or the cardiovascular system
1019,lidocaine + prilocaine,normal intact skin,local anaesthetic agents of the amide type,toxic effects,cream,hypersensitivity,anaphylactoid reactions
1020,lidocaine + epinephrine,only accepted procedures for these techniques as described in standard textbooks are recommended,stimulation of alpha and beta-1 adrenergic receptors,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with a known history of hypersensitivity,NO SPECIFIC DATA AVAILABLE
1021,lidocaine + adrenaline,local or regional anesthesia,combination with epinephrine,potassium-depleting drugs,potassium-depleting drugs,anaesthetise digits,severe side effects :severe allergic reactions
1022,levothyroxine sodium,lithium,synthetic levothyroxine,insulin requirements,insulin therapy may result in increased antidiabetic agent or insulin requirements,untreated subclinical or overt thyrotoxicosis,hyperthyroidism due to therapeutic overdose
1023,levosalbutamol (oral),"adults, adolescents and children",unimpeded by (s)-salbutamol,deleterious cardiovascular effects,epinephrine,patients with a history of hypersensitivity,"nausea, vomiting, burning substernal or epigastric pain"
1024,levosalbutamol,"adults, adolescents, and children",antagonist,deleterious cardiovascular effects,epinephrine,NO SPECIFIC DATA AVAILABLE,"palpitation, fine tremors of the skeletal muscle"
1025,levonorgestrel,emergency contraception,levonorgestrel binds to progesterone and androgen receptors,emergency contraception,emergency contraception,hypersensitivity,"nausea and vomiting dizziness, fatigue, headache abdominal pain"
1026,levomilnacipran hydrochloride,limitation,unknown,strong cyp3a4 inhibitors,strong cyp3a4 inhibitors,a patient who is being treated with maois,elevated blood pressure
1027,levomenthol + thymol + terpineol + chlorobutanol,amp; terpineol,<NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>
1028,levofloxacin hemihydrate,"mild, moderate and severe infections",inhibiting bacterial topoisomerase iv and dna gyrase,antacids,antacids,patients with a history of hypersensitivity to levofloxacin,"nausea, vomiting, diarrhea, abdominal pain"
1029,levofloxacin (ophthalmic),bacterial conjunctivitis,sterile topical ophthalmic solution,drug interaction,eye drops,patients with a history of hypersensitivity,"transient blurred vision, fever, foreign body sensation, headache"
1030,levodopa + carbidopa + entacapone,levodopa/dopa decarboxylase,inhibiting the decarboxylation of peripheral levodopa,high protein diet,high protein,non-selective maois,diarrhea and stomach pain
1031,levodopa + carbidopa (fc tablet),before physiotherapy increases motor recovery after stroke.,<NO SPECIFIC DATA AVAILABLE>,loss of therapeutic response,ferrous sulphate or ferrous gluconate,patients with hypersensitivity,carbidopa-levodopa
1032,levodopa + carbidopa (cr tablet),levodopa alone,<NO SPECIFIC DATA AVAILABLE,loss of therapeutic response,high protein,suspicious undiagnosed skin lesions or a history of melanoma,prolonged-release tablet
1033,loteprednol etabonate + tobramycin,ocular steroids,aminoglycoside,detected in plasma,plasma,viral diseases,headache
1034,loteprednol etabonate + gatifloxacin,ocular steroids,"aminoglycoside, macrolide, and tetracycline antibiotics",drug interaction,medicines,no steroidal inflammatory medicines,gatifloxacin
1035,loteprednol etabonate,post-operative inflammation,phospholipase a2 inhibitory proteins,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,individuals with known or suspected hypersensitivity,perforation of the globe
1036,losartan potassium + hydrochlorothiazide,hypertension,angiotensin ii,no significant drug-drug pharmacokinetic interactions,digoxin,patients who are hypersensitive,mild
1037,losartan potassium,alone or in combination with other antihypertensive agents,angiotensin ii receptor blocker,active metabolite,potassium supplements or salt substitutes,patients with diabetes,mild and transient
1038,lornoxicam,rheumatoid arthritis,has not been fully determined,increased risk of hypoglycaemia,antacids,"asthma, rhinitis, angioedema or urticaria",NO SPECIFIC DATA AVAILABLE
1039,lorlatinib,monotherapy,kinase inhibitor,the concentration of these medicinal products,tacrolimus,hypersensitivity,cognitive effects (28.8%)
1040,lorazepam,lorazepam is not recommended in anxiety states in children,depressant action,monoamine oxidase inhibitors,alcohol,patients with a previous sensitivity to benzodiazepines,"sedation followed by dizziness, weakness and unsteadiness"
1041,loratadine + pseudoephedrine,this tablet,no central sedative or anti-cholinergic effect,mao) inhibitors,decarboethoxyloratadine,hypersensitive,"increased sweating, thirst, back pain, chest pain"
1042,loratadine,in children over 2 years,no central sedative or anticholinergic effect,alcohol,alcohol,hypersensitivity or idiosyncrasy to their components,sedation and anticholinergic effects
1043,lopinavir + ritonavir,adults and pediatric patients,NO SPECIFIC DATA AVAILABLE,potent cyp3a inducers,potent cyp3a inducers,patients with previously demonstrated clinically significant hypersensitivity,hypercholesterolemia
1044,loperamide hydrochloride,indicated in- acute diarrhea chronic diarrhea abdominal cramps,inhibits the peristaltic activity of the longitudinal and circular smooth muscle,data available,data,acute dysentery,abdominal pain and other gastrointestinal disturbances
1045,lomefloxacin (oral),uncomplicated urinary tract infections,topical ophthalmic application,caffeine,probenecid,"children, growing adolescents, and pregnant women",common side effects arenausea
1046,lomefloxacin (ophthalmic),bacterial infections,topical,"reduction of efficacy, no ophthalmic preparations containing heavy metals",heavy metals,hypersensitivity,"allergic reactions, asthma, dyspnoea"
1047,lithium carbonate,"treatment and prophylaxis of mania, bipolar disorder and recurrent depression",unknown,iodine salts,iodine salts,"renal insufficiency, cardiovascular insufficiency",increased thirst and consequently passing urine
1048,lisinopril,alone or with other antihypertensive agents,competitively inhibits ace,nsaids. may increase serum levels and toxicity,k supplements,patients with diabetes or renal impairment,increased bun and serum creatinine levels
1049,liraglutide,in the presence of at least one weight-related comorbid condition,binds to and activates the glp-1 receptor,delay of gastric emptying,gastric,pregnancy,"nausea, diarrhea, constipation, vomiting"
1050,liposome + perilla + sodium hyaluronate,liposomes and sodium hyaluronate,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1051,linezolid,combination therapy,different from that of other antibacterial agents,interaction with adrenergic and serotonergic agents,serotonergic agents,uncontrolled hypertension,"diarrhea, headache and nausea"
1052,linagliptin + metformin hydrochloride,both,it does not produce hypoglycemia,metformin elimination,cationic drugs,hypersensitivity,nasopharyngitis and diarrhea
1053,mebeverine hydrochloride,symptomatic treatment of irritable bowel syndrome,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,"skin rash, urticaria and angioedema"
1054,mebendazole,"threadworms, whipworms, roundworms and hookworms",inhibits the formation of the worms' microtubules,cimetidine,cimetidine,patients with known hypersensitivity to mebendazole,transient symptoms of abdominal pain and diarrhoea
1055,measles and rubella,simultaneous immunization,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,allergic to any ingredient in the vaccine,pain and tenderness at the injection site
1056,maprotiline hydrochloride,indicated for the treatment of depressive illness,not precisely known,electroshock therapy,guanethidine,patients with known or suspected seizure disorders,"heart block, and syncope"
1057,mannitol,iv infusion,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pulmonary edema or congestive heart failure,"nausea, vomiting, thirst, headache, dizziness"
1058,magnesium sulfate heptahydrate,to prevent convulsion,anticonvulsant properties when administered parenterally,depressants,narcotics,patients with heart block or myocardial damage,"nausea, vomiting, flushing of the skin"
1059,magnesium sulfate,pre-eclampsia and eclampsia,enzymatic reactions,reduction in blood pressure,barbiturates,defect of the heart's electrical message pathways,"nausea, vomiting, flushing of skin, thirst, hypotension"
1060,magnesium oxide,relieving the symptoms of magnesium defciency,renal filtration,kidney stones,medicines,hypersensitivity and severe renal impairment,mild side effects
1061,magnesium hydroxide + liquid paraffin,constipation associated with chronic cholecystitis hernia,laxative ingredient and a lubricant,irritation,"diuretics, famotidine and ranitidine",acute gl conditions like abdominal pain.,"rectal irritation, potassium loss"
1062,magnesium hydroxide,"constipation, heart burn, gas and nausea",osmotic properties,absorption of other drugs,phosphate supplements,laxative is contraindicated,diarrhoea
1063,magaldrate + simethicone,magaldrate may be given to children if necessary.,neutralizes gastric acid,tetracycline,tetracycline,patients with known hypersensitivity to magnesium and aluminium,gastrointestinal side-effects are uncommon
1064,magaldrate,hyperacidity associated with peptic ulcers,absorbed poorly and thus provide a sustained antacid effect,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity to magnesium and aluminium,constipation and diarrhea
1065,macrogol [polypropylene glycol] + electrolytes,adults and children over 12 years of age,electrolytes,decreased efficacy,thisoral solution,hypersensitivity to the active substances,reduction
1066,macitentan,2 years,endothelin receptor antagonist,strong cyp3a4 inhibitors,hiv drugs,NO SPECIFIC DATA AVAILABLE,"headache, influenza, and urinary tract infection"
1067,lyophilized bacterial lysate,prevention,NO SPECIFIC DATA AVAILABLE,drugs,drugs,hypersensivity to the active substance or auxiliary.,drug
1068,lynestrenol,polymenorrhoea,various activities with the natural hormone progesterone,decrease the effectiveness of insulins,activated charcoal,sex steroids,later on the frequency gradually decreases
1069,lymecycline,acute sinusitis,binding to the 30s ribosome subunit,anticoagulants,fe preparations,pregnancy and lactation,lymecycline capsules
1070,lurasidone hydrochloride,"schizophrenia, depressive episodes associated with bipolar i disorder",central dopamine d2 and serotonin 5ht2a receptor,grapefruit: grapefruit and grapefruit juice,grapefruit and grapefruit juice,dementia-related psychosis,"extrapyramidal symptoms, and nausea"
1071,luliconazole,topical treatment,inhibiting the enzyme lanosterol demethylase,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,none,contact dermatitis and cellulitis may occur. application site reactions
1072,lubiprostone,chronic idiopathic constipation (cic) in adults,protein kinase a action independent fashion,diphenylheptane opioids,diphenylheptane opioids,patients with known or suspected mechanical gastrointestinal obstruction,"nausea, stomach pain, swelling of abdominal or stomach area"
1073,mercaptopurine,pediatric or adult,purine antagonist,anticoagulant action of warfarin,enhanced toxicity with myelosuppressive drugs,severe liver disease; severe bone marrow suppression,"hyperuricaemia, bone marrow toxicity"
1074,mepyramine maleate,"insect bites, stings and nettle rash",<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1075,menthol + thymol + eucalyptol + methyl salicylate,brighter,clinically proven antiseptic mouthwash,drug interactions,drug,hypersensitivity,diminish the effects of the mouthwash
1076,menthol + pramoxine hydrochloride,may also be used for rashes,local anesthetic effects,drug interactions,drug,serious burns,"redness, irritation, swelling or pain"
1077,meningococcal polysaccharide vaccine,travellers to countries where the disease is epidemic or highly endemic,freeze-dried,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,adverse reactions usually occur within 48 hours following vaccination
1078,meningococcal conjugate vaccine,individuals from the age of 6 weeks,production of bactericidal antibodies,co-administered,tetanus or diphtheria antigens included in tdap,hypersensitivity,adverse reactions
1079,menaquinone-7,rheumatoid arthritis,active trans-isomer of natural vitamin k2,absorption,orlistat,patients with known hypersensitivity to menaquinone-7,no reports of side effects
1080,memantine hydrochloride,dementia of the alzheimer's type,low to moderate affinity,amantadine,nicotine,patients with known hypersensitivity,bladder infections and increased sexual drive
1081,memantine + donepezil,10 mg of donepezil hydrochloride once daily,different mechanism,interfere with anticholinergic medications,hydrochlorides,patients with known hypersensitivity,memantine hydrochloride
1082,meloxicam,"osteoarthritis, rheumatoid arthritis",non-steroidal anti-inflammatory drug,impossible to avoid such combined prescription,oral anticoagulants,aspirin or nsaids,oedema of the lower limbs may occur during treatment
1083,melatonin,numerous conditions,melatonin binds with its receptors,corticosteroids,"tobacco, and alcohol",patients who have autoimmune diseases,headache and depression. drowsiness
1084,megestrol acetate,megestrol oral suspension,unknown,dosage adjustment,zidovudine or rifabutin,known or suspected pregnancy,weight gain
1085,mefloquine,acute malaria infections,antimalarial agent,vaccinations with attenuated live bacteria,vaccinations with attenuated live bacteria,"patients with active depression, a recent history of depression","dizziness, myalgia, nausea, fever, headache, vomiting"
1086,mefenamic acid,fever toothache headache migraine,dual action on prostaglandins,increased adverse effects,warfarin,patients with known hypersensitivity,"vomiting, dizziness, abnormal renal function, pruritus, rashes"
1087,medroxyprogesterone acetate (tablet),nonhysterectomized postmenopausal women,orally or parenterally,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,undiagnosed abnormal genital bleeding,without concomitant estrogens treatment
1088,medroxyprogesterone acetate (injection),adjunctive and/or pallivative treatment,intramuscular injection,decreases efficacy,decreases efficacy,known hypersensitivity,"headache, blurring of vision pain in the back of the leg"
1089,mecobalamin,peripheral neuropathies,it is a cofactor in the enzyme methionine synthase,decreased gi tract absorption,oral contraceptives,hypersensitivity,gi discomfort
1090,meclizine hydrochloride,"nausea, vomiting, motion sickness, vertigo",depending on dosage,toxicity,alcohol,hypersensitive,"drowsiness, dry mouth, and on rare occasions, blurred vision"
1091,meclizine + pyridoxine,prevention and treatment,through nerve pathways to the vomiting center,gastrointestinal motility,ethanol,patients who are hypersensitive,"drowsiness, dry mouth and, on rare occasions, blurred vision"
1092,mebhydrolin napadisylate,allergic disease,blocking of histamine receptors,mask the warning symptoms of damage caused by ototoxic drugs,anti-depressants,hypersensitivity,"nausea, vomiting, diarrhoea or constipation"
1093,metolazone,"hypertension, alone or in combination with other antihypertensive drugs",it inhibits reabsorption of sodium in the distal tubules,lithium excretion,bile acid,pregnancy,bun
1094,metoclopramide hydrochloride,adults and pediatric patients,blocks dopamine receptors,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a history of tardive dyskinesia,"dysgeusia, headache, and fatigue"
1095,methylprednisolone sodium succcinate,methylprednisolone sodium succinate im/iv,minimal mineralocorticoid properties,potassium-depleting agents,amphotericin b injection,systemic fungal infections,anaphylactic reaction with or without circulatory collapse
1096,methylprednisolone acetate,"asthma, atopic dermatitis, contact dermatitis",binds to and activates intracellular glucocorticoid receptors,convulsions,hepatic enzymes such as phenobarbital,systemic fungal infections,"urticaria, hyperpigmentation or hypopigmentation"
1097,methylprednisolone,enia,potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system,blood thinners,blood thinners,systemic fungal infections,mild annoyances to serious irreversible bodily damage
1098,methylphenidate hydrochloride,methylphenidate,norepinephrine and dopamine reuptake inhibitor,elimination of phenytoin,methylphenidate,"alcoholics, emotionally unstable patients, drug abusers",very rarely liver damage
1099,methylergonovine maleate,"following delivery of the placenta, for routine management of uterine atony","increases the tone, rate, and amplitude of rhythmic contractions",potent cyp 3a4 inhibitors,grapefruit juice,hypertension; toxemia; pregnancy; and hypersensitivity,"rash, and foul taste"
1100,methyldopa,hypertension,centrally acting,ferrous sulfate or ferrous gluconate,ferrous sulfate or ferrous gluconate,"active hepatic disease, such as acute hepatitis and active cirrhosis","angina pectoris, congestive heart failure"
1101,methyl salicylate + menthol + camphor,cream,"methyl salicylate, menthol and camphor cream",drug interactions,drug,hypersensitivity,redness or irritation
1102,methyl salicylate + menthol,this cream,menthol increases the penetration of drugs,warfarin from protein-binding sites,protein,application to broken skin or raw surfaces,mild to moderate local irritation
1103,methoxy polyethylene glycol-epoetin beta,including patients on dialysis and patients not on dialysis,chemically synthesized continuous erythropoietin receptor activator,no indication of an effect of concomitant medications,medicinal products,uncontrolled hypertension,adverse reactions
1104,methoxsalen,biopsy,not known,photosensitising agents,coal tar,patient with melanoma or possessing a history of melanoma,nausea
1105,methotrexate,alone or in combination with other anticancer agents,inhibits dihydrofolic acid reductase,decreased effectiveness with folic acid,decreased effectiveness with folic acid,aids,impaired fertility
1106,methocarbamol,man,not been established,anticholinesterase agents,anticholinesterase agents,hypersensitive,headache
1107,methimazole,in patients with graves' disease with hyperthyroidism,inhibits the synthesis of thyroid hormones,vitamin k activity,meals,hypersensitivity to the drug or any of the other product components,"periarteritis, and hypoprothrombinemia."
1108,methenamine hippurate,after eradication of the infection by other appropriate antimicrobial agents,antibacterial activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"severe hepatic insufficiency, or severe dehydration",NO SPECIFIC DATA AVAILABLE
1109,metformin hydrochloride,in children from 10 years of age and adolescents,it does not produce hypoglycemia,alcohol,alcohol,"alcohol intoxication, alcoholism",improve gastrointestinal tolerability
1110,mesna,ifosfamide-induced hemorrhagic cystitis,reducing the viscosity of pulmonary secretions,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to thiol-containing compounds.,not treated with concurrent cytotoxic therapy
1111,mesalazine [5-aminosalicylic acid],mild to moderately active ulcerative colitis,appears to be topical rather than systemic,risk of renal reactions,nsaids and azathioprine,hypersensitivity,"headache, nausea, dizziness, asthenia"
1112,meropenem trihydrate,pneumonia and nosocomial pneumonia urinary tract infections,bactericidal action by interfering with bacterial cell wall synthesis,reduce serum valproic acid levels,elimination half-life,patients who have demonstrated hypersensitivity to this product,"nausea, vomiting, diarrhea, headache"
1113,mitomycin c,indicated in diabetic foot infections;,enzymatically reduced to its active metabolite within susceptible cells,increased incidence of cardiotoxicity,increased incidence of cardiotoxicity with doxorubicin,pregnancy and lactation,haemolytic-uraemic syndrome
1114,misoprostol,nsaid users at high risk of complications from gastric ulcer,mucosal protective properties,high doses of antacid,antacid,pregnancy,"diarrhea, abdominal pain"
1115,mirtazapine,tablets,unknown,alcohol &amp; diazepam,alcohol,patients with a known hypersensitivity,"dizziness, drowsiness, dry mouth, increased appetite, weight gain"
1116,mirabegron,overactive bladder (oab) syndrome,dual mechanism,dose-adjustment,food,patients with hypersensitivity to the active substance,tachycardia and urinary tract infections
1117,minoxidil,males and females,widening blood vessels and inhibiting androgen hormone,alter the stratum corneum barrier,tretinoin or dithranol,"patients with red, inflamed infection, or irritated or painful scalp",minor dermatological reactions
1118,minocycline hydrochloride,pre- and post-operative prophylaxis of infection,<NO SPECIFIC DATA AVAILABLE>,penicillins,milk and milk products,patients with hypersensitivity to tetracyclines,reported
1119,miltefosine,adults and adolescents,no mechanism has been identified definitely,inhibit human cytochrome p450 enzymes,rats,NO SPECIFIC DATA AVAILABLE,"elevated transaminases, and elevated creatinine"
1120,milnacipran hydrochloride,not approved for use in pediatric patients,it inhibits norepinephrine uptake,increased risk of bleeding,antipsychotic agents,concomitant use with maoi or within 2 wk after withdrawal,migraine
1121,miglitol,adults with type 2diabetes mellitus,inhibits membrane-bound intestinal -glucosidase enzymes,insulin increases the risk of hypoglycaemia,charcoal,patient with diabetic ketoacidosis,"diarrhoea, flatulence, skin rash."
1122,mifepristone + misoprostol,this kit,misoprostol,aspirin,misoprostol,history of allergy or known hypersensitivity,misoprostol
1123,mifepristone,medical alternative to surgical termination of intra-uterine pregnancy,binding to the intracellular progesterone receptor,termination of pregnancy,grapefruit juice,patients with chronic adrenal failure,"skin rashes, urticaria, hot flashes and dizziness"
1124,midazolam,short-term treatment of insomnia,inhibitory neurotransmitter gamma-aminobutyric acid,antihistamines,midazolam,"severe respiratory insufficiency, severe hepatic insufficiency",fluctuations in vital signs have been noted
1125,micronised diosmin + hesperidin,acute hemorrhoidal attacks,inhibiting the release of inflammatory mediators,drug incompatibility,drug,anyone having a hypersensitivity to any ingredient in the product,discontinuation of treatment is not required
1126,miconazole nitrate + hydrocortisone,pathogenic yeasts,miconazole is imidazole antifungal agents,amphotericin,amphotericin,pregnant mother and lactating mother,decrease in the production of natural hormones
1127,miconazole nitrate (topical),gram-positive bacteria,not stain skin or clothes,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,no contraindication,no side effect
1128,miconazole nitrate (oral gel),for the treatment of oral and gastrointestinal candidiasis,metabolized,miconazole may inhibit their metabolism,astemizole and cisapride,patients with known hypersensitivity to the active ingredient,"nausea and vomiting, diarrhea with long term use and rarely allergic reactions"
1129,metronidazole + neomycin sulphate + polymyxin b + nystatin,mixed vaginal infections,antifungal activity,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,hypersensitive,"skin rash, urticaria may occur rarely"
1130,metronidazole + miconazole nitrate,candidiasis,miconazole inhibits ergosterol synthesis,reduced carbamazepine metabolism,pimozide,porphyria,"local irritation and sensitisation, contact dermatitis"
1131,metronidazole,all forms of amoebiasis,bactericidal action,alcohol,alcohol,patients with a history of hypersensitivity,"metallic taste, nausea, vomiting, diarrhoea, drowsiness"
1132,metoprolol tartrate,patients with acute myocardial infarction,catecholamines,cardioselectivity,drugs that inhibit cyp2d6,severe heart failure,alsobeenreported
1133,multivitamin [injection],intravenous,intravenous,folic acid may lower the serum concentration of phenytoin,folic acid,known hypersensitivity to any of the components,allergic reactions
1134,multivitamin [adult preparation],vitamin deficiencies,vitamin e is an antioxidant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitive,no side-effect
1135,mucopolysaccharide polysulphate + salicylic acid,mild to moderate anti-inflammatory,topical/localised only,contraceptive failure,drugs or herbal products,"first trimester, during late pregnancy or on the breast area during lactation","redness, burning sensation and rash"
1136,moxonidine,high blood pressure,low affinity for central alpha-2-adrenoceptors,drink alcohol,alcohol,if you: are allergic (hypersensitive),"dry mouth, drowsiness"
1137,moxifloxacin hydrochloride + xanthan gum,bacterial conjunctivitis,antimicrobial,drug-drug interaction studies,drug-drug,<NO SPECIFIC DATA AVAILABLE,tearing
1138,moxifloxacin hydrochloride + dexamethasone,amp; dexamethasone,inhibitting the dna gyrase &amp; topoisomerase iv,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,viral diseases of cornea &amp,dexamethasone
1139,moxifloxacin hydrochloride (tablet),acute bacterial sinusitis,inhibiting topoisomerase ii (dna gyrase),nsaids,nsaids,patients with a history of hypersensitivity,"nausea, vomiting, diarrhea, headache and dizziness"
1140,moxifloxacin hydrochloride (ophthalmic),bacterial conjunctivitis,antimicrobial,drug-drug interaction,solution,patients with a history of hypersensitivity,"decreased visual acuity, dry eye"
1141,moxifloxacin hydrochloride (injection),infections in adults &gt,NO SPECIFIC DATA AVAILABLE,class iii antiarrhythmics,class ia and class iii antiarrhythmics,persons with known hypersensitivity to moxifloxacin,"oral, iv or sequential therapy"
1142,morphine sulfate,morphinebelongs,mu-1 receptors,delay the absorption of mexiletine,mexiletine,concurrent admin with maois or within 2 wk after treatment,nausea
1143,montelukast sodium,prophylaxis and chronic treatment of asthma,selective and orally active leukotriene receptor antagonist,no dose adjustment,bioavailability and other conditions were not significantly observed with food &amp,patients who are hypersensitive,"suicidal tendencies, tremor"
1144,monosulfiram,parasiticide,ectoparasiticide,drug interactions,drug,alcohol,few side-effects
1145,monosemicarbazone adrenochrome,prevention and treatment of surgical and non-surgical capillary bleedings,rapid onset of action,drug interaction,drug,there are no known contraindications,no adverse reactions have been reported at the recommended dosages
1146,monobasic sodium phosphate + dibasic sodium phosphate,occasional constipation,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,if you have kidney disease if you have heart problems,NO SPECIFIC DATA AVAILABLE
1147,mometasone furoate + formoterol fumarate,this inhaler contains formoterol,long-acting beta-2 agonist- laba,caution,xanthine derivatives,patients with known hypersensitivity,hypokalemia
1148,mometasone furoate (topical),corticosteroid- responsive dermatoses,not known,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,individuals with a history of sensitivity reactions,"burning, pruritus and skin atrophy"
1149,mometasone furoate (nasal spray),adults and pediatric patients 2 years of age and older,not known,drug interactions,drug,hypersensitivity,"nosebleeds, and coughing"
1150,mometasone furoate (inhalation capsule),4 years of age and older,not known,ketoconazole,ketoconazole,primary treatment of status asthmaticus or other acute episodes of asthma,mild
1151,molnupiravir,emergency use,inhibits viral reproduction,medications,n-hydroxycytidine,patients with known hypersensitivity to molnupiravir,"diarrhoea, nausea, feeling dizzy, headache"
1152,mizolastine,urticaria,blocks histamine h1-receptors,alcohol,alcohol,patients who are hypersensitive to the drug,"dry mouth, diarrhoea, abdominal pain"
1153,mycophenolic acid,adult patients receiving a kidney transplant,immunosuppressive agent,medicines may decrease mycophenolic acid concentration,antacids,physician supervision,"anemia, leukopenia, constipation"
1154,mycophenolate mofetil,class iii-v lupus nephritis,non-competitive,acid concentration,hormonal contraceptives,women who are breastfeeding,"diarrhea, leukopenia, sepsis"
1155,mupirocin,impetigo,mupirocin inhibits bacterial protein synthesis,drug interaction,drug interaction has been identified with mupirocin ointment,hypersensitivity reactions,"burning, stinging or pain, itching"
1156,multivitamins & multiminerals [a-z prenatal preparation],throughout the pregnancy and in the postnatal period,special formulation,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity to any of the ingredients,allergic sensitization has been reported following oral administration of folic acid
1157,multivitamin with l-lysine,improves appetite,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity,no untoward effects
1158,multivitamin & normal saline,intravenous,intravenous administration,folic acid may lower the serum concentration of phenytoin,folic acid,known hypersensitivity to any of the components,hypersensitive to any component of the preparation
1159,multivitamin & multimineral essentials [for nursing mother],lactating mother to ensure balanced intake of essential vitamins and minerals,special vitamins and minerals preparation comprising of important vitamins and minerals,<NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,patients with a known hypersensitivity to any of the ingredients,no clinically significant side effects or toxicity are reported
1160,multivitamin & multimineral [for nursing mother],throughout pregnancy and when breast feeding,"support when planning conception, throughout pregnancy and while breast feeding",<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity,generally well tolerated
1161,multivitamin & multimineral [a-z teen girls preparation],complete multivitamin,mineral supplement,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity to any of the ingredients,allergic sensitization has been reported following oral administration of folic acid
1162,multivitamin & multimineral [a-z teen boys preparation],complete multivitamin,mineral supplement,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity to any of the ingredients,allergic sensitization has been reported following oral administration of folic acid
1163,multivitamin & multimineral [a-z syrup preparation],children,antioxidant vitamins,no interactions have been observed,no interactions have been observed,patients with a known hypersensitivity to any of the ingredients,well tolerated
1164,multivitamin & multimineral [a-z silver preparation],vitamin and mineral deficiencies for adults over 45 years of age,scientifically adjusted,drug interactions,drug,do not take this product if taking other vitamin a supplements,folic acid
1165,multivitamin & multimineral [a-z juniors syrup preparation],the treatment and prevention of vitamin and minerals deficiencies,"balanced amounts of all the important vitamins, essential minerals and trace elements",interactions,interactions,patients who are hypersensitive to any of its components,generally well tolerated
1166,multivitamin & multimineral [a-z junior infusion preparation],this iv,lyophilized powder/cake for infusion,direct addition of this iv to intravenous fat emulsions,intravenous fat,NO SPECIFIC DATA AVAILABLE,anaphylactic reactions following parenteral multivitamin administration
1167,multivitamin & multimineral [a-z gold preparation],vitamins &amp; minerals deficiencies. as a complete daily nutritional supplement,"film coated tablet, which combines 32 high potency vitamins and minerals",drug interactions,drug,patients with known hypersensitivity to any of the ingredients,diarrhoea may occasionally occur during treatment with beta carotene
1168,multivitamin & multimineral [a-z for infanrs & childrens],malnourished infants,special formulation,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,children severely malnourished or sick,no significant side-effects
1169,multivitamin & multimineral,tablet,enzyme system,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients hypersensitive to any of its components,"minerals, but at level substantially higher than those in this tablet"
1170,multivitamin & cod liver oil,multivitamin syrup with cod-liver oil is indicated for growing children,hormones,drug,drug,patients with a known hypersensitivity to any of the ingredients,allergic reactions may be seen
1171,multivitamin & 5% dextrose,intravenous,intravenous administration,folic acid may lower the serum concentration of phenytoin,folic acid,known hypersensitivity to any of the components,hypersensitive to any component of the preparation
1172,multivitamin [pediatric preparation],children and infants,"synthesis of catecholamines, carnitine, and steroids",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with haemochromatosis or wilsons disease,nontoxic
1173,nelfinavir,hiv infection,"selective, competitive, reversible hiv protease inhibitor",increased serum levels/effects with azole antifungal agents,"omeprazole, nevirapine",patients with clinically significant hypersensitivity to any of its components,mild intensity
1174,nefopam hydrochloride,"post-operative, dental, musculo-skeletal and acute traumatic pain",its mechanism is not defined,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a history of convulsive disorders,"nausea, nervousness, dry mouth, lightheadedness"
1175,nebivolol hydrochloride,elderly patients,anticoagulant,nebivolol should not be combined with other -blockers,nebivolol should not be combined with other -blockers,"severe bradycardia, heart block greater than first degree","headache, nausea and bradycardia"
1176,nebivolol + hydrochlorothiazide,essential hypertension,diuretic action,calcium level non-steroidal anti-inflammatory drugs,calcium level non-steroidal anti-inflammatory drugs,"bradycardia, hypotension",hydrochlorothiazide
1177,nateglinide,adults with type 2 diabetes mellitus.,the amount of existing glucose levels,corticosteroids,"thiazide diuretics, thyroid hormones",diabetic ketoacidosis.,"accidental trauma, bronchitis, cough"
1178,natamycin,natamycin sterile ophthalmic suspension,binding to sterols in the fungal cell membrane,may increase spread of fungal eye infection,topical corticosteroid,individuals with a history of hypersensitivity to any of its component,hyperemia
1179,naproxen sodium + esomeprazole magnesium,amp,amp,high-fat food,high-fat food,coronary artery bypass graft (cabg) surgery,the most common adverse reactions
1180,naproxen sodium,acute gout,non steroidal anti-inflammatory drug,antacids &amp; sucralfate,antacids &amp; sucralfate,"patients who have experienced asthma, urticaria, or allergic-type reactions","visual disturbances, hearing disturbances"
1181,naphazoline + zinc sulfate,bacterial and viral conjunctivitis,zinc ions,mao-blockers,mao-blockers,infants,does not affect the success of the treatment
1182,naphazoline + pheniramine,allergic conjunctivitis,antihistamine,increased pressor effects,tca,angle closure glaucoma,increased or decreased intraocular pressure
1183,nandrolone phenylpropionate,selected cases of disseminated mammary carcinoma,one week after injection,insulin,insulin,pregnancy,inhibition of spermatogenesis
1184,nandrolone decanoate,"established osteoporosis, disseminated breast cancer in women",enhanced anabolic and a reduced androgenic activity,undesirable effects,injectables,"pregnancy, male breast carcinoma, prostatic carcinoma",NO SPECIFIC DATA AVAILABLE
1185,naltrexone,naltrexone has not been shown to provide any therapeutic benefit,it blocks the action of opioids,increased risk of naltrexone-induced lethargy,increased risk of naltrexone-induced lethargy,acute hepatitis or hepatic failure; acute opioid withdrawal,inj-site reactions
1186,naloxone hydrochloride,diagnosis of suspected or knownacuteopioid overdosage,not fully understood,decreased effect of opioid analgesics,decreased effect of opioid analgesics,NO SPECIFIC DATA AVAILABLE>,"nausea, and vomiting"
1187,nalidixic acid,urinary tract infection caused by susceptible gram-negative organisms,"inhibiting bacterial dna synthesis, possibly by interfering with dna polymerization",toxicity,melphalan,"infants under 3 months, epilepsy, cns lesions",visual disturbances and convulsions
1188,nalbuphine,moderate to severe pain,primarily a kappa agonist/partial mu antagonist,hazardous interactions,alcohol,hypersensitivity to nalbuphine hydrochloride,few side-effects
1189,naftifine hydrochloride,allylamine antifungal,the exact mechanism of action against fungi is not known,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pruritus
1190,naftidrofuryl oxalate,peripheral vascular disorders,5ht2-blocking activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hyperoxaluria or recurrent calcium-containing kidney stones,kidney stones
1191,nabumetone,use the lowest effective dose for the shortest duration consistent with individual patient treatment goals,both prostaglandin g/h synthase 1 and 2,antihypertensive effect of ace-inhibitors,nsaids,"asthma, urticaria, or allergictype reactions",edema
1192,nab-paclitaxel [nanoparticle albumin-bound paclitaxel],non-small cell lung cancer,microtubule inhibitor,medicines known to inhibit,medicines known to inhibit,patients who experience a severe hypersensitivity reaction,non
1193,nirmatrelvir + ritonavir,indicated for mild-to-moderate covid-19,ritonavir inhibits the cyp3a mediated metabolism,plasma concentrations,drugs that induce cyp3a,history of clinically significant hypersensitivity reactions,"diarrhea, hypertension, and myalgia"
1194,niraparib,partial response to platinum-based chemotherapy,did not significantly affect the pharmacokinetics,active substances,active substances,breast-feeding,monotherapy
1195,nintedanib,"locally advanced, metastatic or locally recurrent non-small cell lung cancer",inhibition of the src pathway,hormonal contraceptives,st. johns wort,"peanut or soya, or to any of the excipients","diarrhea, nausea and vomiting, abdominal pain"
1196,nimodipine,regardless of their post ictus neurological condition,blocking calcium channels or select voltage-sensitive areas,strong cyp3a4 inducers,increased plasma concentrations with cimetidine or sodium valproate,use within 1 mth of mi or an episode of unstable angina,"headache, dizziness, flushing (feeling of warmth), heartburn"
1197,nimesulide,acute pain; extra-articular disorders,"anti-inflammatory, anti-pyretic, and analgesic properties",nsaids,nsaids,pregnancy; children &lt,increases in liver enzymes
1198,nilotinib,advanced renal cell carcinoma,multi-tyrosine kinase inhibitor,chronic use of strong cyp3a4 inducers,grapefruit or grapefruit juice,patients with known hypersensitivity to pazopanib,electrolyte imbalances
1199,nikethamide,injection,the effective doses are close to those causing toxic effects,increased risk of cardiac arrythmias,maois,"hyperthyroidism, phaeochromocytoma","skin irritation, eye irritation, respiratory irritation"
1200,nifedipine,renal hypertension,inhibitor of calcium channel blocker,ulcer healing drugs: metabolism of nifedipine increases,anti-bacterials: rifampicin,"cardiogenic shock, advanced aortic stenosis, nursing mothers",few cases of jaundice have been reported
1201,nicotinic acid [niacin],alcoholism) should be excluded,raising hdl levels,metabolic clearance,bile,patients with a known hypersensitivity,"flushing, itching, pruritis, nausea and gi upset"
1202,nicorandil,angina pectoris,"it therefore reduces preload and afterload, and improves coronary blood flow",beta-blockers,alcohol,patients who have shownhypersensitivity to nicorandil,hypotension and reflex tachycardia at high doses
1203,nevirapine,adults and in pediatric patients 15 days and older,it binds directly to reverse transcriptase,reduced levels/effects of methadone,methadone,hypersensitivity. lactation. severe hepatic impairment,"skin rash, nausea, vomiting, headache"
1204,netarsudil dimesylate,patients with open-angle glaucoma or ocular hypertension,rho kinase inhibitor,eye drops,eye drops,NO SPECIFIC DATA AVAILABLE,conjunctival hyperemia
1205,netarsudil + latanoprost,open-angle glaucoma or ocular hypertension,latanoprost is a selective fp receptor agonist,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitive,amp
1206,neratinib,extended adjuvant treatment of adult patients,kinase inhibitor,proton pump inhibitors,proton pump inhibitors,patients with known hypersensitivity,"diarrhea, hepatotoxicity."
1207,nepafenac,0.1% sterile ophthalmic suspension,ocular tissue hydrolase,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with previously demonstrated hypersensitivity,"foreign body sensation, lid margin crusting"
1208,neostigmine methyl sulphate,excluded,indirectly stimulates both nicotinic and muscarinic receptors,propafenone antagonise effect,"aminoglycosides, clindamycin, lincomycin",patients with peritonitis or mechanical obstruction,overdose
1209,neomycin sulphate + polymyxin b sulphate + pramoxine,first aid cream,hcl,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitive,no common side effects have been reported
1210,neomycin sulfate + bacitracin zinc + polymyxin b sulfate (ophthalmic),superficial infections of the external eye,binding to membrane phospholipids.,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,hypersensitivity,"rash, itching, burning, anaphylactic reactions"
1211,neomycin sulfate + bacitracin zinc + polymyxin b sulfate,local treatment of chronic varicose or other indolent ulcers,combined antibiotic action,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,neonates,injection
1212,neomycin sulfate + bacitracin zinc,antibiotic therapy,bacitracin inhibits bacterial cell wall synthesis,increased risk of nephrotoxicity,aminoglycosides,hypersensitivity,allergic reactions
1213,obeticholic acid,indicated for the treatment of primary biliary cholangitis,agonist for fxr,bile acid absorption,bile acid binding resins,patients with complete biliary obstruction,"pruritus, fatigue &amp; stomach pain and discomfort"
1214,nystatin (topical),"not indicated for systemic, oral, intravaginal or ophthalmic",binding to sterols in thefungal cell membrane,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a history of hypersensitivity,cream
1215,nystatin (oral),in those born of mothers with vaginal candidiasis,poorly absorbed from the gastrointestinal tract,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,no systemic effects or allergic reactions
1216,nortriptyline,depression and nocturnal enuresis.,blocking the neuronal reuptake,adrenaline,adrenaline,patients with hypersensitivity to nortriptyline,euphoria and mania
1217,norgestrel + ethinyl estradiol + ferrous fumarate,sterilization,inhibition of ovulation,concomittant use,severe pruritus and jaundice with troleandomycin,selected patients being treated for metastatic disease,cholestatic jaundice
1218,norgestrel,not for use as emergency contraception,thickening the cervical mucus to inhibit sperm penetration,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known or suspected pregnancy,headache dizziness nausea increased appetite
1219,norethisterone acetate,metropathia hemorrhagic,progestational actions,not known,not known,hypersensitivity to the active substances,subside with a duration of treatment
1220,norepinephrine,cardiac arrest and profound hypotension,stimulates 1- and -adrenergic receptors,risk of producing ventricular tachycardia or fibrillation,monoamine oxidase inhibitors (maoi) or antidepressants,patients with mesenteric or peripheral vascular thrombosis,hypotension
1221,nizatidine,activeduodenal ulcer,no demonstrable antiandrogenic action,increases in serum salicylate levels,concurrently,patients with known hypersensitivity to the drug,fever
1222,nivolumab,patients with unresectable or metastatic melanoma,pd-1 pathway-mediated inhibition of the immune response,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,none,"fatigue, diarrhea, rash, pruritus, nausea"
1223,nitroglycerin (sublingual tablet),indicated,guanylate cyclase,ergotamine,ergotamine,hypersensitivity to nitroglycerin,"vertigo, dizziness, weakness, palpitation"
1224,nitroglycerin (sublingual spray),acute relief of an attack or prophylaxis,pharmacological,bioavailability of dihydroergotamine,alcohol,"hypotension, hypovolaemia, severe anaemia","headache, facial flushing, dizziness, nausea, vomiting"
1225,nitroglycerin (oral preparation),prophylaxis of angina pectoris,vasodilator effect on both peripheral arteries and veins,heparin,alcohol,patients with a known hypersensitivity,"tachycardia, postural hypotension and syncope"
1226,nitroglycerin (ointment),chronic anal fissures,release of nitric oxide,medicines for depression,depression,headache,headache and dizziness
1227,nitroglycerin (iv infusion),peri-operative hypertension,pharmacological,mixed with any other medication,blood,patients who are allergic to it,headache
1228,nitrofurazone,infectious conditions,broad spectrum topical antibacterial agent,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known or suspected renal impairment,cross sensitization to other nitrofurazone derivatives
1229,nitrofurantoin + nitrofurantoin microcrystals,nitrofurantoin,slower dissolution and absorption than nitrofurantoin monohydrate,reduce both the rate and extent of absorption,magnesium trisilicate,<NO SPECIFIC DATA AVAILABLE>,nausea
1230,nitrofurantoin,prophylaxis of urinary tract infections,inactivates or alters bacterial ribosomal proteins,renal tubular secretion,uricosuric drugs,hypersensitivity to nitrofurantoin,"nausea, headache, and flatulence."
1231,nitrazepam,"short-term management of insomnia,",sleep-inducing activity,levodopa,levodopa,porphyria,"aspiration, increased bronchial secretion, dyspnoea"
1232,nitazoxanide,diarrhea,antiprotozoal,plasma protein,plasma protein,patients with known hypersensitivity,"abdominal pain, vomiting and headache"
1233,oral rehydration salt [powder],all age groups,glucose based oral rehydration salt,drug interactions,drug,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1234,oral rehydration salt [flavored],indicated for diarrhea,dextrose,drug,drug,patients with known hypersensitivity,no significant side effects
1235,oral polio vaccine,poliovaccines are vaccines used to prevent poliomyelitis,secretory iga antibody,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,febrile illness or any active infection,paralysis
1236,oral cholera vaccine,the vaccine can be administered to anyone above the age of 1 year,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,subjects with either known hypersensitivity to any component,"acute gastroenteritis, diarrhea, fever, vomiting"
1237,ondansetron,repeat courses of emetogenic cancer chemotherapy,is not known,dosage adjustment,no dosage adjustment,patients known to have hypersensitivity to the drug,headache
1238,omeprazole (mups tablet),duodenal and gastric ulcers,ensures greater bioavailability,potential interactions,medicines,patients who have known hypersensitivity to any other components,NO SPECIFIC DATA AVAILABLE
1239,omeprazole,nsaid-associated duodenal and gastric ulcer,inhibitor of gastric acid secretion,"diazepam, warfarin and phenytoin",warfarin and phenytoin,patients with known hypersensitivity to any of the components of the formulation,"nausea, abdominal colic, paresthesia, dizziness and headache"
1240,omega-3 acid ethyl esters [salmon fish oil],adult patients,this mechanism is not well understood,anticoagulants,anticoagulants,patients who exhibit hypersensitivity to any component of this medication,rarely reported
1241,omalizumab,chronic spontaneous urticaria,unknown,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with severe hypersensitivity reaction,asthma
1242,olopatadine hydrochloride (ophthalmic),ocular itching associated with allergic conjunctivitis,low systemic exposure,additive cns depression with cns depressants,additive cns depression with cns depressants,persons with a known hypersensitivity,nausea
1243,olopatadine hydrochloride (nasal spray),adults and children 6 years of age and older,nonsterile aqueous solution,interaction with other medications,medications,NO SPECIFIC DATA AVAILABLE,tell your doctor or pharmacist promptly
1244,olmesartan medoxomil + hydrochlorothiazide,amp,reduces plasma volume,no effects on p450 enzymes,digoxin or warfarin,patients who are hypersensitive,"nausea, headache, dizziness, hyperuricemia"
1245,olmesartan medoxomil,alone or in combination with other antihypertensive agents,olmesartan does not inhibit ace,significant drug interactions,food,patients who are hypersensitive to any component of this product,influenza-like symptoms
1246,olaparib,breast cancer,poly (adp-ribose) polymerase (parp) enzymes,myelosuppressive anti-cancer agents,monotherapy,patients who are hypersensitive,anemia and platelet count decrease
1247,olanzapine,with or without psychotic features and with or without a rapid cycling course,unknown,centrally acting drugs and alcohol,alcohol,patients with a known hypersensitivity to any ingredient of the product,mild and transient anticholinergic effects
1248,ofloxacin + clotrimazole + beclomethasone + lidocaine,superficial bacterial and fungal infections,inhibiting dna gyrase of bacteria,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,viral infections of the ear,systemic side-effects are not common with this ear drops
1249,ofloxacin (oral & injection),mild to moderate infections caused by susceptible strains,bactericidal activity,"antacids containing magnesium, aluminium or calcium may decrease absorption",antacids,patients with a history of epilepsy or with a lowered seizure threshold,clinical side-effects of ofloxacin has been quite low
1250,ofloxacin (ophthalmic),it is indicated for the treatment of external ocular infections,bactericidal activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitive,"burning, stinging, redness, itching or photophobia"
1251,octreotide acetate,carcinoid tumors,suppressing basal and stimulated secretion of growth hormone,bromocriptine,bromocriptine,hypersensitivity,pancreatitis
1252,obinutuzumab,previously untreated chronic lymphocytic leukemia.,activation of the complement cascade,risk for interactions with concomitantly used medicinal products,chop,patients with a known hypersensitivity,infections
1253,oxytetracycline + polymixin b sulphate,local treatment of superficial ocular infections,antibiotic,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE,all medicines may cause side effects
1254,oxytetracycline,oxytetracycline is indicated in- respiratory tract infections,inhibits cell growth by inhibiting translation,"antacids containing aluminium, calcium, magnesium, zinc or iron salts","antacids containing aluminium, calcium, magnesium, zinc or iron salts",children under 12 years of age,"anorexia, nausea, vomiting, diarrhoea, glossitis"
1255,oxyphenonium bromide,oxyphenonium,anticholinergic drug,reduced gastric motility interferes with absorption of other drugs,antihistamines,hypersensitivity,"dryness of mouth, headache, palpitations"
1256,oxyphencyclimine hydrochloride,peptic ulcer disease,antagonizing the action of acetylcholine,antagonistic effect with parasympathomimetics,parasympathomimetics,toxic megacolon; myasthenia gravis,"suppression of lactation, urticaria, constipation"
1257,oxymorphone hydrochloride,pre-operative &amp; post-operative medication for support of anesthesia,the precise mechanism of the analgesic action is unknown,drug-drug interactions,drug,anaphylaxis,flushing
1258,oxymetazoline hydrochloride (nasal preparation),otitis media,topical agent on the nasal mucosa,mao inhibitors,mao inhibitors,"patients with cardiovascular disease, hyperthyroidism",discomfort
1259,oxymetazoline hydrochloride (cream),persistent facial erythema associated with rosacea in adults,vasoconstrictor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,application site dermatitis
1260,oxybutynin chloride,pediatric patients aged 6 years and older,inhibiting the muscarinic action of acetylcholine,drug-drug interaction studies,drug,patients with urinary retention,"abdominal pain, dry nasal and sinus mucous membranes"
1261,oxybuprocaine hydrochloride,used to temporarily numb the front surface of the eye,oxybuprocaine binds to sodium channel,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,hypersensitivity reactions; transient stinging and blurring of vision
1262,oxiconazole nitrate,dermal infections,inhibition of ergosterol biosynthesis,drug interactions,drug interactions between oxiconazole,individuals who have shown previous hypersensitivity to oxiconazole,"pruritus, burning, irritation and allergic contact dermatitis"
1263,oxcarbazepine,adults,blockade of voltage-sensitive sodium channels,enzyme cyp2c19,medicinal products,patients with hypersensitivity,very rarely clinically significant hyponatraemia
1264,oxazepam,older people,enhancing the effect of a natural chemical in the brain (gaba),alcohol,alcohol,allergic reaction,drowsiness
1265,oxaprozin,for relief of the signs and symptoms of osteoarthritis,not completely understood,antihypertensive agents,lithium,known hypersensitivity to nsaids,"depression, sedation, somnolence"
1266,oxaliplatin,adjuvant treatment of stage iii colon cancer,intracellular hydrolysis,myelosuppression,taxane derivatives,pregnancy,aspartate and alanine transaminases increased
1267,ospemifene,moderate to severe dyspareunia,binding to estrogen receptors,estrogens,fluconazole,women who are or may become pregnant,adverse reactions
1268,osimertinib,patients with metastaticepidermal growth factor receptor,third-generation tyrosine kinase inhibitor,if concurrent use is unavoidable,unavoidable,NO SPECIFIC DATA AVAILABLE,"qtc interval prolongation, cardiomyopathy, keratitis"
1269,oseltamivir,when the influenza virus is circulating in the community,oseltamivir carboxylate inhibits neuraminidase,clinically significant drug interactions,amoxicillin,patients with known hypersensitivity to any of the components of the product,nausea and vomiting
1270,ornidazole,treatment of susceptible anaerobic infections,it is converted to reduction products,clearance of 5-fluorouracil,oral anticoagulants,epilepsy or in peripheral neuropathy,"dizziness, headache, lassitude)"
1271,orlistat,obese adolescents should be treated with orlistat only,lipase inhibitor,interactions with commonly prescribed medications,alcohol,patients with chronic malabsorption syndrome,gastrointestinal in nature. common gastrointestinal
1272,oral rehydration salt [rice based],saline,glucose is then absorbed through intestinal wall with salt,drug,drug,infants,NO SPECIFIC DATA AVAILABLE
1273,pefloxacin mesylate dihydrate,septicemia,inhibiting the subunit-a of dna gyrase,concurrent administration,aluminium and/or magnesium hydroxide gel,"children under 15 years of age, pregnant and lactating mothers","nausea, vomiting, diarrhoea, dyspepsia"
1274,pazopanib hydrochloride,not been demonstrated,multi-tyrosine kinase inhibitor,chronic use of strong cyp3a4 inducers,grapefruit or grapefruit juice,patients with known hypersensitivity,hepatic toxicity and hepatic impairment
1275,paroxetine hydrochloride,paroxetine,inactive,alcohol,antacids,patients with a hypersensitivity,social anxiety disorder
1276,paricalcitol,adults and pediatric patients 10 years of age and older,binding of the vdr,"cholestyramine, mineral oil","cholestyramine, mineral oil",hypercalcemia or vitamin d toxicity,"hypertension, hypersensitivity, nausea, and edema"
1277,parecoxib,postoperative pain in adults,a prodrug of valdecoxib,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,change in your blood pressure (up or down)
1278,paracetamol+tramadolhydrochloride,moderate to moderately severe pain in adults,binding of parent and m 1 metabolite to -opioid receptors,NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,patients who have previously demonstrated hypersensitivity,"somnolence pruritus, rash, increased sweating"
1279,paracetamol + caffeine,headache,weak anti-inflammatory activity,colestyramine,domperidone,patients with severe renal function impairment and hepatic disease,mild
1280,paracetamol (iv infusion),mild to moderate pain,poorly understood,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with severe hepatic impairment or severe active liver disease,rare
1281,pantoprazole sodium sesquihydrate,indicated where suppression of acid secretion has therapeutic benefit,proton pump inhibitor,drug interactions,drug,patients with known hypersensitivity,headache and diarrhea are the common side effects
1282,paracetamol,"fever, common cold and influenza",primarily in the cns,anticonvulsants or oral steroid contraceptives,alcohol,hypersensitivity,mild
1283,pancuronium bromide,adjunct to general anesthesia,competitive acetylcholine antagonist,prior suxamethonium,prior suxamethonium,patients with know hypersensitivity,"rarely, hypersensitivity reactions"
1284,pancreatin,patients with chronic pancreatitis cystic fibrosis,"enzymes with amylase, protease and lipase activity",bursting out of the content in the stomach,antacid,patients with known hypersensitivity to the drug,"nausea, vomiting and abdominal discomfort"
1285,palonosetron,read,blocking the actions of serotonin,drug interactions,injection,patients known to have hypersensitivity,headaches and constipation
1286,paliperidone palmitate,schizophrenia in adults,unclear,strong inducer of cyp3a4 and/or p-gp,cyp3a4 and/or p-gp,known hypersensitivity,injection site reactions
1287,paliperidone,schizophrenia,a centrally active dopamine type 2 (d2) antagonist,alcohol,alcohol,NO SPECIFIC DATA AVAILABLE,the most common adverse reactions
1288,palbociclib,initial endocrine-based therapy in postmenopausal women,inhibitor of cyclin-dependent kinases,grapefruit or grapefruit juice,grapefruit or grapefruit juice,NO SPECIFIC DATA AVAILABLE,"wbc decreased, neutrophils decreased, neutropenia"
1289,padimate o + avobenzone + oxybenzone + titanium dioxide,normal skin types when exposed to intense sunlight photodermatoses,"non-greasy, water resistant",drug interactions,drug,known hypersensitivity to any of its components,signs of irritations
1290,paclitaxel,gemcitabine,anti-microtubule agent,toxicity,medicines,patients with severe hepatic impairment,hives after paclitaxel is given
1291,ozenoxacin,adult and pediatric patients 2 months of age and older,inhibition of bacterial dna replication enzymes,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,none,rosacea and seborrheic dermatitis
1292,oxytocin,selected cases of uterine inertia,increasing the intracellular ca 2+,severe hypertension,prophylactic administration of a vasoconstrictor,cases where vaginal delivery is not indicated,anaphylactic reaction
1293,phenoxymethyl penicillin [penicillin v],mild to moderately severe bacterial infections,acid-stable,"empty stomach, preferably one hour before meals","empty stomach, preferably one hour before meals",patients with hypersensitivity to penicillins,transient discolouration of the teeth
1294,phenobarbital,short-term treatment of insomnia,"gaba a receptors, increasing synaptic inhibition",alcohol or other cns depressants,alcohol,phenobarbital sensitivity or a history of latent porphyria,"nausea, vomiting and constipation"
1295,pheniramine maleate,all itching skin conditions,inverse agonist,alcohol,alcohol,newborn and premature infants,overdose
1296,pethidine hydrochloride,anaesthetic adjunct and for obstetric analgesia,mu-receptor agonist,alcohol,alcohol,patients with renal impairment,"gastrointestinal : nausea and vomiting, constipation."
1297,pertuzumab,use in ... read more,humanized monoclonal antibody,drug-drug interactions,"docetaxel, paclitaxel, or carboplatin",patients with known hypersensitivity,headache
1298,permethrin + crotamiton,scabies and pruritus,scabicidal and antipruritic,reducing the immune response to the mite,corticosteroids,inpatients with known hypersensitivity,skin irritation
1299,permethrin,"if one is infected, all family members must be treated together",it acts on the nerve cell membrane to disrupt the sodium channel current,risk of exacerbating the scabies infestation,corticosteroids,patients with known hypersensitivity to any component of pyrethroids,irritation
1300,peritoneal dialysis solutions,indicated for peritoneal dialysis,sodium chloride,drug interactions,drug,patients with excessive obesity and in pregnancy,amino acids and water soluble vitamins may be lost
1301,perindopril arginine + amlodipine,concurrently at the same dose level,inhibits ace in humans and in animals,reduce blood pressure,nitroglycerine,during pregnancy and for lactating women,amlodipine given separately
1302,perindopril arginine,"essential hypertension, stable coronary artery disease, congestive heart failure",blocks the action of ace,nsaids may also increase the risk of renal impairment,k supplements,"management of hypertension of children, during pregnancy &amp; lactation",reversible increase in blood urea and creatinine
1303,perampanel,patients with epilepsy from 4 years of age and older,unknown,plasma concentrations,plasma concentrations,none,"dizziness, somnolence, fatigue, irritability"
1304,pentoxifylline,peripheral arterial occlusive disease,the precise mode of action,caution,cimetidine,patients with hypersensitivity,clinical trials or post-marketing- investigations
1305,pentosan polysulfate sodium,interstitial cystitis,two sulfate groups per carbohydrate monomer,similar,placebo,patients with known hypersensitivity,alopecia
1306,pentazocine hydrochloride,moderate to severe pain,mixed opioid agonist and antagonist actions,ataxia flushing and tremor associated with serotonin syndrome,fluoxetine,patients who are hypersensitive to it,"nausea, vomiting, constipation"
1307,pemirolast potassium,allergic conjunctivitis,blocks the action of endogenous histamine,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with previously demonstrated hypersensitivity,"burning of eye, dry eye, ocular discomfort"
1308,pemetrexed,withcisplatin,thymidylate synthase inhibitor,2 days,aspirin,patients with a history of severe hypersensitivity reaction,radiationrecall
1309,pembrolizumab,melanoma,pd-1 pathway-mediated inhibition of the immune response,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,none,chemotherapy
1310,pegylated erythropoietin,not indicated for use: in the treatment of anemia due to cancer chemotherapy,greater activity in vivo as well as increased half-life,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,seizures
1311,peginterferon alfa-2a [pegylated interferon alfa-2a],chronic hepatitis b,"it has antiviral, antiproliferative and immune-regulating activity",anemia,ribavirin,neonate or infants,"skin problems, hair loss"
1312,pegfilgrastim [pegylated filgrastim],in patients with non-myeloid malignancies,regulates the production and release of functional neutrophils from bone marrow,mixed with other medicinal product,sodium chloride solutions,patients with a history of serious allergic reactions,allergic reactions
1313,podophyllotoxin,for the removal of external genital warts,antimitotic action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity; pregnancy; lactation; child,renal failure; hepatotoxicity
1314,pizotifen,not effective in relieving migraine attacks once in progress,inhibiting the peripheral actions of serotonin and histamine,alcohol,common cold,patients with known hypersensitivity to any of its ingredients,increase in body weight and drowsiness
1315,pivmecillinam,infections caused by mecillinam-sensitive organisms,the site of action differs from that of other penicilins,<NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to penicillins and cephalosporins,"nausea, vomiting and diarrhoea or indigestion"
1316,pitavastatin calcium,adult patients with primary hyperlipidemia or mixed dyslipidemia,inhibiting hmg-coa reductase,gemfibrozil or other fibrates,gemfibrozil or other fibrates,patients with active liver disease,"rhabdomyolysis, myopathy and liver enzyme abnormalities"
1317,pirfenidone,adults,"orally active, small molecule that shows a wide range of biologic activity",NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with concomitant use of fluvoxamine,"nausea (32.8% versus 13.3%),"
1318,piracetam,myoclonus,not fully understood,anti-epileptic drugs,thyroid extract,patients with severe renal insufficiency,"nervousness, agitation, irritability, anxiety and sleep disturbances"
1319,piperacillin + tazobactam,moderate to severe infections,beta-lactamase inhibitor,probenecid,probenecid,patients with a history of allergic reactions,infections
1320,pipecuronium bromide,used as a muscle relaxant during anesthesia,nondepolarizing neuromuscular blocking agent,enhanced block when used with drugs that have neuromuscular blocking activity,corticosteroids,hypersensitivity,"transient hypotension, bradycardia, reduced cardiac output."
1321,pioglitazone + metformin hydrochloride,patients with type 2 diabetes,metformin hydrochloride,reduced metabolism,renal tubular secretion,acute or chronic metabolic acidosis,"upper respiratory tract infection, diarrhea, peripheral edema and headache"
1322,pioglitazone + glimepiride,sulfonylurea,amp;glimepiride,decrease in ethinyl estradiol plasma concentrations,oral contraceptive,known hypersensitivity,hypoglycemia
1323,pioglitazone,monotherapy,insulin,loss of contraception,oral contraceptive,patients with known hypersensitivity to any of its components,"upper respiratory tract infection (13.2%),"
1324,pimecrolimus,not indicated for use in children less than 2 years of age,not known,systemic drug interactions,cream,individuals with a history of hypersensitivity,viral infection
1325,pimavanserin,parkinson's disease psychosis.,unknown,strong cyp3a4 inhibitors,strong cyp3a4 inhibitors,<NO SPECIFIC DATA AVAILABLE,"nausea, constipation"
1326,pilocarpine hydrochloride (oral),patients with sjogrens syndrome,predominant muscarinic action,beta adrenergic antagonists because of the possibility of conduction disturbances,beta adrenergic antagonists,patients with uncontrolled asthma,exaggerated parasympathetic stimulation
1327,pilocarpine hydrochloride (ophthalmic),ocular hypertension,directly stimulates cholinergic receptors,belladonna alkaloids,belladonna,acute iritis,headache
1328,phytomenadione (oral),newborn babies,it is absorbed from small intestine and taken up by the liver,vitamin k1,warfarin overdosage,hypersensitivity,no adverse effects have been associated with oral administration
1329,phytomenadione (injection),antibiotics,hepatic carboxylase system,vitamin k-1,coadministration of anticonvulsants,patients with known hypersensitivity to any of its constituents,anaphylactoid reactions and venous irritation or phlebitis
1330,phospholipids,preferably by 8 hours of age,replenishes surfactant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hyperphosphataemia
1331,pholcodine,temporary relief of non-productive dry cough,mild sedative effect with little or no analgesic action,not to be used with maoi or within 14 days of stopping treatment,alcohol,maois,ataxia
1332,phenytoin sodium,only when oral phenytoin administration is not possible,increasing efflux or decreasing influx of sodium ions,valproic acid,valproic acid,a history of hypersensitivity to phenytoin,hyperglycaemia
1333,prednisolone,drug hypersensitivity reactions,directly inhibits the action of the phospholipase a2 enzyme,reduces the amount of potassium in the blood,prednisolone reduces the amount of potassium in the blood,systemic infections,"increased appetite, indigestion, nervousness or restlessness"
1334,precipitated sulpher + salicylic acid,sulfur,synergistic keratolytic effect,certain medicines,alcohol,hyppersensitivity,sulfur
1335,prazosin hydrochloride,alone or added to the therapeutic regimen,inhibition of postsynaptic alpha-1-adrenoreceptors,reduction in blood pressure,calcium antagonist therapy,patients with known sensitivity to prazosin &amp,"depression, nervousness"
1336,prasugrel hydrochloride,primary or delayed pci,irreversible binding of its active metabolite,nsaids,nsaids,patient with a history of prior transient ischemic attack or stroke,"headache, back pain, dyspnea, nausea, hypertension"
1337,pramoxine hydrochloride + calamine,temporary relief of pain and itching associated with minor burns,calamine causing a cooling sensation and provides anti-itching action,no significant interactions,multiple medications,NO SPECIFIC DATA AVAILABLE>,local skin reaction
1338,pramipexole,moderate to severe restless legs syndrome,unknown,possible drug-drug interactions,alcohol,patients with known hypersensitivity,pruritus and rash
1339,pralidoxime chloride,in severe poisoning,forming an oxime complex,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known hypersensitivity to the drug,mild to moderate pain
1340,povidone iodine,cream,liberating elemental iodine slowly,lithium therapy,lithium therapy,serious cavities and in children under the age of 2 years,"metabolic acidosis, hypernatraemia, and impairment of renal function"
1341,potassium citrate + citric acid,uricosuric agent,potassium citrate is absorbed and metabolized to potassium bicarbonate,toxicity,cardiac glycosides,severe renal impairment with oliguria or azotemia,without any unpleasant side effect
1342,potassium citrate,ofuric acidlithiasis with or without calcium stones,therapy does not alter the urinary saturation of calcium phosphate,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with hyperkalemia,hyperkalemia
1343,potassium chloride,replacement of potassium deficit diuretic,potassium ion is the principal intracellular cation of most body tissues,potassium-sparing diuretics,potassium-sparing diuretics,metabolic acidosis,"nausea, vomiting, diarrhoea and abdominal cramps"
1344,posaconazole,patients receiving remission-induction chemotherapy for acute myelogenous leukemia,posaconazole blocks the synthesis of ergosterol,other medicinal products that are metabolized by cyp3a4,"midazolam, triazolam, alprazolam",persons with known hypersensitivity,"diarrhea, nausea, fever, vomiting"
1345,ponatinib hydrochloride,ph+ all,kinase inhibitor,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,none,"abdominal pain, rash, constipation, headache, dry skin"
1346,polysaccharide pneumococcal vaccine,persons 50 years of age or older and persons aged 2 years,type-specific antibodies,zostavax,vaccines other than zostavax,anaphylactic/anaphylactoid or severe allergic reaction,injection-site pain/soreness/tenderness
1347,polysaccharide diphtheria toxoid conjugate vaccine,9 months through 55 years of age,menactra induces the production of bactericidal antibodies,simultaneous administration of the 2 vaccines or administration of menactra,menactra,severe allergic reaction,solicited adverse events
1348,polymyxin b sulfate,it may be indicated in serious infections caused by susceptible strains of the following organisms,NO SPECIFIC DATA AVAILABLE,neurotoxic and/or nephrotox-ic drugs,general anesthetic,NO SPECIFIC DATA AVAILABLE,nephrotixic reactions
1349,polygeline + electrolytes,"calcium chloride, sodium chloride and potassium chloride",replenishing the bodys fluid,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,"injection site reactions such as redness, pain or swelling"
1350,polyethylene glycol 3350 + electrolytes,resolving fecal impaction,excreted in fecal water,drug interactions,drug,patients with known hypersensitivity to the active substance,hyperkalaemia and hypokalaemia
1351,polyethylene glycol + propylene glycol,sterile eye drops,polyethylene glycol 400,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,allergic condition occurs to any ingredients of the product
1352,polyethylene glycol,only be used by the person for whom it is prescribed,osmotic effect,drug interactions,drug,patients with known or suspected bowel obstruction and patients known to be allergic,urticaria suggestive of an allergic reaction
1353,proparacaine hydrochloride,prior to surgical operations,anesthetic action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity,"occasional temporary stinging, burning and conjunctival redness"
1354,propantheline bromide,adjunctive therapy in the treatment of peptic ulcer,dual,antacids or absorbent antidiarrhoeals,absorbent antidiarrhoeals,hypersensitivity,"dry mouth, dry skin, mydriasis"
1355,propafenone hydrochloride,documented ventricular arrhythmias,slowing the influx of sodium ions into the cardiac muscle cells,increased plasma levels,grapefruit juice,uncontrolled congestive heart failure,"change in taste, constipation"
1356,promethazine theoclate,doctor,blocking the histamine receptors in the vomiting centre,monoamine oxidase inhibitor,alcohol,rare hereditary problems,not
1357,promethazine hydrochloride (injection),amelioration of allergic reactions to blood or plasma,metabolized in the liver,epinephrine,epinephrine,comatose states,increases and decreases in blood pressure
1358,promethazine hydrochloride,pre-operative sedation in surgery and obstetrics,sulfoxides,alcohol,alcohol,children less than two years of age,do not exceed the recommended dose
1359,progesterone (vaginal pessary),in- luteal phase support,structurally and biologically identical to natural endogenous progesterone,concomitant vaginal products,concomitant vaginal products,missed abortion or ectopic pregnancy,less
1360,progesterone (vaginalgel),throughout the day,NO SPECIFIC DATA AVAILABLE>,do not use progesterone at the same time as any other medicines,do not use progesterone at the same time as any other medicines,if you have unexplained vaginal bleeding,breast tenderness
1361,progesterone (capsule),threatened / recurrent abortion,micronised progesterone,metabolism,ketoconazole,miscarriage and tissue left in the uterus,side effects are less when vaginal route is used
1362,procyclidine hydrochloride,adjunctive treatment of all forms of parkinsonian syndrome,antimuscarinic antiparkinsonian agent of relatively low toxicity,absorption of ketoconazole,ketoconazole,diarrhoea and cardiovascular disease,dryness of the mouth is generally the only adverse effect
1363,prochlorperazine maleate,"radiation therapy, cancer chemotherapy, surgery, and other conditions.",blockade of histamine h,antacids,propanolol and phenobarbital,children,skin rash; yellowing of the skin or eyes.
1364,procaine penicillin + benzyl penicillin,long acting penicillin is required,inhibited by penicillinase and other lactamases,mixed in infusion fluids,infusion fluids,hypersensitivity,allergic reactions
1365,probiotic combination [9 billion],gastrointestinal problems,chelation of metal ions,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,hypersensitive,probiotics are generally well tolerated
1366,probiotic combination [20 billion],antibiotic regimen,freeze-dried,drug interaction,drug,hypersensitivity to it,stomach gas and bloating
1367,probiotic combination [14 strains],the original multi-strain,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1368,probiotic combination [10 billion],supports digestive health and relieves constipation,digestive,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,stomach gas and bloating
1369,primaquine phosphate,malaria,unclear,prolong the qt interval,drugs,acutely ill patients,"rarely, leucopenia, agranulocytosis"
1370,pregabalin,pregabalin cr tablet,has not been fully elucidated,significant pharmacokinetic drug interactions,pregabalin,patients with known hypersensitivity,increased weight and increased appetite
1371,prednisolone acetate,steroid-responsive inflammation,it suppresses the immune system,drug interactions,drug,viral diseases,fungal and viral infections of the cornea
1372,prednisolone + neomycin sulphate + polymixin b sulphate,steroid,bactericidal,oral anticoagulants,oral anticoagulants,viral diseases,delayed wound healing
1373,rabies immunoglobulin,always be used in conjunction with rabies vaccine,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,contraindication,"hypotension, dyspnoea, and urticaria"
1374,rabeprazole sodium,active duodenal ulcer active benign gastric ulcer,inhibiting the gastric h + /k + -atpase,interaction with liquid antacids,ketoconazole or itraconazole,pregnancy and during breastfeeding,"increased or decreased appetite, muscle pain, drowsiness, dizziness"
1375,rabeprazole + amoxicillin + clarithromycin,amp; rabeprazol,clarithromycin,interactions,terfenadine,patients with known hypersensitivity,adverse reactions
1376,quinine sulfate,"uncomplicated, severe and complicated falciparum malaria",both as a suppressive drug and in the over clinical attack of malaria,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,in case of black water fever,"tinnitus, headache, nausea and visual disturbances"
1377,quetiapine fumarate,in combination with a mood stabilizer,unknown,electrolyte imbalance or to increase qt interval,electrolyte imbalance or to increase qt interval,patients who are hypersensitive to it,"somnolence, dizziness, dry mouth"
1378,pyrimethamine,resistance to pyrimethamine is prevalent worldwide,folic acid antagonist,the concomitant use of other antifolic drugs,bone marrow suppression,patients with known hypersensitivity,anorexia and vomiting may occur
1379,pyridoxine hydrochloride + doxylamine succinate,the treatment of nausea and vomiting of pregnancy,vitamin b6 analog,concurrent use of alcohol and other cns depressants,alcohol,women,cns depressants
1380,pyridoxine hydrochloride,certain hereditary disorders,aids in the release of glycogen stored in the liver and muscles,"do not start, stop, or change the dosage of any other medicines",without your doctor's approval,NO SPECIFIC DATA AVAILABLE,pyridoxineusually has no side effects when used in recommended doses
1381,pyridostigmine bromide,myasthenia gravis paralytic ileus,longer duration of action and fewer gastrointestinal side effects,acetylcholine,gastrointestinal tract,mechanical intestinal or urinary obstruction,nicotinic
1382,pyrazinamide,only be used in conjunction with other effective antituberculous agents,bacteriostatic or bactericidal,contraceptive effect of oestrogens,uricosuric agents,with acute gout,blood clotting mechanisms have also been rarely reported
1383,pyrantel pamoate,do not use this medication in children younger than 2 years,depolarizing neuromuscular blocking agent,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to pyrantel or any ingredient in the formulation,"headache, dizziness and rash"
1384,pseudoephedrine hydrochloride,bronchodilator,main and direct mechanism of action,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,severe hypertension and coronary artery disease,rare
1385,pseudoephedrine + guaiphenasine + triprolidine,expectorant combination,direct,reverse the hypotensive action of drugs which interfere with sympathetic activity,amp,known hypersensitivity to any of its constituents,skin rashes with or without irritation
1386,prucalopride succinate,adults in whom laxatives fail to provide adequate relief,selective stimulator of the 5-ht4 receptors,cyp-mediated metabolism,alcohol,people with renal impairment requiring dialysis,nausea and diarrhoea
1387,"protein, fat, carbohydrate, vitamin & mineral",total diet replacement,no data has found,drug interactions,drug,hypersensitivity,NO SPECIFIC DATA AVAILABLE
1388,protamine sulfate,treatment ofheparinoverdosage,neutralising the anticoagulant activity of both drugs,incompatible with certain antibiotics,protamine sulfate has been shown to be incompatible with certain antibiotics,patients who have shown previous intolerance to the drug,"systemic hypertension, nausea, vomiting and lassitude"
1389,protamine crystallised insulin aspart,patients with diabetes mellitus,inhibiting the output of glucose from the liver,growth hormone and danazol,alcohol,NO SPECIFIC DATA AVAILABLE,hypoglycemia
1390,propylthiouracil,in patients with graves' disease with hyperthyroidism,inhibits the synthesis of thyroid hormones,vitamin k activity,vitamin k,hypersensitivity to the drug or any of the other product components,nausea muscle pain vomiting headache upper stomach pain or tenderness sleepiness
1391,propranolol hydrochloride,prophylaxis of migraine,b-adrenergic receptor blocking drug,drugs,drugs,"bronchospasm, cardiogenic shock","nausea, dizziness, insomnia, paresthesia"
1392,propofol,induction and maintenance of general anaesthesia,gaba-a receptors,inhibit the synthesis of adrenocortical hormones,inhalation,allergy,pain at the site of injection
1393,ribavirin,in combination with other antiviral drugs,not clear,nucleoside reverse transcriptase inhibitors,azathioprine,"if this drug is used during pregnancy, or if the patient becomes pregnant",psychiatric and central nervous system effects
1394,rhubarb extract + salicylic acid,oral solution,cyclo-oxygenase,no known interactions,preparation,hypersensitivity,temporary discoloration of teeth or oral mucosa
1395,retapamulin,only,selectively inhibits bacterial protein synthesis,topical products to the same area of skin,topical products to the same area of skin,patients with hypersensitivity,application site irritation
1396,repaglinide,combination with metformin,binds to specific receptors in the cell membrane,hypoglycaemia,inducers of the cytochrome p450 enzyme system,"diabetic ketoacidosis, with or without coma",hypoglycemia
1397,remdesivir,only authorized for hospitalized adult and pediatric patients,adenosine nucleotide prodrug,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity to remdesivir,increased liver transaminases
1398,relugolix,adult patients with advanced prostate cancer,gnrh receptor antagonist,co-administration,combined p-gp and strong cyp3a inducers,NO SPECIFIC DATA AVAILABLE,rare side effects
1399,regorafenib,for the treatment of metastatic colorectal cancer,kinase inhibitor,cyp3a4 inducers,cyp3a4 inducers,NO SPECIFIC DATA AVAILABLE>,"asthenia/fatigue, decreased appetite and food intake"
1400,red clover [trifolium pratense],osteoporosis,mimic the action of estrogens,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with estrogen receptor-positive neoplasias,"headache, nausea and rash"
1401,recombinant follicle stimulating hormone (rfsh),hcg,no luteinizing hormone (lh) activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,pregnancy or lactation,may cause twins or multiple births
1402,rasagiline,idiopathic parkinson's disease,unknown,antidepressants,"dextromethorphan, antidepressants","meperidine, tramadol, methadone","dizziness, spinning sensation, joint pain, headache"
1403,ranolazine,patients who have not achieved an adequate response with other antianginal drugs,unknown,cyp 3a inhibitors,drugs,with pre-existing qt prolongation with hepatic impairment,adverse events
1404,ranitidine hydrochloride,amp,it does not affect pepsin secretion,inhibits hepatic metabolism of coumarin anticoagulants,coumarin anticoagulants,patients hypersensitive,uncommon
1405,ranibizumab,neovascular (wet) age-related macular degeneration,inhibits their biologic activity,intraocular inflammation,verteporfin photodynamic therapy,patients with retinal vein occlusion,increased
1406,ramucirumab,single agent or in combination with paclitaxel,vegfr2 antagonist,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,paclitaxel
1407,ramipril + hydrochlorothiazide,combination therapy,thiazide diuretic,acute renal failure,acetyl salicylic acid or indomethacin,patients with hypersensitivity,"headache, dizziness, asthenia, nausea, vomiting"
1408,ramipril,hypertension,angiotensin converting enzyme (ace) inhibitor,nsaids,nsaids,patients with hypersensitivity to ramipril,"dizziness, headache, fatigue and asthenia"
1409,ramelteon,insomnia,melatonin receptor agonist,alcohol,alcohol,history of angioedema,"somnolence, dizziness, fatigue, nausea"
1410,racepinephrine,asthma,"widening the airways, reducing spasms of bronchial muscles of asthma patients",additive adrenergic side effects,additive adrenergic side effects. use with mao inhibitors,NO SPECIFIC DATA AVAILABLE,"headache, loss of appetite, nausea &amp"
1411,racecadotril,acute diarrhea,inhibiting the membrane-bound enkephalinase,drug interactions,loperamide or nifuroxazide,hypersensitivity,"headache, erythema multiforme, urticaria"
1412,rabies vaccine,treatment of patients following suspected rabies contact,after reconstitution,immunosuppressants,immunosuppressants,"severe fever, febrile infection, acute disease, progressive chronic diseases",allergic skin reactions
1413,roflumilast,in adult patients with a history of frequent exacerbations,increased levels of intracellular cyclic amp are responsible for the therapeutic actions,use of strong cytochrome p450 enzyme inducers,strong cytochrome p450 enzyme inducers,hypersensitivity,"decreased appetite, weight decreased"
1414,rocuronium bromide,suxamethonium is contraindicated,competitively binding to nicotinic cholinergic receptors,de,suxamethonium,hypersensitivity,only a slight increase in mean plasma histamine levels
1415,rizatriptan benzoate,adults and in pediatric patients 6 to 17 years old,presumably exerts its therapeutic effects in the treatment ofmigraine headacheby,mao-a inhibitors and non-selective mao inhibitors,mao-a inhibitors and non-selective mao inhibitors,ischemiccoronary artery disease,medication overuse headache
1416,rivastigmine tartrate,patients with idiopathic parkinson's disease,binds reversibly with and inactivates chlolinesterase,concomitantly with othercholinomimetic substances,othercholinomimetic substances,patients with hypersensitivity,nausea (38%) and vomiting (23%)
1417,rivaroxaban,co-administered with aspirin,rivaroxaban does not inhibit thrombin,pharmacodynamic effects,strong cyp3a4 inducer,patients with known hypersensitivity,"increased chance of bleeding, spinal or epidural hematoma"
1418,rituximab,previously untreated and previously treated cd20-positivecll,it binds to the antigen on the cell surface,increased risk of renal toxicity,cisplatin,"patients with active, severe infections",reactivation of hepatitis b virus. fever and rigors.
1419,ritodrine hydrochloride,premature labour,a selective 2-adrenoceptor agonist,adrenergic blocking drugs,adrenergic blocking drugs,patients with known hypersensitivity to the active ingredient,"nausea, vomiting, flushing, sweating, tremor, hypokalaemia"
1420,risperidone (oral),tablet,selective monoaminergic antagonist,chronic administration with carbamazepine reduces plasma clearance,carbamazepine,patients with a known hypersensitivity to the product,nausea and vomiting
1421,risperidone (injection),for the treatment of schizophrenia,unclear,alcohol,alcohol,known hypersensitivity,inadvertent injection into a blood vessel
1422,risedronate sodium + calcium,steroid medicines,antiresorptive agent,antacids,tablet,NO SPECIFIC DATA AVAILABLE,headache
1423,risedronate sodium,prevent and treat osteoporosis in postmenopausal women,antiresorptive agent,antacids,tablet,patients with known hypersensitivity,mild joint or back pain; headache.
1424,ringer's lactate solution,very often,lactate ions are metabolized ultimately to carbon dioxide and water,drug interactions,drug,hypersensitivity,"extravasation, and hypervolemia"
1425,rimexolone,postoperative inflammation following ocular surgery,glucocorticoid receptor agonist,no information provided,no information provided,those persons with hypersensitivity to any component of the formulation,"vision, discharge, discomfort, ocular pain, increased intraocular pressure"
1426,riluzole,amyotrophic lateral sclerosis,unknown,hepatotoxic drugs,hepatotoxic drugs,patients with a history of severe hypersensitivity reactions,"hepatic injury, neutropenia, interstitial lung disease"
1427,rifaximin,noninvasive strains of e. coli,action on the beta-subunit of the dna-dependent rna polymerase,in patients with normal liver function,normal liver function,patients with a hypersensitivity,"flatulence, headache, abdominal pain"
1428,rifampicin + isoniazid + pyrazinamide + ethambutol,tuberculosis,bactericidal,decreases efficacy of gout therapy agents,decreases efficacy of gout therapy agents,hypersensitivity,ethambutol
1429,rifampicin + isoniazid + pyrazinamide,pulmonary tuberculosis,active bactericidal antituberculosis drugs,sulfinpyrazone,sulfinpyrazone,drug-induced hepatitis,unwanted effects chiefly occurring during intermittent therapy
1430,rifampicin + isoniazid,continuation phase treatment of tuberculosis,bactericidal anti-tb drugs,loss of glucose control,anticonvulsants,drug-induced hepatitis,unwanted effects chiefly occurring during intermittent therapy
1431,rifampicin,resistance to rifampin and the patient is not responding to therapy,blocking rna transcription,reduced absorption by antacids,antacids,patients with a history of hypersensitivity,"nausea, vomiting, anorexia, diarrhoea"
1432,riboflavin,vitamin b2,antioxidant activity,drying medications,drying medications,hypersensitivity,"diarrhea, an increase in urine, and other side effects"
1433,salmeterol + fluticasone propionate,long-acting 2-agonist and inhaled corticosteroid,respective mechanisms of action of both drugs,increased systemic exposure,co-administering known strong cyp3a4 inhibitors,patients with a history of hypersensitivity,"tremor, subjective palpitations and headache"
1434,salicylic acid + lactic acid,topical solution,lactic acid affects the keratinisation process,drug interactions,drug,not for prolonged use in high concentrations and on large areas of the body,"diarrhoea, vomiting"
1435,salicylic acid,mild to moderate acne blackheads and whiteheads redness &amp,slight antiseptic,interfere with treatment or increase skin irritation,topical preparations,patient known to be sensitive,severe skin irritation
1436,salbutamol + ipratropium (solution for inhalation),salbutamol sulfate &amp; ipratropium bromide,additive activity of this solution is due to the combined local effect on the lung,halogenated hydrocarbon anaesthetics,halogenated hydrocarbon anaesthetics,hypertrophic obstructive tachyarrhythmia,fine tremor of skeletal muscles and nervousness
1437,salbutamol + ipratropium (inhaler),regular aerosol bronchodilator,sulphate) and ipratropium bromide,risk of adverse cardiovascular effects,ipratropium bromide,patients hypersensitive,bromide
1438,salbutamol (inhaler),prophylactically before exertion or to prevent exercise-induced asthma,selective 2-adrenoceptor agonist,non-selective beta-blocking drugs,non-selective beta-blocking drugs,patients with a history of hypersensitivity,few
1439,salbutamol,asthma,predominant beta-2 adrenergic activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,palpitations and muscle cramps
1440,sacubitril + valsartan,this is usually administered in conjunction with other heart failure therapies,angiotensin receptor blocker,use with an arb,an arb,in patients withdiabetes,"hyperkalemia, cough, dizziness"
1441,saccharin sodium,high concentrations,NO SPECIFIC DATA AVAILABLE,drug,drug,NO SPECIFIC DATA AVAILABLE,headaches breathing difficulties diarrhoea and skin problems
1442,s-amlodipine besilate (levamlodipine),alone or in combination with other antihypertensive agents,anti-hypertensive isomer,blood pressure,simvastatin,patients with known sensitivity to amlodipine,"fatigue, nausea, abdominal pain and somnolence"
1443,ruxolitinib,adult and pediatric patients 12 years and older,a kinase inhibitor,fluconazole doses of greater than 200 mg daily,fluconazole,patients with a history of hypersensitivity,non-melanoma skin cancer
1444,rupatadine fumarate,seasonal &amp; perennial allergic rhinitis and urticaria,dual mode of action,"co-administered with statins, cns depressants or alcohol",grapefruit and grapefruit juice,hypersensitivity,"nausea, oropharyngeal pain, rash, thirst, vomiting"
1445,roxithromycin,infections caused by susceptible microorganisms- respiratory infections,inhibits protein synthesis,"antacids, h2- receptor antagonists and food",antacids,arterial spasm and severe ischaemia,"nausea, abdominal pain, diarrhoea and hypersensitivity rash"
1446,roxatidine,hydrochloric acid in the gastric juice,dose-dependent,protease inhibitors,protease inhibitors,"lactation, porphyria",may reduce leucocytes and/or thrombocytes
1447,roxadustat,adult patients with symptomatic anemia associated with chronic kidney disease,hypoxia-inducible factor prolyl hydroxylase inhibitor,drug-drug interaction,gemfbrozil,NO SPECIFIC DATA AVAILABLE,nausea
1448,rotavirus vaccine,4- to 10-week intervals,exact immunologic mechanism of action is not fully understood,ability to drive and use machines,oral polio vaccine,subjects with history of intussusception,no increase in the incidence or severity
1449,rosuvastatin,heterozygous hypercholesterolemia,selective and competitive inhibitor of hmg-coa reductase,gemfibrosil,gemfibrosil,if- known hypersensitivity to product components liver disease,"headache, myalgia, constipation"
1450,rosiglitazone + metformin hydrochloride,management of type 2 diabetes mellitus should include diet control,different mechanisms of action,interfering drug,interfering drug,renal disease or renal dysfunction,"metformin patients, and that were more common in metformin"
1451,ropinirole,moderate-to-severe primary restless legs syndrome,unknown,dopamine antagonists,dopamine antagonists such as neuroleptics,patients known to have a hypersensitivity to ropinirole,"fainting, drowsiness, hallucinations"
1452,sildenafil citrate,erectile dysfunction,enhances the effect of nitric oxide,fungal infections,organic nitrates,"patients who are using organic nitrates, either regularly or intermittently","headache, flushing, dyspepsia, nasal congestion"
1453,sevoflurane,only by persons trained in the administration of general anesthesia,volatile halogenated general anaesthetic,mac,mac,patients with known sensitivity,"nausea, vomiting, delirium, seizure"
1454,sevelamer hydrochloride,patients with end-stage renal disease,calcium-free and aluminium-free nonabsorbed polymer phosphate binder,drug,drug-drug,patients with known hypersensitivity,"dyspepsia, peritonitis"
1455,sevelamer carbonate,within the context of a multiple therapeutic approach,"non-absorbed phosphate binding crosslinked polymer, free of metal and calcium",consequences,levothyroxine,patients with known hypersensitivity,NO SPECIFIC DATA AVAILABLE
1456,sesame oil + cactus extract + beeswax,completely natural,ointment,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>
1457,sertraline hydrochloride,sertraline,prolonged elimination half-life offers a benefit of once daily administration,adverse effect,atenolol,patients with moderate to severe hepatic impairment,"upset stomach, diarrhoea, constipation, vomiting"
1458,sertaconazole nitrate,interdigital tinea pedis and other topical fungal infections,14 alpha-lanosterol demethylase enzyme,drugs,cream,hypersensitivity,"contact dermatitis, dry skin, burning skin, application site skin tenderness"
1459,sennosides,hard stools,release of active anthraquinones into the colon by colonic bacteria,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"nausea or vomiting, undiagnosed abdominal pain, intestinal obstruction",reversible melanosis coli
1460,semaglutide (tablet),adults with type 2 diabetes mellitus,albumin binding,gastric emptying,gastric emptying,patients with multiple endocrine neoplasia syndrome type 2,"nausea, abdominal pain, diarrhea, decreased appetite"
1461,semaglutide (injection),not been studied in patients with a history of pancreatitis,albumin binding,gastric emptying,gastric,a personal or family history of medullary thyroid carcinoma,insulin
1462,selexipag,pulmonary arterial hypertension,hydrolyzed by carboxylesterase 1,inhibitors,amp,NO SPECIFIC DATA AVAILABLE,"nausea, diarrhoea, vomiting, headache"
1463,selegiline hydrochloride,three principal outcome measures employed,inhibition of mao-b,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity,NO SPECIFIC DATA AVAILABLE
1464,secukinumab,moderate to severe plaque psoriasis,human monoclonal antibody that targets il-17a cytokine,live vaccines,live vaccines,serious hypersensitivity reaction,"diarrhea, and upper respiratory tract infection"
1465,secnidazole,indicated,oral administration,disulfiram,disulfiram,hypersensitive to imidazole derivatives,rarely serious
1466,saxagliptin,limitation,saxagliptin inhibits dipeptidyl peptidase iv,glycaemic lowering effect,concomitant cyp3a4 inducers,"type 1 diabetes, diabetic ketoacidosis.","pancreatitis, heart failure, hypoglycemiawith"
1467,saquinavir mesylate,over the age of 16 years,binds to the protease active site,certain drugs or drug classes,certain drugs or drug classes,patients with clinically significant hypersensitivity,"nausea, vomiting, diarrhea"
1468,salvia officinalis,daily,deodorant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,NO SPECIFIC DATA AVAILABLE
1469,salsalate,rheumatoid arthritis,inhibition of prostaglandin synthesis,sulfinpyrazone,alcohol or concurrent use with corticosteroids,hypersensitivity to aspirin or nsaids,local irritation
1470,salmon calcitonin,active paget's disease in patients who do not respond to alternative treatments,it inhibits osteoclastic bone resorption and reduces bone turnover,decrease serum concentration of lithium,cardiac glycosides,hypersensitivity. patients with hypocalcaemia,diabetogenic effect
1471,salmeterol xinafoate,both adolescents and adults,intracellular adenyl cyclase,monoamino oxidase inhibitors,monoamino oxidase inhibitors,acute episodes of asthma or copd,"skin reactions, muscle cramps, non-specific chest pain"
1472,sodium dichloroisocyanurate,effervescent water purification tablets,it rapidly dissolves into water to kill micro-organisms,acids and compounds containing ammonia,ammonia,do not use with other products,may cause long term adverse effects in the aquatic environment
1473,sodium cromoglicate + xylometazoline hydrochloride,nasal spray,local effect on the nasal mucosa,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity to any ingredients of the preparation,no serious side effects have been reported
1474,sodium cromoglicate [4%],nasal,no vasoconstrictor or antihistaminic activity,interaction with other drugs,drugs,hypersensitivity,local irritation
1475,sodium cromoglicate [2%],some patients,the exact mechanism of action of the drug remains to be elucidated,drug interactions,sodium cromoglycate,individuals who have shown hypersensitivity to the drug,eye drops
1476,sodium chloride + potassium chloride + sodium acetate,cholera,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1477,sodium chloride + dextrose,persistent vomiting,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with known allergy to corn or corn products,"if an adverse reaction does occur, discontinue the infusion"
1478,sodium chloride (tablet),deficiency,provides a source of sodium where a deficiency exists,impair the efficacy of antihypertensive drugs,300 mg,"edema, heart disease",no side effects have been reported
1479,sodium chloride (ophthalmic solution),certain eye conditions,reduce the edema or swelling of the cornea,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,individuals with known hypersensitivity,"other effects not listed above, contact your doctor or pharmacist"
1480,sodium chloride (nasal preparation),dry nasal membranes including dry nose resulting from cold and allergy medications,non-drug,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,do not share this medication with others,"stinging, sneezing, increased nasal discharge, or salty taste"
1481,sodium chloride (intravenous solution),each 100 ml solution,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"extravasation, and hypervolemia"
1482,sodium bicarbonate,alkalinization of urine,it increases plasma bicarbonate,potentially hazardous interactions,antacid,hypoventilatory states,"headache, nausea or irritability"
1483,sodium alginate + sodium bicarbonate + calcium carbonate,all cases of epigastric and retrosternal distress,physical and does not depend on absorption into the systemic circulation,drug intake and the administration of other medicinal products,drug,patients with known or suspected hypersensitivity,"constipation, flatulence, stomach cramp or belching"
1484,sodium alginate + potassium bicarbonate,pepsin into the esophagus,physical and does not depend on absorption into the systemic circulation,thyroid hormones,"iron salts, thyroid hormones",patients with known hypersensitivity,"nausea, constipation, diarrhea or headache"
1485,snake venom antiserum,tourniquets,antitoxin globulins and their derivatives,risk of increased severity of acute anaphylaxis,adrenergic blockers,no known contraindications,reduction in adverse reactions
1486,sitagliptin + metformin hydrochloride,both sitagliptin and metformin is appropriate,pharmacologic mechanism of action of metformin hcl,"monitoring of blood glucose levels is recommended, especially when thyroid hormone therapy",levothyroxine,anaphylaxis or angioedema,"diarrhea, upper respiratory tract infection, and headache"
1487,sitagliptin,not be used in patients with type 1 diabetes,dpp-4 inhibitor,oral contraceptive,digoxin,anaphylaxis or angioedema,insulin
1488,simvastatin,not responded adequately to diet and other appropriate measures,extensively metabolised in the liver,clinically significant adverse interactions,placebo,active liver disease,"headache, fatigue, insomnia, gastrointestinal effects"
1489,simethicone,anecdotal use as an antifoaming agent,antifoaming properties,absorb the silicone,antacids,NO SPECIFIC DATA AVAILABLE,no adverse effect has been noted after oral ingestion
1490,silver sulfadiazine,topical prophylaxis,not been fully elucidated,inactivate enzymatic debriding agents,oral hypoglycemic agents,"pregnant women approaching or at term, on premature infants, or on newborn infants",skin necrosis
1491,silodosin,effective treatment option for bph who are not responding to tamsulosin,post-synaptic alpha-1 adrenoreceptors,pde5 inhibitors with alpha-blockers,strong p-glycoprotein inhibitors,patients with a history of hypersensitivity to silodosin,"headache, nasopharyngitis and nasal congestion"
1492,somatostatin,severe acute haemorrhage,identical in structure and action to natural somatostatin,drugs exerting the same effects,drugs,during pregnancy and the immediate post-partum period,"nausea, vertigo, and flushing have been reported rarely. nausea and vomiting"
1493,solifenacin succinate,patients with overactive bladder syndrome,competitive muscarinic receptor antagonist,renal impairment,warfarin,patients with hypersensitivity,mild or moderate severity
1494,sofosbuvir + velpatasvir,without cirrhosis,nucleotide analog hcv ns5b polymerase inhibitor,drugs,drugs,patients for whom ribavirin is contraindicated,headache and tiredness
1495,sofosbuvir,not recommended for treatment of chc,nucleotide analog inhibitor,bcrp inhibitors,antiviral,women who are pregnant or may become pregnant and men whose female partners are pregnant,fatigue and headache
1496,sodium valproate,all types of epilepsy,not been established,drug metabolism,drug,pregnancy and in women of childbearing potential,acute pancreatitis and hyperammonemia
1497,sodium thiosulfate,sequential use with sodium nitrite,sulphur-donating substrate for the enzyme rhodanese,drug,drug,NO SPECIFIC DATA AVAILABLE,osmotic disturbances
1498,sodium succinate + cytochrome c + adenosine + nicotinamide,thiseye drops,nicotinamide is said to be involved in the process of creating atp,interaction with other drugs,eye drops,patients with known hypersensitivity to any ingredient of the product,this drug may cause more or less discomfort in some patients
1499,sodium stibogluconate,cancer/tumors (unspecified) and solid tumors,not clearly understood,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"hypersensitivity, significant renal impairment, breast feeding","reduced appetite, metallic taste in mouth,nausea,vomiting"
1500,sodium polystyrene sulfonate,excessive use of potassium supplements,cation exchange polymer that contains a sodium counterion,drug interactions,laxatives,patients with hypokalemia,"anorexia, nausea, vomiting, and constipation"
1501,sodium picosulfate + magnesium oxide + citric acid,anhydrous citric acid,NO SPECIFIC DATA AVAILABLE,chelation with magnesium,tetracycline and fluoroquinolone antibiotics,patients with severely reduced renal function,"nausea, headache and vomiting"
1502,sodium picosulfate,constipation,locally in the colon,laxative action,antibiotics,hypersensitivity,"nausea, vomiting"
1503,sodium nitroprusside dihydrate,immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises,thiocyanate is eliminated in the urine,risk of severe hypotension,phosphodiesterase inhibitors,"patients with known inadequate cerebral circulation, or in moribund patients",cyanide poisoning
1504,sodium hypochlorite,"around the eyes, nose and mouth",oxidizing agent,drug,drug,no known contraindications,NO SPECIFIC DATA AVAILABLE
1505,sodium hyaluronate + carboxymethylcellulose sodium,eye drops,ocular lubricants,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients who are hypersensitive to any component of this preparation,transient blurring of vision
1506,sodium hyaluronate (ophthalmic),all forms of dry eye and for post-surgical lubrication,surgery,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,known hypersensitivity,"transient burning sensation, temporarily blurred vision and transient rise in intraocular pressure"
1507,sodium hyaluronate (injection),osteoarthritis (oa) of the knee,tissue lubricant,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,past and present infections or skin diseases,"gastrointestinal complaints, injection site pain"
1508,sodium fusidate (topical),skin infections,antibacterial activity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,severe hepatic failure,hypersensitivity reactions
1509,sodium fusidate (oral),treatment,inhibits bacterial protein synthesis,drugs,drugs,hypersensitivity,change of liver function
1510,sodium fluoride (mouthwash),sodium fluoride is an antiseptic,cariostatic agent,absorption,magnesium salts,children less then 3 yr of age or when drinking water,"hypersensitivity reactions, rash, nausea, vomiting"
1511,sodium dihydrogen phosphate + disodium hydrogen phosphate,aqueous oral solution,mild osmotic laxative,dangerous,lithium,renal failure,sodium biphosphate
1512,sulphamethoxazole + trimethoprim,us,sequential blockade of two bacterial enzyme systems,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,patients with documented megaloblastic anaemia due to folate deficiency,"malaise, headache, nausea and vomiting"
1513,sulphadoxine + pyrimethamine,malaria,synergism,folate antagonists,folate,marked liver parenchymal damage or blood dyscrasias,amp; pyrimethamine at the recommended dose is well tolerated
1514,sulindac,rheumatoid arthritis,non-steroidal anti-inflammatory agents,adverse renal effects,protein,"children, pregnant or lactating women","drowsiness, dizziness, headache and nervousness"
1515,sulfinpyrazone,"chronic gouty arthritis, intermittent gouty arthritis",competitively inhibiting tubular reabsorption of uric acid,renal tubular secretion,probenecid,gastro-intestinal inflammation or ulceration,"upset stomach, vomiting, loss of appetite and joint pain"
1516,sulfasalazine,rheumatoid arthritis &amp; juvenile arthritis,under investigation,reduced absorption,folic acid,patients with intestinal or urinary obstruction and porphyria,"anorexia, headache, nausea, vomiting"
1517,sulfacetamide sodium,conjunctivitis and other superficial ocular infections,the spectrum of activity is similar for all,silver preparations,incompatible with silver preparations,individuals who have a hypersensitivity to sulfonamides,"local irritation, stinging and burning"
1518,sulconazole nitrate,tinea versicolor,inhibits the growth of the common pathogenic dermatophytes,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients who have a history of hypersensitivity to any of the ingredients,no systemic effects and only infrequent cutaneous adverse reactions
1519,sucralose + acesulfame potassium,tea,synergistic effect,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1520,sucralose,"children, pregnant women and any person who wants to reduce calorie intake",eliminated after consumption,drug,drug,no known contraindication,no known side effects
1521,sucralfate,adults and adolescents over 14 years old,sucralfate inhibits the action of pepsin and bile.,stress ulceration,enteral feeds,patients with hypersensitivity to sucralfate,nausea (2.3%)
1522,strontium ranelate,postmenopausal women,reducing bone breakdown and stimulating rebuilding of bone,antibiotics),milk or milk products or calcium supplements,if you experience an allergic reaction,"nausea, diarrhoea, headache and skin irritation"
1523,streptomycin,only,aminoglycosides,nephrotoxicity,cephalosporins. reduced excretion with nsaids,hypersensitivity,"muscular weakness, amblyopia"
1524,streptokinase,always commence within 6 hours of the onset of pain,converts plasminogen to plasmin,contraindicated,acetylsalicylic acid,potential for internal bleeding,adverse reactions
1525,spironolactone,congestive heart failure,both as a diuretic and as an antihypertensive drug,half-life of digoxin,digoxin,"patients with acute renal insufficiency, significant impairment of renal function",gi symptoms
1526,spiramycin,"infections of the respiratory tract, buccal cavity, skin and soft tissues",stimulation of dissociation of peptidyl-trna,absorption of carbidopa,levodopa,patients with meningitis,"nausea, vomiting, diarrhea"
1527,spectinomycin,male,30s ribosomal subunit,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"nausea, chills, fever and insomnia"
1528,sparfloxacin,prophylactic use in different urological and ophthalmic operations,inhibits the supercoiling activity of dna gyrase,"salts, oxides and hydroxides of magnesium, aluminium and calcium","salts, oxides and hydroxides of magnesium, aluminium and calcium",individuals with a history of hypersensifivity and in achilles tend,"diarrhea, nausea, headache"
1529,sotalol hydrochloride,after cardiac surgery,non-cardioselective beta-blocker,clonidine,clonidine,patients suffering fromdiabetic keto-acidosis or metabolic acidosis,class i and class ii (cardiac action potential duration prolongation) effects
1530,sorafenib tosylate,hepatocellular carcinoma,kinase inhibitor,inducers of isoenzyme cyp3a4,inducers of isoenzyme cyp3a4,patients with known severe hypersensitivity,pain and peripheral neuropathy
1531,somatropin,reduced dose level recommended for ghd adults,pharmacodynamic effects,cytochrome p450-metabolized drugs,oral estrogen,severe non-proliferative diabetic retinopathy,"headaches, muscle pain, joint stiffness"
1532,tedizolid phosphate,only,inhibition of protein synthesis,coadministration,coadministration,none,"nausea, headache, diarrhea, vomiting, and dizziness"
1533,tea tree oil + geothermal water + vitamin e,gel,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,contraindicated,NO SPECIFIC DATA AVAILABLE>
1534,tea tree oil + geothermal water (hair & body),shampoo,geothermal water : it is natural hot water and has skin healing benefits.,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,oily and dry hair
1535,tea tree oil + geothermal water (eye),-,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1536,tea tree oil + echinacea + geothermal water,fungus from oral cavity,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,NO SPECIFIC DATA AVAILABLE
1537,tazarotene,plaque psoriasis,rapid deesterification,concomitant dermatologic medications and cosmetics,flame,"if this drug is used during pregnancy, or if the patient becomes pregnant","pruritus, erythema and burning"
1538,tapentadol hydrochloride,moderate to severe acute pain in patients 18 years of age or older,dual mechanism of action,decreased efficacy with strong enzyme inducers,phenobarbital,patients with impaired pulmonary function,"urticaria, blood pressure decreased"
1539,tamsulosin hydrochloride + dutasteride,amp,complementary mechanisms of action,combination with other alpha-1 adrenergic blockers,cimetidine,women and children and adolescents,combination therapy
1540,tamsulosin hydrochloride,functional symptoms of benign prostatic hyperplasia,extremely bound to human plasma protein,concurrent administration of other alfa1-adrenoceptor antagonists,"atenolol, enalapril or nifedipine",patients with hypersensitivity to it,"dizziness, abnormal ejaculation and"
1541,tamoxifen citrate,breast cancer,oestrogen antagonist and oestrogen agonist,risk of thromboembolic events,coumarin,patients who have experienced hypersensitivity,changes in liver enzyme levels
1542,tafluprost,patients with open-angle glaucoma or ocular hypertension,selective fp prostanoid receptor agonist,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients who are hypersensitive to any component of this product,eye irritation and blurred vision
1543,tadalafil,tadalafil is indicated in- erectile dysfunction,selective phosphodiesterase type 5 (pde5) inhibitor,hiv protease inhibitors,grapefruit juice,hypersensitivity reactions,"nasal pharyngitis, nasal congestion"
1544,tacrolimus (topical),moderate to severe atopic dermatitis,"binding to an intracellular protein, fkbp-12",cyp3a4 inhibitors,ointment,patients with a history of hypersensitivity to tacrolimus,very few and rare type of side-effects
1545,tacrolimus (oral),kidney transplant patients,not known,adverse reactions,cyp3a inhibitors,patients with a hypersensitivity to hco-60,<NO SPECIFIC DATA AVAILABLE
1546,suxamethonium chloride,anesthesia,imitating the action of acetylcholine,neuromuscular blocking effects,psychiatric drugs,new-born infants,"rash, excessive salivation"
1547,suvorexant,insomnia,antagonism of orexin receptors,alcohol concentrations,alcohol,patients with narcolepsy,sleep-walking
1548,super antioxidant [vitamins & minerals],prevent certain types of cancer,manganese,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with a known hypersensitivity to any of the ingredients,vitamin a are reversible
1549,sunitinib,advanced renal cell carcinoma,inhibits cellular signaling by targeting multiple receptor tyrosine kinases,decreased plasma cone with strong cyp3a4 inducers,grapefruit juice,"hypersensitivity, renal impairment",neutropenia
1550,sumatriptan,if a clear diagnosis of migraine headache has been established.,"a metering, atomizing spray pump",ergot-containing drugs,foods,angioedema and anaphylaxis,common side effects : unusual or unpleasant taste in the mouth;
1551,sulphonated surfactant,acne prone and oily skin conditions,displacement of air,drug,drug,hypersensitivity,"mild irritation, skin sensitization"
1552,testosterone undecanoate,if the body is unable to produce enough on its own,exogenous sources,food,food,if you are hypersensitive,troublesome or continues.
1553,testosterone decanoate,certain types of infertility due to spermatogenic disorders,normalization of gonadotropin levels,adjustment of dose or intervals,testosterone,prostatic carcinoma or breast carcinoma,sodium retention
1554,terlipressin acetate,short term management of bleeding oesophageal varices,<NO SPECIFIC DATA AVAILABLE,medications that can prolong the qt interval,medications that can prolong the qt interval,pregnancy,"paleness, increased blood pressure, abdominal pain, nausea"
1555,teriparatide,treatment of postmenopausal women with osteoporosis,binding to specific high-affinity cell-surface receptors,increase serum calcium,digoxin hydrochlorothiazide,patients with hypersensitivity,"arthralgia, pain, and nausea"
1556,terfenadine,"allergic rhinitis, hay fever, and allergic skin disorders",reversible binding of terfenadine to h1-receptors,non-nucleoside reverse transcriptase inhibitors,drugs,porphyria,erythema multiforme and galactorrhoea.
1557,terconazole,only for vulvovaginitis caused by the genus candida,antibacterial activity in vitro but not against usual vag flora,potential pharmacokinetic interaction,drugs,patients known to be hypersensitive,flu
1558,terbutaline sulfate,12 years of age and older,at least in part,patients receiving other sympathomimetics,patients receiving other sympathomimetics,patients with known hypersensitivity to terbutaline,"tremor, headache, tonic cramp and palpitations"
1559,terbinafine hydrochloride,tinea capitis,depending on the concentration of the drug and the fungal species test in vitro,a reduction in dose of the 2d6-metabolized drug,2d6-metabolized drug,individuals with hypersensitive to terbinafine,"liver failure, some leading to death or liver transplant"
1560,terazosin hydrochloride,single therapy,induction of apoptosis of prostate cells,"interaction with analgesics/anti-inflammatory, cardiac glycosides",drugs,patients known to be hypersensitive,"dizziness, lack of energy, peripheral oedema;"
1561,tenoxicam,symptomatic treatment,"anti-inflammatory, analgesic and antipyretic properties",k-sparing diuretics,methotrexate,patients,mild and transient
1562,tenofovir disoproxil fumarate,chronic hepatitis b virus infection in adults hiv infected adults,phosphorylation to the active diphosphate form,renally eliminated or are known to affect renal function,oral contraceptives,patients with known hypersensitivity,"nausea, vomiting, diarrhea and flatulence"
1563,tenofovir alafenamide,adults with compensated liver disease,hydrolysis,drug drug interactions,drugs,none,"headache, stomach pain, tiredness, cough, nausea, back pain"
1564,tenecteplase,reduction of mortality associated with acute myocardial infarction,binds to fibrin and converts plasminogen to plasmin,bleeding,heparin and aspirin,patients with acute myocardial infarction,assent-2
1565,temozolomide,newly diagnosed glioblastoma multiforme,inactive prodrug,valproic acid,valproic acid,pregnancy,"rarely, myelodysplastic syndrome and secondary malignancies"
1566,temazepam,for patients with short-term insomnia,benzodiazepines,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,women who are or may become pregnant,drowsiness headache tiredness nervousness dizziness nausea
1567,telmisartan + hydrochlorothiazide,alone or with other antihypertensive agents,independent of the pathways for angiotensin ii synthesis,interfere with certain laboratory tests,angiotensin ii receptor blockers,patients with known hypersensitivity,allergy
1568,telmisartan,indicated in- hypertension : treatment of essential hypertension in adults,independent of the pathways for angiotensin ii synthesis,diabetes,aliskiren,known hypersensitivity,cardiovascular risk reduction
1569,telbivudine,not been evaluated in black/african american or hispanic patients,it undergoes phosphorylation via interaction with cellular kinases,risk of myopathy,hmg-coa reductase inhibitors,increased risk ofperipheral neuropathy,gi effects
1570,teicoplanin,serious infections due to staphylococci or streptococci,in vitro bactericidal activity,concurrent nephrotoxic or ototoxic drugs,concurrent nephrotoxic or ototoxic drugs,patients who have exhibitedprevioushypersensitivity,gastrointestinal
1571,tegaserod,irritable bowel syndrome with constipation,serotonin type-4 (5ht4) receptor partial agonist,oral contraceptives,"oral contraceptives, and warfarin",patients with severe renal or hepatic impairment,"abdominal pain, diarrhea, nausea, flatulence, headache"
1572,tioconazole,only for candidal vulvovaginitis,tioconazole inhibits ergosterol synthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,sensitive to imidazoleantifungalagents,mild irritation
1573,tinidazole,only,antimicrobial actions,"alcohol, disulfiram","alcohol, disulfiram",patients with organic neurological disorders,"headache, tiredness, furry tongue and dark urine"
1574,timolol maleate,patients with ocular hypertension or open-angle glaucoma,reduction of aqueous humour formation,pupil size,epinephrine,patients with bronchial asthma,"nausea, constipation, hypoglycaemia"
1575,tigecycline,infections caused by susceptible strains of the designated microorganisms,inhibits protein translation in bacteria,drug,warfarin,patients who have known hypersensitivity to tigecycline,injection site inflammation &amp;
1576,tiemonium methylsulphate,pain related to functional disorders of the digestive tract and biliary system,competitive antagonist,possible drug interaction,tablet,urethroprostatic disorder involving a risk of urine retension,hypotension &amp; tachycardia
1577,ticlopidine hydrochloride,failed aspirin therapy,inhibition of bothplatelet aggregation and release ofplateletgranule constituents,avoid concurrent use with clopidogrel,clopidogrel,hypersensitivity to the drug,"diarrhoea, nausea, dyspepsia"
1578,ticagrelor,adult patients with acute coronary syndromes,selective adenosine diphosphate (adp) receptor antagonist,simvastatin and lovastatin doses greater than 40 mg,aspirin,hypersensitivity,"dyspnea,bleeding,headache,cough,dizziness,nausea"
1579,tibolone,cannot take other medicines used to prevent osteoporosis,"estrogenic, androgenic and progestagenic properties",decrease its therapeutic effect,decrease its therapeutic effect,pregnancy and lactation,headache and migraine
1580,thymus vulgaris extracts,women having periods expectant mothers new mothers,selective antibacterial properties,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity,NO SPECIFIC DATA AVAILABLE
1581,thiotepa,in haematological diseases in adult and paediatric patients,radiomimetic action,decreased concentrations of the active 4 ohcp,medicinal products,pregnancy and lactation,NO SPECIFIC DATA AVAILABLE
1582,thioridazine,only,strong -adrenergic blocking effect,cns depressants,cns depressants,drugs,rarely
1583,thiopental sodium,brief (15 minutes) procedures,ultrashort-acting depressant of the central nervous system,highly protein bound drugs,metoclopramide,absence of suitable veins for intravenous administration,"respiratory depression, myocardial depression, cardiac arrhythmias"
1584,thiamine hydrochloride,beriberi and wernick's encephalopathy,decarboxylation of -ketoglutaric acid,hazardous drug interactions,vitamin b1,comatose patients,vitamin b1
1585,theophylline,asthma,smooth muscle relaxation and suppression of the response of the airways to stimuli,side effects,oral contraceptive,patients with hypersensitivity,"gastrointestinal discomfort, headache, nausea"
1586,thalidomide,moderate to severe neuritis,not fully understood,other drugs that have the potential to cause peripheral neuropathy,other drugs,pregnancy and lactation,hypersensitivity reaction
1587,tetracycline hydrochloride (topical),first aid to help prevent skin infection,passively diffuses through porin channels in the bacterial membrane,change the dose,prescription or nonprescription medicine,do not use in eyes over large areas of the body longer than 1 week,not all of these side effects may occur
1588,tetracycline hydrochloride (oral),urinary tract infections with susceptible organisms,protein synthesis,contraceptives,contraceptives,systemic lupus erythematosus,epigastric distress and nausea
1589,tetracycline hydrochloride (ophthalmic),bacterial conjunctivitis,bacteriostatic,may interfere with the bactericidal action of penicillin,impaired absorption with antacids containing divalent and trivalent cations,patients with hypersensitivity,"burning, irritation, visual disturbances"
1590,tetrabenazine,withhuntington's disease.,reversible human vesicular monoamine transporter type 2 inhibitor,maoi therapy,maoi therapy,"actively suicidal, or in patients with untreated or inadequately treated depression","parkinsonism, dysphagia, sedation andsomnolence"
1591,tetanus antitoxin [equine],to provide temporary passive immunity,antitoxic globulins,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,allergic reactions to equine protein and to allergic individuals,serum sickness
1592,trastuzumab,one or more chemotherapy regimens for metastatic disease,mediator of antibody-dependent cellular cytotoxicity,anthracycline-based therapy,anthracycline,NO SPECIFIC DATA AVAILABLE,"cardiomyopathy, infusion reactions"
1593,tranexamic acid,interventions,antifibrinolytic,direct admixture of tranexamic acid with whole blood,whole blood,thromboembolic disease,"nausea, diarrhea, gastric pyrosis"
1594,tramadol hydrochloride,moderate to severe painful conditions,stimulation of mu-opioid receptors,monoamine oxidase (mao) inhibitors,monoamine oxidase (mao) inhibitors,acute intoxication with alcohol,"dizziness/vertigo, nausea, constipation"
1595,torsemide,hypertension alone or in combination with other antihypertensive agents,it inhibits the NO SPECIFIC DATA AVAILABLE + /k + /2ci carrier system,salicylate toxicity,cholestyramine,patients who are anuric or with hepatic coma,NO SPECIFIC DATA AVAILABLE
1596,torasemide,hypertension,diuretic actions,lithium toxicity,nsaids,patients who are anuric,mild and transient
1597,topotecan,ovarian cancer,the same mechanism of action as irinotecan,neutropenia,bone marrow supression with other cytotoxic drugs,"pregnancy, lactation, severe renal or hepatic impairment","gi upset, total alopecia, headache, dyspnoea"
1598,topiramate,adults and children aged 6 years and above,not fully characterized,agents,alcohol,hypersensitivity,"leucopenia, thrombocytopenia and serious skin reaction"
1599,tolvaptan,hypervolemic or euvolemic hyponatremia,selective vasopressin v2-receptor antagonist,moderate cyp 3a inhibitors,cyp 3a inducers,"patients who cannot perceive thirst, pregnancy, breast-feeding","thirst, dry mouth, weakness, constipation"
1600,tolterodine tartrate,"urinary urgency, frequency, and/or urge incontinence","competitive, specific muscarinic receptor antagonist",persons devoid of cyp2d6 metabolic pathway,poor metabolisers,"urinary retention, uncontrolled narrow angle glaucoma",mild to moderate
1601,tolperisone hydrochloride,post-thrombotic venous and lymphatic circulation disorders,"centrally acting muscle relaxant, which acts on the central nervous system",visual accommodation,methocarbamol,myasthenia gravis and nursing mother,"muscular weakness, headache, nausea, vomiting"
1602,tolperisone + lidocaine,individual cases,lidocaine stabilizes the neuronal membrane,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,nursing mother,"headache, nausea, vomiting and rarely hypersensitivity reactions"
1603,tolnaftate,andringworm,antifungal,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"in theeyes, nose,mouth, orvagina",not a complete list of possible side effects
1604,tolfenamic acid,post-operative pain and fever,direct antagonistic action on its receptors,"loop diuretics, b-blockers and ace inhibitors",aluminium hydroxide,"severe heart, kidney or liver failure",potentially fatal: blood dyscrasias and hepatitis
1605,tofacitinib,moderately to severely active rheumatoid arthritis,inhibiting jaks,reduced clinical response,potent cyp inducers,NO SPECIFIC DATA AVAILABLE,monotherapy
1606,tocilizumab,rheumatoid arthritis,binds to both soluble and membrane-bound il-6 receptors,decrease in effectiveness is undesirable,exercise caution,hypersensitivity,injection site reactions
1607,tobramycin (ophthalmic),external bacterial infections of the eye caused by susceptible organisms,bactericidal,patients receiving other drugs with neuromauscular blocking agents,ototoxic,hypersensitive,localized ocular toxicity
1608,tobramycin (nebuliser solution),cystic fibrosis patients with pseudomonas aeruginosa,binding to 30s and 50s ribosomal subunits,"inhaled corticosteroids, other anti pseudomonal antibiotics","inhaled corticosteroids, other anti pseudomonal antibiotics",patients with a known hypersensitivity to any aminoglycoside,transient and resolved without discontinuation of the regimen
1609,tizanidine hydrochloride,following surgery,spinal cord,long term coadministration,alcohol,concomitant use of tizanidine with strong inhibitors,hepatitis
1610,titanium dioxide + butyl methoxydibenzoyl methane + padimate + oxybenzone,lotionis,absorbing the sun's ultraviolet radiations,drug interactions,drug,allergic reaction,some of the side-effects may be rare but serious
1611,tiotropium (dry powder inhaler),bronchospasm associated with chronic obstructive pulmonary disease,predominantly a site-specific effect,renal clearance,cimetidine 400 mg three times daily or ranitidine,patients with a history of hypersensitivity to atropine,"constipation, increased heart rate, blurredvision"
1612,tropicamide + phenylephrine hydrochloride,pre-operative,selective alpha-1 agonist,interfere with the antihypertensive action,ophthalmic cholinesterase inhibitors,patients with hypersensitivity to any of the components,systemic effects
1613,tropicamide + phenylephrine + lidocaine,intraocular anesthesia,<NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE,headache
1614,tropicamide,diagnostic procedure,blocking the responses of the iris sphincter muscle,ophthalmic cholinesterase inhibitors,ophthalmic cholinesterase inhibitors,persons showing hypersensitivity,"dryness of the mouth, tachycardia, headache, allergic reactions"
1615,trimipramine,trimipramineis a tricyclic antidepressant,serotonergic,barbiturates,barbiturates,"cardiac arrhythmias, heart block","agitation, confusion (elderly)."
1616,trimetazidine dihydrochloride,adults,trimetazidine dihydrochloride inhibits fatty acid pathway,beta-blockers,nitrates,patients who have hypersensitivity,"dizziness, headache, abdominal pain"
1617,trimebutine maleate,postoperative paralytic ileus,noncompetitive spasmolytic agent,druginteractions,d-tubocurarine-induced curarization,patients with known hypersensitivity,"dry mouth, foul taste, diarrhea, dyspepsia"
1618,trihexyphenidyl hydrochloride,parkinsonism,its mechanism of action has yet to be fully elucidated,tricycllic antidepressants,alcohol,patients with hypersensitivity,minor
1619,trifluridine,sterile eye drops,it stops replication of herpes viral dna,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity reactions or chemical intolerance,"mild, transient burning or stinging sensation upon instillation"
1620,trifluoperazine,the management of psychotic disorders,pharmacodynamic effects,antihypertensive effects,alcohol,comatose patients,"transient restlessness, dystonias or may resemble parkinsonism"
1621,trifarotene,9 years of age and older,unknown,ethinylestradiol and levonorgestrel,contraceptives containing ethinylestradiol and levonorgestrel,NO SPECIFIC DATA AVAILABLE,"application site irritation, application site pruritus, and sunburn"
1622,triamcinolone acetonide (topical),corticosteroid responsive dermatoses,anti-inflammatory,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity to any of the components of the preparation,"burning, itching, irritation, dryness"
1623,triamcinolone acetonide (nasal spray),adults and children 6 years of age and older,allergy-induced watery nasal discharge,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with hypersensitivity,"epistaxis, nasal irritation"
1624,triamcinolone acetonide (injection),stevens-johnson syndrome,antiinflammatory actions,congestive heart failure,aspirin,patients with a sensitivity to the active or inactive ingredients,"altered menstrual cycle, hirsutism"
1625,triamcinolone + neomycin + nystatin + gramicidin,steroid,gramicidin,"do not start, stop, or change the dosage",other products for the skin,patients with perforated tympanic membranes,prolonged use may cause sensitivity reactions
1626,tretinoin (topical),acne vulgaris,unknown,acne treatments,morning,patients with a personal or family history of cutaneous epithelioma,burning or slight irritation
1627,tretinoin (oral),tretinoin is for the induction of remission only,unknown,toxicity,hepatic p450,patients who are sensitive to parabens,tretinoin.
1628,trelagliptin succinate,approved for use as a first line treatment when metformin cannot be used,selectively and continually inhibiting dpp-4,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"pregnant, breast-feeding, possibly pregnant, or planning to become pregnant",decreased blood sugar
1629,travoprost + timolol maleate,prostaglandin analogue or topical beta blocker,complementary,NO SPECIFIC DATA AVAILABLE>,<NO SPECIFIC DATA AVAILABLE,hypersensitive,ocular hyperemia
1630,travoprost,patients with open-angle glaucoma or ocular hypertension,rapidly hydrolyzed by esterases in the cornea,reduced therapeutic effect with nsaids,nsaids,patients with hypersensitive,ocular hyperaemia
1631,trastuzumab emtansine,unresectable locally advanced or metastatic breast cancer,both trastuzumab and dm1,potent cyp3a inhibitors,potent cyp3a inhibitors,patients with a known hypersensitivity,NO SPECIFIC DATA AVAILABLE
1632,vancomycin hydrochloride,dental or surgical procedures,immediate inhibition of cell wall synthesis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,patients with known hypersensitivity to vancomycin,anaphylactic reactions
1633,valsartan + hydrochlorothiazide,hypertension,thiazide diuretic,excessive reduction in blood pressure,"alcohol, barbiturates, or narcotics",patients who are hypersensitive,rare
1634,valsartan,for hypertension,angiotensin ii antagonist acting on the at1 subtype,co medication,co medication,patients who are hypersensitive to any component of this product,rare
1635,valganciclovir,adult and pediatric solid organ transplant (sot) patients who are at risk,intestinal and hepatic esterases,drug-drug interactions,renally excreted drugs,patients with known hypersensitivity,impairment of fertility fetal toxicity
1636,valacyclovir,hiv infected individuals,antiviral drug,no dosage adjustment,"digoxin, antacids",hypersensitivity or intolerance,"nausea (15%), headache (14%),"
1637,ursodeoxycholic acid,cholestasis (jaundice) viral hepatitis,"it reduces cholesterol absorption, suppresses liver cholesterol synthesis",bile-acid binding drugs,charcoal and cholestyramine,non-functioning gall-bladder calcified and pigmented gallstones,"nausea, vomiting, diarrhoea"
1638,urokinase,adults,endogenous fibrinolytic system,oral anticoagulant,oral anticoagulant,pregnancy &amp; immediate postpartum period,"overt bleeding, haemorrhagic complications"
1639,urea (25%),consumers and diabetics,dose-dependent,hazardous drug interaction,hazardous drug,allergy,burning and irritation
1640,urea (10%),ichthyosis and dry skin conditions,"therapeutic effects depend on local concentrations, not on systemic absorption of the drug",hazardous drug interaction,hazardous drug,contraindicated,burning and irritation
1641,upadacitinib,moderate to severe active rheumatoid arthritis,janus kinase (jak) inhibitor,strong cyp3a4 inhibitors,strong cyp3a4 inducers,NO SPECIFIC DATA AVAILABLE,"upper respiratory tract infections, nausea, cough, and pyrexia"
1642,undenatured type ii collagen + glucosamine sulfate + chondroitin sulfate,"osteoarthritis, rheumatoid arthritis",oral tolerization,drug interaction,drug,<NO SPECIFIC DATA AVAILABLE,some may feel stomach problems
1643,undenatured type ii collagen + glucosamine sulfate + boswellia serrata + boron,osteoarthritis,unique,blood thinner medications,calcium fructoborate,"hypersensitivity to chicken, egg &amp; shellfish",amp
1644,undenatured type ii collagen,osteoarthritis rheumatoid arthritis,unique,not known,not known,patients with known hypersensitivity to chicken or egg,constipation and headache.
1645,ulipristal acetate [for uterine fibroids],moderate to severe symptoms,blocking the receptor of a hormone in the body called progesterone,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,genital bleeding,"common side effects areendometrial thickening, hot flush, headache"
1646,ulipristal acetate [for emergency contraception],5 days) of unprotected sexual intercourse or contraceptive failure,inhibition or delay of ovulation,drugs,drugs,hypersensitivity to active substances and in pregnancy,"headache, nausea, abdominal pain, dysmenorrhea"
1647,typhoid polysaccharide vaccine,travellers to high endemic areas household contact of carriers,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,subjects suffering from acute severe febrile illness,local reactions at the injection site
1648,tulobuterol hydrochloride,chronic asthma and chronic bronchitis,highly selective action on beta-2 adrenoceptors,corticosteroids and diuretics,xanthines,hypersensitivity to sympathomimetic amines,less frequent adverse reactions
1649,tto thermal toothpaste,faster relief from dental hypersensitivity,twice daily brushing,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1650,trypan blue,ophthalmic surgery,the dye does not penetrate the capsule,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,when a non-hydrated (dry state),discoloration of high water content hydrogen intraocular lenses
1651,trospium chloride,muscarinic antagonist,parasympatholytic,increase the serum concentration of trospium,increase the serum concentration of trospium,"angioedema, rash and anaphylactic reaction",post-approval
1652,"vitamin a, vitamin b complex, vitamin c , vitamin d and vitamin e",multivitamin maintenance dosage,water-soluble and three fat soluble,pyridoxine can reduce the effect of levo-dopa,folic acid may increase the metabolism of some antiepileptics,hyperparathyroidism,thiamine
1653,vitamin a,concomitant therapy of mucosa illnesses,antixerophthalmic,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypervitaminosis,"irritability, vomiting, loss of appetite, headache"
1654,vinpocetine,acute cardiovascular disorders,increases cerebral metabolism,heparin,heparin,"severe ischaemic heart disease, severe rhythm disorders and pregnancy","transient hypotension, tachycardia"
1655,vinorelbine tartrate,first-line treatment,inhibits microtubule formation,vaccines,aprepitant,"pregnancy, lactation","dose limiting granulocytopenia, leukopenia and anaemia"
1656,vincristine sulfate,inacute leukemia,inhibiting microtubule formation in the mitotic spindle.,toxicity,miconazole,patients receiving radiation therapy through ports which include liver,dose limiting neurotoxicity
1657,vinblastine sulfate,previously untreated patients with advanced hodgkins disease,it blocks glutamic acid utilization,side effects,vaccines,pregnancy; lactation,"nausea, vomiting, gi bleed"
1658,vildagliptin + metformin hydrochloride,combination of vildagliptin and metformin hydrochloride,does not produce hypoglycemia,drug interactions,"metformin hydrochloride (1,000 mg once daily",any of the excipients,"headache, tremor, dizziness, nausea, hypoglycaemia"
1659,vildagliptin,monotherapy,slowing the inactivation of incretin hormones,glucose-lowering effect,glucose,patients with moderate to severe renalimpairment,"mild and transient, not requiring treatment discontinuations"
1660,vilazodone hydrochloride,adults,not fully understood,strong cyp3a4 inhibitors,strong cyp3a4 inhibitors,monoamine oxidase inhibitors,seizures
1661,vilanterol trifenatate + fluticasone furoate,asthma,the mechanisms of action described below for the individual components,beviprex with other anticholinergic-containing drugs,beviprex with other anticholinergic-containing drugs,risk of overdose,asthma
1662,vilanterol + umeclidinium + fluticasone furoate,asthma,not known,anticholinergics,diuretics,severe hypersensitivity to milk proteins,copd : most common adverse reactions
1663,verteporfin,predominantly classic subfoveal choroidal neovascularization,low-intensity nonheat-generating laser light,compounds that quench active oxygen species or scavenge radicals,radiation therapy,patients with porphyria or a known hypersensitivity,increased lft.
1664,vericiguat,adults with symptomatic chronic hf,"directly stimulating sgc, independently of and synergistically with no",potential for hypotension,pde-5 inhibitors,pregnancy,NO SPECIFIC DATA AVAILABLE
1665,verapamil hydrochloride,adrenaline in halothane anaesthesia,l-type calcium channel blocker,lipid lowering agents,cardiac glycosides,patients with known hypersensitivity,"rash, flashing; hepatic : elevated liver enzyme"
1666,venlafaxine hydrochloride,physician who elects to use venlafaxine tablets,unknown,anticoagulants,anticoagulants,concomitant use with maois,may impair platelet aggregation
1667,venetoclax,in the presence of 17p deletion or tp53 mutation,orally bioavailable small-molecule inhibitor of bcl-2,moderate cyp3a inhibitors,"grapefruit products, seville oranges, and starfruit",at initiation and during the dose-titration phase,"neutropenia, diarrhoea, and upper respiratory tract infection"
1668,vecuronium bromide,adjunct to general anaesthesia,neither vagolytic nor ganglion blocking activity,neuromuscular blocking agents,suxamethonium,NO SPECIFIC DATA AVAILABLE,rare
1669,varicella virus vaccine,individuals 12 months of age and older,both cell-mediated and humoral immune responses,interfere with the expected immune response,blood products,individuals with a history of anaphylactic or severe allergic reaction,varicella-like rash (injection site)
1670,varenicline tartrate,smoking cessation treatment,varenicline blocks the ability of nicotine to activate 42 receptors,alcohol,alcohol,hypersensitivity,abnormal liver function test
1671,vardenafil,treaterectile dysfunction,selective inhibitor of cyclic guanosine monophosphate,alcohol,alcohol,patients who have shown hypersensitivity to vardenafil,"headache, flushing, stuffy or runny nose"
1672,yellow fever vaccine,any country that requires an international certificate of vaccination for entry,stimulation of production of endogenously produced antibodies,blood tests for dengue or japanese encephalitis,blood tests for dengue or japanese encephalitis,if you or your child are allergic to,loss of consciousness
1673,xylometazoline hydrochloride,nasal congestion,increases the volume of nasal airflow,drug interactions,drug,patients with transsphenoidal hypophysectomy,nausea and dryness of the nasal mucosa.
1674,white soft paraffin + liquid paraffin + wool alcohol,amp; wool alcohol,eye ointment,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensivity,"stinging/redness in the eye, widened pupils or blurred vision"
1675,white soft paraffin + liquid paraffin,emollient in the symptomatic relief of dry skin conditions.,emollients with occlusive properties,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,prolong use may cause folliculitis
1676,water for injection,"a vein, muscle, or under the skin",distillation or reverse osmosis,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE
1677,warfarin sodium,prophylaxis,irreversibly inhibits the enzyme,without the advice of a physician,"non-prescription products, without the advice of a physician",actual or potential hemorrhagic conditions,"nausea, vomiting, diarrhea, hypersensitivity, rash"
1678,voriconazole,it is indicated for use in patients 12 years of age and older,voriconazole binds and inhibits ergosterol synthesis,adverse reactions,phenytoin or efavirenz,co-administration,"blurred vision, headache, chest pain, nausea and diarrhea"
1679,voglibose,only when impaired glucose tolerance has not been improved,blocks pancreatic alpha-amylase,insulin resistance,insulin preparations and improving agents for insulin resistance,"diabetic ketoacidosis, diabetic pre-coma",ohas
1680,"vitamins [c, e, b9 and b12] and minerals [selenium, copper and zinc]",helps to protect cells against oxidative stress,<NO SPECIFIC DATA AVAILABLE,<NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,<NO SPECIFIC DATA AVAILABLE
1681,"vitamin c, vitamin e, lutein, copper & zinc",age-related eye disease. this is an advanced new antioxidant,exact mechanism of action is not still established,drug interaction,drug,hypersensitivity,zinc salt
1682,vitamin c + vitamin e,cancer prevention,oxidation/reduction reactions,may interfere with vitamin e absorption,"colestyramine, colestipol, and orlistat",patients,reversible
1683,vitamin c + vitamin d3 + folic acid,calcium,water-soluble vitamins,calcium salts,calcium salts,severe renal insufficiency concomitant digoxin therapy,amp; folic acid combinationis well tolerated
1684,vitamin c [ascorbic acid],"pregnancy, lactation, infection, trauma, burns, cold exposure",believed to be involved in biological oxidations and reductions used in cellular respiration,incompatible,incompatible,NO SPECIFIC DATA AVAILABLE,"diarrhoea, abdominal bloating, iron over-absorption"
1685,"vitamin b6, b9 & b12",hyperhomocysteinemia,folic acid,pyridoxine hydrochloride,folic acid,known hypersensitivity,cyanocobalamin
1686,vitamin b12 + elemental iron + folic acid,vitamin b12 and folic acid deficiency,dihydrofolate reductase,no plasma concentrations of phenobarbital,antiepileptic drugs,patients with known hypersensivity to any of its ingredients,"nausea, vomiting, constipation or diarrhoea"
1687,"vitamin b1, b2 & b6","it is also used in beri-beri, peripheral neuritis",essential coenzyme in carbohydrate metabolism,pyridoxine may increase the peripheral metabolism of levodopa,pyridoxine,hypersensitivity,allergic and idiosyncratic reactions are possible at lower levels
1688,"vitamin b1, b6 & b12",b12,vitamin b12,drug interaction,drug,patients on levodopa therapy,allergic reactions
1689,vitamin b complex + zinc,zinc,antioxidant properties,tetracyclines,fluroquinolones,hypersensitivity,specific vitamins but generally at levels substantially higher than recommended doses
1690,vitamin b complex + vitamin c,amp,cofactors,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE,hypersensitivity,thiamine and folic acid
1691,vitamin b complex,physiologically stressful conditions,each of the components playing a specific biological role,vitamin-b complex is not recommended for patients undergoing such therapy,vitamin-b complex is not recommended,hypersensitive,allergic and idiosyncratic reactions are possible at lower levels
1692,zuclopenthixol,schizophrenia.,both dopamine d1 receptors and dopamine d2 receptors,medicines that change the heartbeat,barbiturates,patients with known hypersensitivity,racing heart
1693,zopiclone,short-term treatment,structurally unrelated to existing hypnotics,convulsions,alcohol,patients with severe hepatic insufficiency,"somnolence, dizziness, confusion"
1694,zonisamide,partial seizures in adults withepilepsy,unknown,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,hypersensitivity tosulfonamidesor zonisamide,an incidence at least 4% greater than placebo
1695,zolpidem tartrate,controlled clinical studies,hypnotic action,impaired driving ability,fluoxetine,severe hepatic impairment.,"increased alt serum concentrations, abnormal lft"
1696,zolmitriptan,migraines with or without aura in adults,therapeutic activity of zolmitriptanfor the treatment of migraine headache,NO SPECIFIC DATA AVAILABLE,NO SPECIFIC DATA AVAILABLE,"patients with ischemic coronary artery disease, history of stroke","warm/cold sensation, nausea, heaviness sensation, and dry mouth"
1697,zoledronic acid [for osteoporosis],three annual doses,an inhibitor of osteoclast-mediated bone resorption,drugs that can significantly impact renal function,aminoglycosides or diuretics,pregnancy and lactation,"fever, myalgia, flu-like symptoms"
1698,zoledronic acid [for hypercalcemia],hypercalcaemia of malignancy,decreases in serum calcium and urinary calcium excretion,aminoglycosides,aminoglycosides,pregnancy and lactation,post-dose
1699,ziprasidone,may consider the use of other drugs first,dopamine type 2 (d2) and serotonin type 2,in combination with other drugs,food,patients with known hypersensitivity,"headache, nausea, somnolence"
1700,zinc sulfate monohydrate,zinc deficiency and/or zinc losing conditions,enzyme systems,absorption,penicillamine,those who are hypersensitive,"nausea, vomiting, diarrhoea, stomach upset"
1701,"zinc oxide, octinoxate, enzacamene and avobenzone",cream,absorb uv radiation and convert it to heat,interaction with other topically applied drug products,topically applied drug products,patients with a history of sensitivity to any components of the preparation,irritations
1702,zinc oxide + virgin castor oil,nappy rash,mildly antiseptic water resistant,mask x-ray pictures,x-ray pictures,known hypersensitivity to any of the ingredients listed,NO SPECIFIC DATA AVAILABLE
1703,zinc oxide + ethylhexyl methoxycinnamate + 4-methylbenzylidene camphor + butyl methoxydibenzoylmethane,"amp; reduced skin pigmentation, protection from harmful uv rays, sunblock","zinc oxide has astringent, soothing and protective properties",drug interactions,drug,hypersensitivity,severe allergic reactions
1704,zinc oxide + benzyl alcohol + benzyl benzoate + benzyl cinnamate + lanolin,napkin rash,lanolin,NO SPECIFIC DATA AVAILABLE>,NO SPECIFIC DATA AVAILABLE>,hypersensitivity to any of the ingredients.,local hypersensitivity occasionally
1705,zinc oxide [microfine],regular,"astringent, soothing and protective properties",drug interactions,drug,"cream, lotion",severe allergic reactions
1706,zinc oxide,smooth,sunscreen,hazardous drug interactions,hazardous drug,known hypersensitivity to any component of the preparation,extremely low frequency of hypersensitivity reaction
1707,zinc orotate,oral zinc therapy,anti-free radical action,absorption,penicillamine,NO SPECIFIC DATA AVAILABLE,"nausea, vomiting, metallic taste and stomach upset"
1708,zidovudine,should be given in combination with other antiretroviral drugs,interfering with viral rna-directed dna polymerase,decreased plasma concentration with rifampicin,decreased plasma concentration with rifampicin,hiv and hepatitis b or c virus co-infected patients,"convulsions, pancreatitis"
1709,zaleplon,controlled clinical trials,non-benzodiazepine hypnotic,kinetic,ethanol,patients with known hypersensitivity to any of its components,mild and transient
1710,zafirlukast,asthma in adults and children 5 years of age and older,selective and competitive leukotriene-receptor antagonist,adverse interaction,oral contraceptives without adverse interaction,patients who have previously experienced hypersensitivity to the product,there is no evidence
